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THE ROLE OF MEMBRANE TRANSPORTERS IN TRAUMATIC BRAIN INJURY: 
INTERVENTIONAL AND GENETIC INVESTIGATIONS 
 
Fanuel T. Hagos, PhD 
University of Pittsburgh, 2018 
Traumatic brain injury (TBI) is a leading cause of death and disability in children and young 
adults in the US. The neurovascular unit conceptual frame work emphasizes the dynamic 
interplay between neurons, endothelial cells and glial cells in understanding the pathophysiology 
of TBI. Membrane transporters, as mediators of the movement of numerous endogenous and 
exogenous molecules within the neurovascular unit, are critical components of the functional 
neurovascular unit in TBI. The aim of this thesis is to understand the role of membrane 
transporters in the pathogenesis and pharmacotherapy of TBI through interventional and genetic 
approaches.  
 
In the first part of the thesis, we investigated the utility of inhibition of transporters with 
probenecid, as a therapeutic strategy to simultaneously increase the systemic and brain 
concentration of the anti-oxidant drug, n-acetylcysteine, and the endogenous anti-oxidant, 
glutathione, in TBI. This approach counters oxidative stress, a major injury mechanism in TBI. 
Preclinical pharmacokinetic study showed that probenecid increases plasma and brain levels of 
n-acetylcysteine by inhibiting OAT1 and OAT3 transporters. In rat model of pediatric TBI, n-
acetylcysteine showed potential in attenuating TBI-induced learning and memory deficits. 
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Probenecid caused transient motor function impairment. A combination of the two resulted in 
smaller cortical tissue volume loss. Optimization of dosage regimen for both drugs to enhance 
the effects of n-acetylcysteine and minimize the side effects of probenecid is warranted. 
Metabolomic and pathway analyses of cerebrospinal fluid of TBI patients treated with placebo or 
a combination of probenecid and n-acetylcysteine showed that the combination therapy enriched 
glutathione mediated anti-oxidative stress pathways. 
 
In the second part of this thesis, we examined the association of genetic alterations in 
monocarboxylate transporters – responsible for shuttling lactate within the neurovascular unit –
with clinical outcomes. In discovery and replication cohorts, patients with one or two alternate 
alleles at SLC16A7 rs10506399 showed favorable outcomes. The alternate allele at the SNP was 
associated with increased expression of SLC16A7 which suggests that increased uptake of 
lactate by neurons may be beneficial in TBI. 
 
Collectively, this work has provided interventional and genetic evidence that transporters are 
important component of the injury mechanism and attractive therapeutic targets in TBI.   
 
Keywords: Traumatic Brain Injury, Membrane Transporters, Oxidative Stress, Lactate, 
Metabolomics, N-acetylcysteine, Probenecid, Monocarboxylates, Neurovascular Unit.   
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1. Introduction 
1.1. Review of the Role of Membrane Transporters in TBI 
 
1.1.1. Traumatic Brain Injury – Background 
Traumatic brain injury (TBI) is a major public health problem in the US with annual incidence of 
approximately 1.7 million, of which 50,000 injuries result in death [1], [2]. It is a leading cause 
of death and injury in children and older adolescents. It is estimated that about 2% of the US 
population has motor, cognitive and/or psychosocial impairments caused by a TBI [3, 4] and TBI 
has been associated with increased risk of neurodegenerative diseases such as Alzheimer’s 
disease later in life [5]. Although several pharmacological agents have been studied in TBI 
clinical trials, none of them have shown positive results in terms of survival or relevant clinical 
outcomes [6] [7]; [8]). Nevertheless, significant progress has been made in understanding and 
describing the numerous cellular and molecular processes involved in the pathogenesis of TBI. 
This includes the potentially reversible and/or preventable secondary injury mechanisms such as 
excitotoxicity, oxidative stress, and inflammation that follow the irreversible primary injury 
phase of TBI which consists of shearing and tearing of the brain tissue [9].  
2 
 
 
1.1.1.1. The neurovascular unit, TBI and membrane transporters 
Recently, there has been a growing interest in considering the neurovascular unit – originally 
developed as a framework for stroke – in TBI to expand on the current understanding of 
pathological mechanisms brain injuries [10]. This framework, which is hoped to accelerate the 
discovery of new therapeutic drugs, emphasizes the dynamic interaction among the different 
cells that constitute the neurovascular unit, i.e., neurons, endothelial cells and glial cells. A 
central component of this paradigm is the communication between the different cells (and 
compartments that house the cells) that is mediated by proteins, lipids, hormones, amino acids, 
and neurotransmitters [10]. Since many of these signaling molecules are polar in physiologic 
conditions, they require transporters – a wide variety of transmembrane proteins which regulate 
the trafficking of molecules across the lipid bilayer of cellular membranes – to enter intracellular 
environment or cross compartmental barriers [11-16]. This makes membrane transporters 
important contributors to the dynamic interplay within the neurovascular unit to regain 
homeostasis after TBI. Furthermore, lack of understanding of the nature and extent of the 
distribution of drugs into the brain and within the neurovascular unit has been emphasized as an 
unaddressed area of TBI research and has been consistently linked with the failure of clinical 
trials of drugs in TBI [17]. Transporters regulate the distribution of drugs into and within the 
brain, and could potentially determine the outcome of therapeutic intervention in TBI.  
 
Transporters within the neurovascular unit are important targets for devising new therapies, 
optimizing existing therapies and helping understand the toxicities of certain drugs. For example, 
inducing the expression and/or activity of transporters that are involved in the clearance of 
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certain injury mediators can attenuate brain injury as attempted with inducers of glutamate 
transporters [18]. Given the well-documented role of transporters in restricting the distribution of 
drugs, modulating the relevant transporters could enhance the permeation of drugs to the brain to 
clinically relevant levels [12]. Reversibly, understanding how drugs commonly used in the 
management of acute brain injuries affect the function of transporters could determine how and 
to what extent those drugs should be utilized clinically [13, 19]. In a similar way as drug-drug 
interactions, transporters mediated drug-metabolite interactions, and drug-nutrient interactions, 
could provide new targets for intervention and/or optimize the way we use existing therapies 
[13]. 
 
In this chapter role of membrane transporters as regulators of the movement of injury mediators, 
signaling molecules and therapeutic drugs between cells and across biological barriers in the 
context of TBI will be discussed. Also, therapeutic strategies in TBI that target membrane 
transporters will be reviewed.  
 
1.1.2. Membrane Transporters in CNS – Background 
Membrane transporters are divided into two major superfamilies: (1) the adenosine triphosphate-
binding cassette (ABC) transporters which utilize the energy in the form of adenosine 
triphosphate (ATP) to traffic various substrates across membranes, and (2) the solute carrier 
(SLC) transporters which rely on electrochemical gradient (passive gradient or gradient created 
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by secondary-active transporters) or ionic gradients to facilitate translocation of substrates across 
barriers [20, 21]. Because of regulatory requirements and the critical role transporters play in 
determining the pharmacokinetics of drug molecules and its implication in the efficacy and 
safety of drugs, this aspect of transporters has been a subject of intense research [13, 22]). The 
endogenous role of transporters in mediating physiological and pathological processes has 
remained relatively understudied. However, a growing body of evidence is revealing the 
importance of transporters in regulating the movement of endogenous molecules including 
metabolites, nutrients, signaling molecules, and biosynthesis and degradation by-products 
between cells, tissues and body fluid compartments [23] [24, 25] [21] [13, 26]. Transporters have 
been described as forming a “remote signaling and sensing system” to regulate the 
communication between organs, tissues and cells  [11]  [19, 26] [15]. This role makes 
transporters significant players not only in maintaining homeostasis but also in the initiation, 
progression, and resolution of pathological processes. For example, it is estimated that one in 
four of the SLC transporters is implicated in Mendelian diseases [27]. Numerous studies 
including several genome wide association studies have demonstrated the association of genetic 
variants in ABC and SLC transporters with complex human diseases including diabetes, 
neurodegenerative diseases, liver diseases, cardiovascular diseases and cancer [23] [20, 28] [27] 
[29] [30, 31] [32]. There are also several examples of FDA-approved drugs and drugs in 
development that target transporters directly or indirectly [23]. Interactions with transporters has 
also been described as the mechanism behind the toxicity of some commonly used drugs such as 
statins. In some cases, transporter-mediated toxicity has led to the discontinuation of clinical 
development of drugs [33] Zhang [34].  
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The CNS is very sensitive to fluctuations in the levels of nutrients, neurotransmitters, and toxins. 
Hence, the interaction of the CNS with blood and other peripheral fluids is tightly regulated by 
highly dynamic barriers, namely, the blood-brain barrier (BBB), the blood-cerebrospinal fluid 
barrier (Blood-CSF barrier) and the arachnoid epithelium [35] [36]. Similar barriers also exist 
within the CNS including the ependymal barrier as well as the cellular membrane barriers of the 
neurons and glia [37] [12] [38]. In addition to the physical and cellular structures, the prominent 
feature of all these barriers are numerous efflux and uptake transporters regulating the movement 
of mediators of physiologic and pathologic processes as well as drugs within the CNS, and 
between the CNS and the periphery. The significance of transporters on these barriers in health, 
disease, and pharmacotherapy of the CNS is very well established, years of study have been 
dedicated to understanding and characterizing the expression, distribution, localization, 
regulation and nature of substrates of transporters in the CNS. These have been reviewed 
extensively [12, 14, 24, 30, 39-43]. 
 
A number of recent publications have also reviewed the role of transporters in health and disease 
including in chronic neurodegenerative diseases such as epilepsy, Alzheimer’s Disease (AD), 
Amyotrophic lateral sclerosis (ALS), Parkinson’s Disease (PD), stroke and focal ischemia injury, 
brain tumors and multiple sclerosis (MS), [44] [45] [30].  The role of membrane transporters in 
TBI, on the other hand, has not been explored.  
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1.1.3. Membrane Transporters in TBI 
Despite the general lack of systematic study of membrane transporters in TBI or other acute 
brain injuries, there are several instances where transporters were investigated as central 
components of an important mechanism or pathway in TBI, which will be reviewed below.  
 
1.1.4. SLC Transporters in TBI 
Perhaps the most studied class of SLC transports in TBI are a group of glutamate transporters 
and monocarboxylates transporters. Glutamate transporters will be discussed here and MCT 
transporters will be discussed separately in section 1.1.4.2. Additional SLC transporters such as 
members of the OAT and OATP family of transporters that has not been studied in TBI yet, but 
has been investigated in another type of brain injuries that share a similar mechanism with TBI 
will also be discussed.  
1.1.4.1.    Glutamate Transporters 
Glutamate transporters are responsible for the trafficking of glutamate, the most predominant 
excitatory neurotransmitter in the mammalian brain, from the extracellular space into cells. 
Although essential to basic brain functions such as cognition, memory, and learning [46, 47], 
when present in excessive amount glutamate can be become neurotoxic due to overstimulation of 
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post-synaptic neurons [48]. Because of this, glutamate levels are tightly regulated through close 
coordination between its release and clearance, which depends on glutamate transporters [49].  
 
In TBI, it has been shown, both in preclinical models and in humans, that there is a massive 
release of glutamate into the synapses immediately after injury [50, 51]. This increase in 
extracellular glutamate causes excessive stimulation of N-methyl-D-aspartate (NMDA) 
glutamate receptor and triggers several cellular processes such as Ca++ and Na+ overload, 
activation of phospholipases, endonucleases and proteases, and generation of reactive oxidative 
species that eventually lead to neuronal injury and death [52-54]. This glutamate-mediated 
excitotoxicity is a well-established injury mechanism in TBI that can lead to neurodegeneration 
and negative functional outcomes. Owing to their prominence in modulating of extracellular 
concentration of glutamate, glutamate transporters have been a subject of significant 
investigation in TBI [18].  
 
In the mammalian brain, glutamate transporters comprise of five, sodium-dependent and high-
affinity, subtypes [55]: Excitatory amino acid transporter (EAAT)-1 (also called glutamate-
aspartate transporter or GLAST), EAAT2 (also called GLT-1), EAAT3/EAAC1, EAAT4, and 
EAAT5. EAAT2, expressed throughout the brain and spinal cord, is responsible for greater than 
90% of total glutamate uptake which makes it the most important glutamate transporters [56, 57]. 
At the cellular level, EAAT2 is expressed mainly in pre-synaptic processes of astrocytes and to a 
lower extent, in neurons and oligodendrocytes [58, 59]. EAAT1’s expression is limited to 
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astrocytes with the highest localization in the cerebellum [56, 57, 60]. It has also been detected in 
the spinal cord, cortex and hippocampus. EAAT3 is the neuronal glutamate transporters, 
specifically expressed in neuronal cell bodies and dendrites [61]. It is detected through the brain 
including cortex, hippocampus, cerebellum and basal ganglia [62, 63]. Recently, Akanuma et al. 
have reported that EAAT1 and EAAT3 were expressed in the ependymal and choroid plexus 
epithelial cells respectively [64]. They both face the CSF and appear to be involved in the 
elimination of glutamate from the CSF into the blood vessels. EAAT4 is mainly expressed in the 
soma and dendrites of cerebellar Purkinje cells with limited expression in hippocampus and 
neocortex. EAAT5 is expressed in the rod photoreceptor and bipolar cells in the retina [65]. 
Other sub-family of solute carriers that transport glutamate include SLC17A6, SLC17A7 and 
SLC17A8 which encode the vesicular glutamate transporters (vGLUTs), vGLUT2, vGLUT1 and 
vGLUT3 respectively [66]. These transporters are technically not a type of membrane 
transporters but are involved in trafficking glutamate intracellularly and they are known to be 
expressed only in neurons [67]. 
 
With a few exceptions, studies examining the role of glutamate transporters in TBI are mainly 
focused on EAAT2. In a controlled cortical impact, rat injury model of TBI, Rao et al., found 
that the protein expression of GLT-1 and GLAST was significantly decreased 6-72 h after injury 
and was accompanied by reduced D-[3H]Aspartate binding activity [68]. Another study found 
that, compared to sham-injured rats, in fluid percussion injury rat model of TBI, the Vmax of 
GLT-1 in the cortex and hippocampus was significantly reduced as early as 5 minutes and up to 
2 hours post injury [69]. Rao et al., in CCI TBI model in rats, demonstrated that the RNA and 
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protein expression of GLT1 was decreased 24-72 hours in the ipsilateral hippocampus as 
compared to the contralateral hippocampus or sham-injured rats. Additionally, administration of 
antisense oligodeoxynucleotides specific for GLT-1 resulted in exacerbated hippocampal 
neuronal death and increased mortality in the rat CCI model as compared to control rats infused 
with random oligodeoxynucleotides [70]. Landeghem et al., reported that in the CCI rat model of 
TBI, both GLAST and GLT-1 were down-regulated after injury with lowest expressions 24 to 72 
h post injury [71]. This was accompanied by increase glutamate levels in CSF that reached a 
maximum value at 48 h post injury. In a rat fluid percussion injury (FPI) model of TBI, Yi et al., 
found that GLT1v, but not GLT1a, GLAST or EAAC-1 were acutely downregulate following 
injury [72].  
 
Two studies in human have examined the role of glutamate transporters in TBI using genomic 
approaches. Ritter et al. found that genetic variations in SLC1A1, but not SLC1A6 were 
associated with reduced time to first seizure and increased seizure risk up to 3-years post injury 
in human TBI patients [73]. Specifically, rs10974620 in SLC1A1 was associated with increased 
posttraumatic seizures risk up to 3 years post injury, and rs7858819 associated with increased 
early and later posttraumatic seizures risk from day 2 to 3 years post-injury. In the second human 
study, Madura et al. found that genetic polymorphism at rs7417284 in the promoter region of the 
SLC17A7 gene was associated with severity and duration of sport-related concussion [74]. 
Specifically, those carrying the minor allele were 6.33-times more likely to experience prolonged 
recovery rates.  
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Because the critical role of glutamate membrane transporters in countering the effect of the 
excessive release of glutamate, glutamate transporters, especially EAAT2, have been 
investigated as a target for therapeutic intervention. This approach has also gained traction as a 
preferred approach since antagonists to glutamate receptors have shown unacceptable toxicity 
[18, 75].  
 
Approaches targeting glutamate transporters can be divided into those that intend to increase the 
expression of EAAT2 and those that increase the catalytic activity; the eventual purpose in both 
cases is to increase the clearance of glutamate from the extracellular synaptic environment. An 
extensive review of the molecules targeting EAAT2 for therapeutic purpose for numerous 
neurological conditions such as TBI, hypoxic-ischemic brain injury, spinal cord injury, ALS, 
Alzheimer’s Disease, neuropathic pain has previously been reviewed [18].  Here those molecules 
studied in TBI preclinical models will be summarized.  
 
Ceftriaxone, a β-lactam antimicrobial, is a transcriptional inducer of EAAT2 expression and has 
been investigated preclinically in diverse animal models of glutamate excitotoxity and clinically 
in ALS and stroke patients [76-79]. In the rat lateral FPI TBI model, Goodrich et al. found that 
ceftriaxone prevented the injury-related down expression of GLT1 that was observed in the 
placebo-treated group [80]. Ceftriaxone also mitigates the injury-associated regional astrogliosis 
and reduced cumulative post-traumatic seizure duration. Two studies conducted in the lateral 
CCI model of TBI in rats reported that ceftriaxone reduced glutamate levels in the brain, 
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attenuated cerebral edema and neuronal death, and improved cognitive function (Wei J. et al., 
2012 and Cui C. et al., 2014).  
 
Pituitary adenylate cyclase-activating polypeptide (PACAP), an endogenous peptide with 
neuromodulatory activity, has demonstrated GLT1 expression enhancing properties. In a weight-
drop model of TBI in rats, exogenously administered PACAP significantly improved motor and 
cognitive dysfunction, attenuated neuronal apoptosis, and decreased brain edema [81]. 
Additionally, in a rat model of diffuse axonal injury induced by impact acceleration, PACAP was 
reported to reduce the density of damaged, beta-amyloid precursor protein-immunoreactive 
axons in the corticospinal tract. However, it worth mentioning that the beneficial effects of 
PACAP in TBI may be, at least in part, mediated by other mechanisms [82].   
 
There are two molecules with GLT1 activity modulating capacity that have been studied in TBI: 
riluzole and MS-153. In a FPI model of TBI in rats, riluzole was shown to improve motor [83], 
and behavioral functions [84]. Similarly, in a FPI model of TBI in rats, MS-153 was shown to 
decrease neurodegeneration, loss of microtubule-associated protein 2 and NeuN (+) 
immunoreactivities, and attenuate calpain activation in both the cortex and the hippocampus at 
24 h after the injury [69]. As with PACAP, the beneficial effects of both riluzole and MS-153 are 
at least in part attributed to mechanisms other than GLT1 activity such as anti-inflammatory 
activities and inhibition of voltage-gated Ca channels respectively.  
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In summary, the functions of glutamate transporters in clearing potentially toxic glutamate 
accumulation away from neurons into astrocytes and across the ependymal barrier into the CSF 
and blood demonstrate the critical role membrane transporters play in coordinating the functional 
relationship among different cells within the neurovascular unit. The importance of this function 
is further highlighted by the negative consequence of reduced function of these transporters in 
TBI. The efforts to bolster the capacity of glutamate transporters in TBI as a therapeutic strategy 
has been explored with some success in preclinical TBI models. Translation of these therapeutic 
agents into the clinic has not been successful yet as none have been advanced to studies in TBI 
patients. Nevertheless, two recent studies have reported the discovery of potent activators of 
EAAT2 raising the possibility of targeting EAAT2 effectively in TBI and other neurological 
disorders [85, 86].  
 
1.1.4.2.    MCT Transporters 
The human SLC16 gene family of transporters, also known as the monocarboxylate (MCT) 
family, comprises of 14 members identified based on sequence homology. Only the first four –
MCT1 (SLC16A1), MCT2 (SLC16A7), MCT3 (SLC16A8) and MCT4 (SLC16A3) – are 
demonstrated to transport monocarboxylates including L-lactate, pyruvate, and ketone bodies 
[87, 88].  The transport of monocarboxylates follows a symport mechanism involving an 
exchange with a proton with an equimolar stoichiometry. The only other two de-orphaned 
members of the family are SLC16A2 which encodes for the thyroid hormone transporter MCT8 
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[89] and SLC16A10 encoding MCT10 which transporters aromatic amino acids [90]. In this 
dissertation, only MC1, 2 and 4 will be discussed, based on currently available evidence of the 
involvement of transporter and their substrates in acute brain injury.  
 
Expression of MCT transporters: The study of distribution pattern of MCT transporters 
through the brain has been complicated by cross-reactivity of antibodies, the gap in RNA-protein 
correlation and interspecies differences. However, a large body of evidence, mainly from 
rodents, has established the distinctive expression of the different MCT isoforms in the cells and 
regions of the brain [91, 92]. MCT1 is expressed throughout the brain and specifically on 
endothelial cells, astrocytes and oligodendrocytes [91]. MCT4 exhibits widespread brain 
expression in the brain but it shows the strongest expression in the cortex, hippocampus, 
striatum, and cerebellum. At the cellular level, MCT4 expression is restricted to astrocytes. 
Similarly, MCT2 is expressed throughout the brain with the strongest localization in the cortex, 
hippocampus, and cerebellum. MCT2 is the main isotype expressed in neurons with some studies 
suggesting its level of expression is associated with synapses[92]. MCT3 is expressed in the 
retinal pigment epithelium and the choroid plexus [87].  
 
MCT Transporters Kinetics: Like their expression pattern, MCT1-4 show distinctive kinetic 
properties and substrate specificities which, together with the expression pattern, are highly 
indicative of the specific role each isotype plays within a particular tissue [91, 92]. MCT2 shows 
the highest affinity for both lactate and pyruvate with Km value of about 0.7mM and 0.08mM 
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respectively. This explains, in part, the expression of MCT2 in neuronal cells with its specific 
role being to facilitate uptake of monocarboxylate for consumption in these oxidative cells. 
MCT4, on the other hand, has the lowest affinity with Km of about 35mM for lactate and an 
even greater Km of 150mM for pyruvate. In agreement with this property, MCT4 is expressed in 
astrocytes (and white muscle cells) where its role is to traffic lactate (but not pyruvate) from the 
glycolytic cells to the neurons. The affinity of MCT1 for lactate and pyruvate is 3.5mM and 
1mM respectively which reflects its ubiquitous expression and its function as the routine 
transporter. 
 
Monocarboxylate as an energy source for the brain: Monocarboxylates including pyruvate, 
lactate and ketone bodies are important intermediaries in brain energy metabolism processes. In 
the developing brain, monocarboxylates contribute substantially to the energy needs of the 
developing brain. For example, during the preweaning period, acetoacetate and 3-
hydroxybutyrate, two ketones derived from fatty acids in maternal milk, account up to 30% of 
the total cerebral energy consumption [93]. Monocarboxylates also play a key role in 
maintaining homeostasis when the energy requirement of the brain changes. Under normal 
physiological conditions, the brain uses glucose as its main energy source through glycolysis 
where glucose is metabolized to pyruvate [94]. In aerobic conditions, the pyruvate from 
glycolysis is oxidized and enters the TCA cycle eventually leading to the production of ATP in 
the mitochondria. During extreme but normal physiological conditions such as during extended 
starvation, intense exercise or during periods of high neuronal activity such as long-term memory 
formation, the brain, specifically neurons can utilize lactate and other monocarboxylates as 
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energy source [91, 95-97]. In such situations, lactate could be derived from peripheral tissues, 
mainly the liver or from the brain itself, specifically from the glycolytic astrocytes. The lactate 
specific mechanism in the brain is known as astrocyte-neuron lactate shuttle (ANLS). The ANLS 
involves a sequence of events where synaptically released glutamate initiates neuronal activity 
followed by increased rate of glucose uptake and glycolysis by astrocytes and subsequent release 
of lactate that can be used as energy substrate by neurons via oxidative-derived ATP production 
[98, 99]. Although controversies regarding the specific source of lactate and the magnitude of its 
significance exist, substantial evidence by numerous investigators support the main features of 
the model and the ANLS remains an important paradigm in understanding the brain 
neuroenergetics and role of monocarboxylates [94, 100, 101].  
 
As in extreme physiological conditions, monocarboxylates assume a critical role in pathological 
conditions as such cerebral ischemia and acute brain injuries [101, 102]. Brain energy utilization 
dysfunction is one of the hallmarks of acute brain injuries and is associated with poor prognosis 
[103, 104]. Monocarboxylates, and lactate in particular counter the consequences of the 
imbalance between increased energy demand and inadequate supply due to ischemia – a 
phenomenon known as metabolic decoupling – which is a distinctive characteristics of acute 
brain injuries [105-110]. Like in ANLS, there is unresolved controversy regarding the 
therapeutic efficacy of exogenously administered lactic acid in acute brain injuries in general and 
in TBI in particular. In rodent models of TBI and stroke, exogenous administration of lactate was 
demonstrated to improve histological and cognitive outcomes [111, 112]. However, Lama et al., 
using a modified weight drop model of severe TBI and magnetic resonance spectroscopy, 
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showed excessive build-up of lactic acid in injured brain tissue with potentially detrimental 
effects [113]. Two studies by Glenn et al., using isotope tracers of glucose and lactate, and 
sampling blood from the brain through arterial and jugular bulb catheters, provided evidence that 
large amounts of lactate are transferred from systemic circulation to the brain and the systemic 
derived lactate was directly consumed by injured human brain [105, 106]. However, citing 
technical shortcomings of human studies using microdialysis, limitations of in-vivo and in-vitro 
TBI models, stoichiometry considerations and lack of biological plausibility, some have 
questioned the notion that lactate could be preferentially and beneficially used as a fuel in TBI 
[114].  However, a recent clinical trial of human TBI patients monitored with cerebral 
microdialysis, showed that exogenous hypertonic solution of lactic acid administered as a short 
infusion resulted in increased levels of glucose in the dialysate indicating a clinically beneficial 
glucose sparing-effect [115]. Additional beneficial effects of hypertonic lactate including 
decreased intracranial pressure and dampened glutamate excitotoxicity were also reported. 
Another study has also reported that exogenous lactate infusion improved neurocognitive 
function in mild traumatic brain injury patients [116].  
  
MCTs in brain injuries: Because all the monocarboxylates exist as anionic species in the body, 
they require transporters to effectively cross biological barriers making MCT transporters key 
determinants of the trafficking monocarboxylates from the tissues/cells they are produced to 
where they are consumed. However, relatively little attention has been paid to the role of MCT 
transporters in either the controversy around the specific role of monocarboxylates in normal and 
extreme physiological conditions or acute brain injury.  Most of MCTs related research has 
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focused on the changes in expression of the different MCT isotypes or the effect of small 
molecule inhibitors or genetic manipulation in in-vivo and in-vitro models of diverse acute brain 
injury. These studies, described below, provide evidence on how the monocarboxylates and 
MCTs are essential components of the brain’s adaptation mechanism to altered energy sources 
and requirements in TBI and other brain injuries. 
 
Rosafio et al. observed a region-specific and cell-specific changes in the brain expression of 
MCT1, 2 and 4 transporters the mouse model of stroke at 1 hour and 24 hours following transient 
occlusion of the left middle cerebral artery [117]. At 1 hour, all three MCTs showed increased 
expression in the striatum and surrounding cortex of the ipsilateral section that persisted for 24 h 
or more. Specifically, they demonstrated that neurons, which normally express MCT2 only, 
show strong expression of MCT1 at both time points, and MCT4 at 24 h time point.  
Interestingly, expression of MCT transporters was also observed in areas of the brain distant 
from the injury site, i.e., in the hippocampus (MCT1 and MCT2 in the ipsilateral side and MCT2 
in the contralateral side), contralateral side striatum (MCT1), and contralateral side cortex 
(MCT1, MCT2). Zhang et al. studied the effects of cerebral ischemia by using permanent middle 
cerebral artery occlusion in a spontaneously hypertensive rat model on the expression of MCT 
transporters [118]. In the pre-infarct area, MCT expression was greatly increased in astrocytes 
(mRNA and proteins), endothelial cells (mRNA and protein) and neurons (mRNA). They also 
showed that in the short period of time before cell death occurs, increases in MCT1, MCT2, and 
MCT4 expression were observed in cells within the infarct and bordering the scar, although 
which specific cells have not been identified.  
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Moreira et al. investigated the expression of MCT1 and MCT2 following a focal ischemia 
episode created by unilateral extradural compression of rats, a model of TBI [119]. MCT1 
mRNA expression was increased in ipsilateral and contralateral cortex and ipsilateral 
hippocampus while MCT2 mRNA expression was enhanced in the contralateral hippocampus. 
They also observed strong MCT1 and MCT2 protein expression was found in perilesional 
macrophages/microglia and in an isolectin B4+/S100β+ cell population in the corpus callosum. 
Gao et al. evaluated the protein expression of MCT4 in primary astrocyte-neuron co-cultures in 
an oxygen deprivation (OD) protocol that mimics hypoxic conditions [120]. They found the 
MCT4 expression increased significantly in OD cells. They also found that astrocyte-neuron co-
cultures can tolerate 24h of OD treatment but RNAi-mediated suppression of MCT4 results in 
decreased neuronal survival without affecting astrocytes.  
 
Wang et al. examined the expression of MCT1 and 2 in a rodent model of sleep apnea and stroke 
[121]. They also investigated how MCT2 overexpression, siRNA based knock-down or 
inhibition with small molecule affect middle cerebral artery occlusion induced infarct size. 
Expression of MCT1 mRNA (in cortex and hippocampus) and protein (in cortex) were not 
altered due hypoxia. RT-qPCR, western blot and immunohistochemistry showed an overall 
lowered expression of MCT2 overtime in cortex and hippocampus after intermittent exposure to 
hypoxia. Administration of both, an inhibitor of MCT2, CN-4, and siRNA against MCT2 
resulted in increased infarct size. Conversely, overexpression of hMCT2 resulted in smaller 
infarct size as compared to wild-type controls whether MCAO was preceded by IH or not.   
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In two very similar studies, Schurr et al. and Izumi et al. showed, using hippocampal slices and 
oxygen deprivation, and CN-4 ( inhibitor of MCT transport), endogenously produced 
monocarboxylates, through MCT transporters, are critical at regaining synaptic function and 
morphological integrity even in the presence of glucose [122, 123].  
 
In an in-vivo study of cardiac-arrest-induced transient global cerebral ischemia rat mode, Schurr 
et al. demonstrated that administering the MCT inhibitor, 4-CIN, resulted in a significantly 
greater degree of delayed neuronal damage in the hippocampus [124]. Prins et al., in a CCI 
model of TBI in pediatric rats (35 days postnatal) and adults, reported increased protein 
expression of MCT2 in the ipsilateral cerebral vasculature [125]. Expression of MCT2 was 
greater in the postnatal day 35 rats as compared to adults.  
 
A definitive conclusion regarding the specific ways monocarboxylates and MCTs affect neuronal 
activity and survival, and functional outcomes may not be possible based on these studies 
because of disparities in models of injury employed, modalities of intervention, regions of the 
brain examined, non-selectivity of pharmacologic inhibitors utilized, and time periods of 
interventions and outcomes measured. Nevertheless, these studies provide strong evidence that 
monocarboxylates are critical to brain function and that the brain adaptation mechanism to acute 
injuries involves a significant role for monocarboxylates and their transporters. This points 
toward a greater need in developing a deeper understanding and more research of the role of 
MCT transporters in acuter injuries directly in humans. This could provide mechanist insight into 
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resolving the long-running dispute on whether lactate is a realistic energy substrate or even 
beneficial for neurons in the setting of acute brain injuries.  Leveraging the naturally occurring 
generic variability in SLC16A1, SLC16A3, and SLC16A7, the effect of altered function of these 
transporters in clinical outcomes in human TBI patients could be examined.  
 
1.1.4.3.    Other SLC Transporters 
To date, there are not many SLC transporters extensively studied in TBI other than MCTs and 
glutamate transporters. There are, however, a few SLC transporters that are worth mentioning 
here because 1) they are studied in acute brain injuries that share some pathology mechanism as 
TBI; 2) they transporter substrates that are known to be involved in TBI or 3) they are mediate 
the transporter of drugs that are commonly administered to TBI patients.   
 
1.1.4.3.1.    Prostaglandin Transporters 
Prostaglandins [prostacyclin I2 (PGI2), prostaglandin E2 (PGE2), prostaglandin D2 and 
prostaglandin F2α (PGF2α)] are a group of bioactive lipids derived from arachidonic acid through 
the activity of cyclooxygenase enzymes. In the brain, prostaglandins are released by neurons and 
glia in response to various insults such hypoxia and neuroinflammation in disease conditions 
such as TBI, stroke and neurodegenerative diseases [126]. The effect of prostaglandins in the 
CNS includes regulation of cerebral blood flow, synaptic transmission, and gene expression 
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[127]. The biological effects include body temperature regulation, pain perception, body 
temperature and sleep/wake cycle [127, 128].  
 
Crucial to the specificity of each prostaglandin are transporters that determine the distribution, 
compartmentalization and signal termination of prostaglandins [129]. Several transports are 
known to mediate the trafficking of prostaglandins including SLCO21A (also known as 
prostaglandin transporter), SLCO1A2, SLCO1B1, SLCO2A1, SLCO2B1, SLCO3A1, 
SLCO4A1, SLC22A8, and SLC22A6 [129, 130]. Among the ABC transporters, ABCC4 and 
ABCC1 are known to transporter prostaglandins and glutathione-conjugates of prostaglandin 
respectively [131, 132]. 
 
Several lines of evidence have established the critical role of prostaglandins in TBI in mediating 
neuroinflammation, body temperate dysregulation, and memory loss [126, 133]. The role of 
prostaglandin transporters in these processes is not studied well. In one study, Scafidi et al. have 
studied the changes in expression of SLCO21A in the developing brain of mice in response to 
hypoxia [128]. They observed decreased expression of SLCO21A in neurons compared to 
normoxic conditions while the effect on astrocytes was the reverse of what was observed in 
neurons. Whether these findings imply that prostaglandins could be participating in the 
pathogenesis of brain injuries or help the brain counteract effects of injuries remains to be 
elucidated.  
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1.1.4.3.2.     Nucleoside Transporters 
There are two families of transporters that are responsible for trafficking nucleosides, 
nucleosides analogs and nucleoside like drugs, the concentrative nucleoside transporters (CNTs) 
of the SLC28 family and the equilibrative nucleoside transporters (ENTs) of the SLC29 family 
[134]. By mediating the uptake of nucleosides, these transporters play a key role in salvage 
pathways of nucleotide biosynthesis. Critically, these transporters determine the intracellular and 
extracellular levels of purine and pyrimidine nucleosides, cyclic nucleosides, adenosine and 
other endogenous and exogenous nucleosides. Several studies have examined the changes in 
levels and effects of different types of nucleosides after TBI [135]. Adenosine, in particular, is 
extensively studied in TBI owing to its anticonvulsant effects [136]. Diamon et al. studied the 
association of a variant of the gene SLC19A1, as part of the adenosine signaling regulatory 
cycle, with epileptogenesis or post-traumatic epilepsy risk [137]. These were based on the role of 
SCL29A1 in maintaining the intracellular and extracellular levels of adenosine.  The study 
reported a significant association of epileptogenesis or post-traumatic epilepsy risk with other 
genes of the adenosine signalizing regulatory cycle, not SLC29A1, although the negative finding 
with regards to SLC29A1 could be attributed to the insufficient power of the study among other 
things. Given the increasing interest in understanding the role of nucleosides in TBI [135], focus 
on SLC28 and SLC29 families of transporters would ensure a better understanding of the brain 
distribution and levels of nucleosides.  
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1.1.4.3.3.     Multidrug SLC Transporters 
From drug transport perspective, there are several families of SLC transporters with individual 
members expresses on the BBB and/or blood—CSF barrier and play an active role in mediating 
the uptake and efflux of drugs with a variety of structures and chemical properties. These include 
organic anion transporting polypeptides (OATPs or SLCO), organic cation transporters (OCTs or 
SLC22A), organic cation transporter novel type (OCTN or SLC22A), concentrative nucleoside 
transporter (CNT or SLC28A), equilibrative nucleoside transporters (ENTs or SLC29A), 
multidrug and toxin extruder (MATE or SLC47A), and peptide transporters (PEPT or SLC15A) 
[14, 41, 130]. It is very important to determine if a particular TBI drug candidate’s access to the 
brain is dependent on or restricted by transporters. It is also important to understand the effect of 
TBI disease mechanism on the activity and expression of these transporters. For example, In a 
hypoxia/reoxygenation (H/R) stress model of injury on the rat brain microvessels, Thompson et 
al., showed that H/R resulted in increased expression of Oatp1a4 [138]. Uptake of atorvastatin, a 
statin and Oatp1a4 substrate, which has been investigated for a number of brain injury conditions 
due to its neuroprotective effect, was also increased. This suggests one explanation for the mixed 
results observed with statins in acute brain injuries could be due to their limited distribution to 
the brain and that modulating OATP1A4 transporter could facilitate greater brain penetration. 
 
Drug-drug interactions mediated by these transporters is also possible and could contribute 
towards pharmacotherapy failure or disease progression. Many drugs commonly administrated to 
TBI patients including antibiotics such as cephalosporins, and diuretics such as furosemide are 
known to competitively or non-competitively inhibited these transporters [14, 130, 139]. 
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To conclude, SLC transporters, remain relatively understudied in human disease, especially TBI 
[23]. However, their importance in maintaining brain homeostasis and, modulating the levels 
numerous injury mediators and therapeutic drugs is well demonstrated by the examples provided 
above. More studies of SLC transporters and their substrates are needed to fully understand the 
magnitude and extent of their involvement in pathogenesis and recovery after TBI, as well as 
develop therapies that target SLC transports and their substrates.  
 
1.1.5. ABC Transporters in TBI 
The ABC superfamily of transporters consists of 49 total transporters divided into 7 families, 
designated as A-G, based on sequence homology and functional similarities [21]. The ABCE/F 
subfamily, which lack the transmembrane domain and are involved in protein synthesis and 
expression, are not subject of this review and will not be discussed further. The other five 
families of ABC transporters are involved in trafficking diverse molecules including lipids, 
amino acids, steroid hormones, peptides and protein degradation products, hydrophobic 
molecules, and conjugates of numerous xenobiotic and endogenous molecules, drugs and their 
metabolites, environmental toxins and their metabolites. At the cellular level, ABC transporters, 
with some notable exceptions, are predominantly expressed on the cell membranes and to a 
lesser extent in the membrane of intracellular organelles such as endoplasmic reticulum and the 
Golgi apparatus. Except for ABCD4 (expressed on mitochondria membrane), all members of the 
ABCD subfamily of transporters are localized exclusively in the membrane of the peroxisome 
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[140]. Four members of the ABCB subfamily of transporters, specifically, ABCB6, ABCB7, 
ABCB8, and ABCB10, are localized in the mitochondrial membrane. Certain member of the 
ACB superfamily of transporters such as ABCB1, ABCC1, 2, 3, and 4, and ABCG2 show strong 
expression in excretory or barrier members including the intestine, kidney, BBB, and blood-testis 
barrier membranes. They function as part of regulatory system that selectively allow access to 
certain molecules while rejecting out others.  
 
In the CNS, ABC transporters ‘garnish’ the various cellular and compartmental barriers to ensure 
that various endogenous and exogenous molecules are maintained at optimal levels 
intracellularly or extracellularly to maintain homeostasis. The localization, substrates, functional 
activity, regulation and roles in several cellular processes are extensively studied and reviewed 
here [12, 141]. Also, the role of ABC transporters in several monogenic CNS diseases and 
complex chronic and/or neurodegenerative disease such as ALS, AD, PD an epilepsy are well 
documented and reviewed here [24, 25, 141]. Additionally, the role of ABC transporters in 
determining the distribution of numerous drugs and environmental molecules is well established 
and reviewed here [24, 25]. The role of these transporters in TBI and other acute brain injuries, 
however, is starting to gain attention recently and will be reviewed below.  
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1.1.5.1.    ABCA Transporters 
 
ABCA family of transporters consists of 12 members, ABCA1-10, 12, and 13 [16]. All members 
except ABCA4 and ABCA13 show some degree of expression in the CNS [141]. ABCA 
transporters mediate the trafficking of cholesterol, phospholipid, apolipoproteins and several 
other physiologic lipid compounds [142]. Mutations in four members of the family are known to 
cause monogenic diseases in humans: ABCA1 (Tangier disease), ABCA3 (neonatal surfactant 
deficiency), ABCA4 (autosomal recessive macular dystrophies) and ABCA12 (hereditary 
keratinization disorders) [142]. All of these disorders are related to dysregulation of lipid 
homeostasis. Additionally, ABCA is involved in complex diseases where lipids are part of the 
central mechanism including Alzheimer’s disease [16].  
 
Thus far, only one study has studied the specific role of ABCA family of transporters in TBI. In 
a mice model of TBI [143]. Loane et al., showed accumulation of Aβ after TBI. The 
accumulation of amyloid beta (Aβ) was attenuated by administration of liver X receptor (LXR) 
agonist that induced the expression of ABCA1 thereby enhancing the clearance of Aβ. This was 
accompanied by improved functional recovery.  
 
Furthermore, the substrates of the ABCA family transporters, specifically, apolipoprotein E 
(apoE) and cholesterol-by products are implicated in the pathogenesis of TBI especially in 
transitioning from acute injury to chronic neurodegenerative disease. Evidence from genetic-
association studies, animal models and in isolated neuronal and astrocytic systems have shown 
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that ABCA1, plays a critical role in facilitating cholesterol and phospholipid loading onto 
apolipoproteins [16]. Specifically, in the CNS, ABCA1 mediates the lipidation of ApoE (the 
most abundant lipoprotein in the CNS), trafficking of cholesterol to and from neurons, astrocytes 
and endothelial cells, and Aβ deposition. Separately, the apoE ε4 variant which is a strong 
genetic risk factor for AD, dramatically increased the risk of developing AD in TBI patients 
[144]. It is also associated with worse outcomes including mortality and worse functional 
outcomes in severe, moderate and repetitive TBI through a mechanism that is thought to involve 
dysregulation lipid homeostasis [145, 146] [147].  Given this strong, mechanistically definable, 
interaction between ABCA1 (and other members of the ABCA family), ApoE, and AD on one 
hand, and association of ApoE, TBI and AD, on the other hand, close examination of ABCA 
family transporters as a possible link between TBI and AD is warranted.  
 
1.1.5.2.    ABCB Transporters 
 
This subfamily of transporters has 11 members, ABCB1-11 [148]. ABCB1 (also known as P-
glycoprotein, P-gp, or MDR1) is perhaps the most studied of any transporters in CNS or 
otherwise, owing to its prominence as the most quintessential transporter involved in effluxing 
numerous drugs and other xenobiotic molecules from cells and compartments thereby 
significantly altering their pharmacokinetic properties including permeation to the CNS [141, 
149]. A major endogenous substrate of ABCB1 is Aβ and decreased the clearance of Aβ due to 
downregulation of ABCB1 has been implicated in AD [150, 151]. More recently, it has been 
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shown to mediate the transport of several endogenous molecules including endogenous opioid 
peptide although the implication in health and disease of these findings is yet to be studied [152]. 
Other members of ABCB family include ABCB11 (which is the bile salt export pump or BSEP), 
the mitochondrial transporters (ABCB6, ABCB7, ABCB8 and ABCB10), ABCB4 and ABCB2. 
To date, only mRNA expression of ABCB2-11 has been detected in various brain structures and 
the discussion here will be limited to ABCB1.  
 
In a single-center study in human TBI patients, Cousar et al. found that ABCB1 genotype was 
associated with functional outcome recovery. The specific mechanism of the effect remains 
unknown, but it could be by affecting the transport of drugs or endogenous substrates [153]. In 
another study in brain tissue from human TBI patients, Willyerd et al., demonstrated that 
although the expression of ABCB1 doesn’t seem to be altered, they observed possible proteolysis 
of ABCB1 into peptide fragments with the implication that degraded ABCB1 could lose its 
function [154].  
 
ABCB1 is well-known for its effects on the brain permeation of therapeutic drugs, however, this 
aspect is not yet explored during TBI. However, in a closely related brain injury – focal cerebral 
ischemia – Spudich et al. demonstrated that inhibiting ABCB1 increases the accumulation of two 
neuroprotective drugs in the brain [155]. This study, in addition to the numerous studies 
conducted in various CNS diseases, imply that due to the profound effect of ABCB1 on drug 
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distribution into the brain, whether drugs administrated in TBI are substrates of ABCB1 should 
be considered.  
 
1.1.5.3.    ABCC Transporters 
 
The ABCC family of transporters consists of 13 members, 9 of which are transporters (ABCC1-6 
and ABCC10-12), one is a truncated protein with no transport capacity (ABCC13), one is an ion 
channel (cystic fibrosis transmembrane regulator gene), and two are cell surface receptors (SUR1 
and SUR2) [156]. In the CNS, ABCC1-5 are the best-characterized members of the family. 
ABCC7, 8, 10, 11, and 12, while their expression and localization in the CNS are known, their 
specific functions remain unknown [141, 157]. Substrates of ABCC transporters include 
endogenous and exogenous organic anions including a large number of drugs and their 
metabolites. Often, ABCC transporters work in conjunction with OAT transporters to mediate a 
vectorial transport process of organic anions.  
 
ABCC1, 2, 3 generally show preference to conjugates of lipophilic compounds including 
glucuronate, sulfate, glutathione conjugates, and bile acid conjugates [156, 157]. ABCC4 and 5 
substrates include cAMP, cGMP, nucleotide analogs, and glutamate conjugates [157, 158]. 
ABCC6 transports small peptides and GSH conjugates. ABCC1, 2 and 4 are also reported to 
transport reduced GSH [157] [159].  
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Expression and localization of the two structurally closely related ABCC transproters, ABCC1, 
and ABCC4, are well-established [141, 156]. They are reported to be expressed in BBB, choroid 
plexus, microglia, and astrocytes. ABCC2 is enriched brain capillary endothelial cells and 
choroid plexus. Only limited data exists suggesting possible expression of ABCC3 in BBB, CP. 
ABCC5 show a high level of expression in the BBB, neurons, and glia [158]. 
 
Studies of ABCC transporters in TBI: A study by Willyerd et al. examined the changes in 
protein expression of ABCC1 following TBI in brain tissue of TBI patients [154]. The study 
reported an increased expression of ABCC1 compared to non-TBI controls that could possibly 
alter the levels of endogenous and exogenous substrates of ABCC1. In the second study, Cousar 
et al. studied the association of SNPs within ABCC1 and ABCC2 genes with neurological 
outcomes in human TBI patients [153]. They reported that ABCC1, but not ABCC2, genotype 
was associated with neurological functional recovery after TBI.  
 
Studies are underway to examine the role of MRP4 in TBI through its role in effluxing 2',3'-
cAMP from intracellular space – where it opens mitochondrial permeability transition pores – to 
extracellular space where it gets converted to the neuroprotective adenosine by CNPase [135].  
 
SUR1, encoded by ABCC8, is nonselective cation channel. Although not strictly transporters of 
‘small molecules’ as the definition of transporters is applied for the purposes of this dissertation, 
it plays a significant role in the pathogenesis of TBI and other acute brain injuries. Its expression 
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in the neurons, astrocytes and/or endothelial cells is upregulated in TBI, stroke, spinal cord 
injury and SAH. Mechanistic studies in animal models of acute CNS injuries and human genetic 
association studies have confirmed the role of ABCC8 in edema formation [160-164]. Clinical 
trials with glyburide, an inhibitor of SUR1, are underway in stroke and TBI to prevent edema 
formation [165, 166].  
 
The fact that there are only a few studies examining the role of ABCC transporters in TBI 
indicate the area is highly underappreciate for its role in TBI given the main endogenous 
substrates of these transporters such as GSH (and its conjugates such as 4-HNE), cyclic 
nucleotides, and prostaglandins are of paramount importance in the pathogenesis of neuronal 
death and injury in TBI. GSH is an important intracellular anti-oxidant and plays a key role in 
countering major injury mechanisms in TBI. In the brain ABCC transporters, in coordination 
with EAAC3 and cystine/glutamate exchanger, facilitate the biosynthesis, distribution, 
compartmentalization and recycling of GSH, GSSH (oxidized form of GSH), and GSH 
conjugates with toxic reactive molecules such as 4-HNE  [158, 167, 168]. Furthermore, ABCC1 
and ABCC4, along with ABCB1 and ABCG2, are the major determinants of the distribution of 
many drugs into the brain [169] further highlighting the relevance of this transporter family in 
TBI.  
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1.1.5.4.    ABCD Transporters 
 
The ABCD subfamily of transporters consists of four members, three of which (ABCB1, 2 and 
3) are expressed on the peroxisomal membrane while the fourth one, ABCD4, is localized on the 
endoplasmic reticulum membrane [140, 170, 171]. Although functional redundancy among the 
three perixosomal transporters has been reported, each has the main responsibility for 
transporting a specific type of fatty acids: ABCD1 is the main transporter for very-long-chain 
fatty acids-CoA (VLCFA-CoA), ABCD2 transporters C24:6w3, ABCD3 transporters 
docosahexaenoic acid (DHC)-CoA, trihydroxycoprostanoyl (THC)-CoA, dicarboxylic acid 
(DCA)-CoA and pristanoyl-CoA [170].  
 
Peroxisomes, in coordination with mitochondria, are responsible for chain shortening of very 
long-chain fatty acids followed by β-oxidation, the major mechanism for degradation of fatty 
acids [171]. A vital step in this process is the trafficking of fatty acid substrates for beta-
oxidation into the peroxisome and ABCD transporters play a critical role [172]. In fact, 
mutations in the ABCD1 gene result in X-linked adrenoleukodystrophy (X-ALD) which results 
in impaired peroxisomal β-oxidation and accumulation of VLCFA in tissues, especially the brain 
and the adrenal glands [173].  
 
To date, ABCD transporters have not been investigated in acute brain injuries. Lipid β-oxidation, 
on the other hand, is known to contribute to neuronal damage and death in TBI and other brain 
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injuries [174]. Hence, the close examination of ABCD transporters in lipid β-oxidation mediated 
neuronal injury and death is warranted.  
 
Additionally, polyunsaturated fatty acids (PUFAs), specifically, eicosapentaenoic acid (EPA), 
docosahexaenoic acid (DHA), and α-linolenic acid (ALA) have been reported to improve 
outcomes in preclinical TBI model when administered exogenously.[175]. PUFA are known to 
interact with ABCD transporters and predicted as substrates [176], indicating the need to 
investigate whether ABCD transporters are directly involved in the metabolism and therapeutic 
efficacy of exogenously administered and therapeutic DHA, EPA, and ALA. 
 
1.1.5.5.    ABCG Transporters 
 
To date, there are five members of the ABCG subfamily identified in humans: ABCG1, 2, 4, 5, 
and 8 [148, 177, 178]. ABCG1,4,5, and 8 are involved in the transport of cholesterol, plant 
sterols and various precursors intermediaries of sterol biosynthesis, as well as some synthetic and 
semisynthetic sterols[177, 179]. ABCG1 and 4 are known to play a significant role in the lipid 
transport and metabolism in macrophages. Loss of function mutations in ABCG5 or 8 are 
identified as causative in sitosterolemia, a rare autosomal-recessive lipid metabolism disorder 
[178]. In CNS, the mRNA or protein of these transporters are reported to be expressed in various 
cell types and barriers, however, the specific functions are not yet elucidated.  
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ABCG2, first identified as multidrug resistance protein in human breast cancer cell lines – hence 
its other name ‘breast cancer resistance protein ‘(BCRP) [180] - is the best-studied member of 
the family. In the CNS it has been identified in BBB, choroid plexus, pericytes, astrocytes, 
microglia and neuronal progenitor and stem cells [141]. Most of the studies have been focused 
on the BBB and choroid plexuses, where ABCG2 along with PGP and MRPs is known to play a 
critical role in restricting access of anticancer and other drugs from permeating into the brain.  
 
With regards to its endogenous substrates and physiological role, it was through genetic studies 
that its function as urate transporters was established. Reduced function mutations in ABCG2 
were associated with increased serum uric acid levels and gout [181]. Subsequently, more 
endogenous and exogenous substrates of ABCG2 has been identified including porphyrins, 
amyloid beta and numerous therapeutic drugs [182-184]. It has also been implicated in a number 
of pathological conductions including PD and AD in the CNS [182, 183, 185].  
 
A recent study has provided insight as to what the role ABCG2 could play in TBI. In the study, 
Adams et al., reported that a genetic variant of ABCG2, ABCG2 c.421C>A, was associated with 
Glasgow Outcome Scale (GOS) a measure of functional outcome recovery, after severe TBI in 
an age-dependent manner [186]. Patients with the variant allele at ABCG2 c.421C>A have 
decreased protein expression of ABCG2 and associated increased blood uric acid levels. Since 
uric acid is a potent antioxidant, the favorable outcome in patients with the variant allele was 
attributed to possible increased levels of uric acid in the brain. However, other functions of 
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ABCG2 such as clearance of the toxic porphyrins [184, 187, 188], and its general role as the 
gate-keeper against toxic substances of stem cells, could not be overruled. 
 
1.1.5.6.    ABC Transporters and Pharmacoresistance 
 
Resistance to pharmacotherapy mediated by transporters, especially efflux transporters, is a well-
established phenomenon. While this phenomenon is a well-recognized hurdle in the treatment of 
brain cancer and HIV infection, lately, it has been gaining recognition in other brain disorders 
such as epilepsy, depression, schizophrenia, and ALS [25, 30]. For example, in ALS, Trotti D, 
Pasinelli P and colleagues have shown that there is an increase in both expression and activity of 
Pgp and BCRP in the BBB which results in progressive resistance to the CNS penetration of 
rizuloze, the only drug currently approved for ALS [189]. They also demonstrated that 
administrating elacridar, an inhibitor of Pgp and BCRP, improved efficacy of riluzole in ALS 
[190]. In acute brain injuries, a study by Spudich et al. showed that Inhibition of ABCB1 
resulted in the accumulation of neuroprotective drugs after focal cerebral ischemia suggesting the 
possibility of phamacoresitance in acute brain injuries [155]. Similarly, Ibbotson et al. 
demonstrated that in a rat model of hypoxia-reoxygenation stress, there is an increased 
expression of Abcc1, Abcc2 and Abcc4 transporters in the BBB that is mediated by Nrf2 
signaling [191]. Also, Wang et al. showed that activating Nrf2 through the administration of 
sulforaphane increases the expression of P-gp, Bcrp, and Mrp2 in rat brain capillaries which was 
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accompanied by decreased uptake of verapamil a P-gp substrate [192]. Interestingly, Nrf2 is 
activated in TBI in response to oxidative stress.  
 
Although disruption in BBB observed in TBI could negate the impact of the increased expression 
of efflux transporters following TBI, it is important to consider that in many patients the 
disruption may be limited to small area. Also, often injury to brain tissue and cells occurs further 
away from the point of impact where there is no breakage of BBB. Additionally, the function of 
efflux transporter localized on the membrane of neurons, astrocytes, and other brain cells could 
be as important in conferring resistant to pharmacotherapy as those expressed on BBB. Hence, 
due consideration needs to be paid to transporters mediated pharmacoresistance in TBI.  
 
In summary, ABC transporters, like the SLC transporters, are underexplored in TBI. As stated 
above, one or more mechanistic link exists between the function of each of the ABC transporters, 
and disease pathogenesis and outcomes in TBI, suggesting potentially powerful impact ABC 
transporters could have on outcomes following TBI. To date, studies of ABC transporters in TBI 
are limited to a few genetic association studies in humans and ever fewer mechanist studies in 
animal models. This calls for more rigorous and systematic investigation ABC transporters in 
TBI. 
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1.1.6. Conclusion – TBI and Membrane Transporters 
The summary of membrane transporters investigated for their role in TBI is presented in Table 1. 
The role of membrane transporters in TBI remains under-studied. The limited number of studies 
that have investigated the role of membrane transporters in TBI have provided important insight 
into the functions of transporters within the neurovascular unit in TBI. In general, there are four 
ways transporters could impact outcomes in TBI. First, immediately after TBI, transporters are 
involved in helping the brain manage the aftermath of the injury, for example, by clearing injury 
mediators. This is exemplified by glutamate transporters that remove excess glutamate from 
synapsis to prevent excitotoxicity, and by MRP transporters that efflux out potentially damaging 
by-products such as 4-HNE after they are conjugated with GSH. Additionally, in the immediate 
time after injury, transporters also play a critical role in directing the movement of substrates that 
would be needed in higher amounts in neurons in the context of injury. For example, MCT1, 2 
and 4 work in close coordination to direct lactate from the periphery or astrocytes to neurons to 
be used as energy source. Second, transporters play a significant role in the transition of TBI 
from acute brain injury to a chronic neurological disease. For example, patients with reduced 
function in ABCA1 due to genetic variants or due to decreased expression as a result of disease 
or injury could be at higher risk to develop TBI-related AD. Third, transporters dynamically 
control the uptake of many drugs aimed at the brain and their distribution within the brain. 
Understanding the nature of drugs or candidate drugs in development with respect whether it is a 
substrate or inhibitor of transporters becomes highly relevant as a drug that can’t distribute to its 
target in sufficient quantities won’t be effective. Forth, transporters determine the levels of 
potential small molecule biomarkers in the CSF or blood – two main compartments which allow 
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routine measurement of biomarkers – if the biomarker is transporter substrate. This could have a 
profound impact on how the levels of biomarkers in CSF or blood are interpreted relative to the 
levels in the brain. The same could also hold true where biomarkers are measured in the 
parenchyma of the brain either by dialysis or by homogenization in case of preclinical TBI 
studies.  
 
It is hypothesized that systematic study of membrane transporters in the neurovascular unit in 
TBI will enable identifying targets for therapeutic intervention, provide insight into the details of 
pathological processes involved in TBI, and help determine the most promising drug candidates 
for development in TBI.  
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Table 1. Summary of Membrane Transporters investigated for their role in TBI 
Transporter 
TBI Model or Type of 
Clinical Study 
Major Finding Reference 
EEAT 
(SLC1A) 
CCI in rats Decreased RNA protein expression of 
EEAT2 at 6-72 h after injury. 
[68] 
[68][66] 
FPI in rats Decreased Vmax of EEAT2 in cortex and 
hippocampus 5 minutes to 2h after injury. 
[69] 
CCI in rats Decreased RNA and protein expression 
of EEAT2 in hippocampus 24-72 h post 
injury. Administration of antisense 
oligodeoxynucleotides targeting EEAT2 
resulted in exacerbated hippocampal 
neuronal death and increased mortality 
[193] 
Genetic association, 
time to first seizure and 
seizure risks as 
outcomes 
GG genotype at SLC1A1 rs10974620 
was associated with increased 
posttraumatic seizures risk. TT genotype 
at SLC1A1 rs7858819 was associated 
with increased early and later 
posttraumatic seizures risk.  
[73] 
FPI in rats Ceftriaxone prevented the injury-related 
down expression of Slc1a3, and reduced 
cumulative post-traumatic seizure 
duration. 
[80] 
CCI in rats Ceftriaxone reduced glutamate levels, 
attenuated cerebral edema and neuronal 
death, and improved cognitive function.  
[194, 195]  
SLC17A7 Genetic association,  Patients carrying the minor allele at 
SLC17A7 rs7417284 were more likely to 
experience prolonged recovery. 
[74] 
SLC16A 
(MCT) 
Unilateral extradural 
compression in rats 
Increased MCT1 mRNA expression in 
ipsilateral and contralateral cortex, and 
ipsilateral hippocampus. Increased MCT2 
mRNA expression in contralateral 
hippocampus.  
[119] 
CCI in Rats Increased protein expression of MCT2 in 
the ipsilateral cerebral vasculature.  
[125] 
Transient occlusion of 
the left middle cerebral 
artery in mice 
Region-specific and cell-specific changes 
in the brain expression of MCT1, MCT2 
and MCT4.  
[117] 
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SLC19A1 
(ENT1) 
Genetic association, 
post-traumatic epilepsy 
risk as outcome 
Significant association of epiloptogenesis 
after TBI was found with other genes of 
the adenosine signaling regulatory cycle, 
but now with SL29A1. 
[137] 
SLCO1A4 
(OATP1A4) 
Hypoxia/Reoxygenation 
stress, Rat brain 
microvessels 
Increased expression of Oatp1a4 and 
increased uptake of atorvastatin, an 
Oapt1a4 substrate 
[138] 
ABCA1 CCI in Mice Administration of LXR agonist increased 
expression of ABCA1 leading to 
increased clearance of Aβ. 
[143] 
ABCB1 
(Pgp 
MDR1,) 
Genetic association, 
GOS score 
dichotomized to 
favorable v unfavorable 
outcomes 
Patients homozygous for the T allele at 
ABCB1 rs1045642 were less likely to be 
have poor outcome versus those 
possessing the C allele 
[153] 
Protein expression 
study of brain tissue 
from human TBI 
patients 
No change in expression of ABCB1. 
Proteolysis of ABCB1 into peptide 
fragments.  
[154] 
Focal ischemia injury in 
mice 
Abcb1 was upregulated on capillary 
endothelium. Pharmacological 
inhibition or genetic knockout 
enhanced the accumulation and 
efficacy of neuroprotectants that are 
Abcb1 substrates. 
[155] 
ABCC 
(MRP) 
Genetic association, 
GOS dichotomized to 
favorable v unfavorable 
outcomes 
For ABCC1 rs4148382, patients 
homozygous for the G allele were less 
likely to be assigned poor outcome versus 
those possessing the A allele 
[153] 
Protein expression 
study of brain tissue 
from human TBI 
patients 
Expression of ABCC1 was increased in 
brain cortical tissue in TBI patients.  
[154] 
Hypoxia/Reoxygenation 
stress, Rat 
Increased expression of Abcc1, Abcc2, 
and Abcc4 in BBB mediated by Nrf2 
signaling. 
[191] 
ABCG2 
(BCRP) 
Genetic association, 
GOS 
ABCG2 c.421C>A was associated with 
GOS after severe TBI in age dependent 
manner.  
[186] 
CCI = Controlled Cortical Impact; FPI = Fluid Percussion Injury;  
GOS = Glasgow Outcome Scale 
 
41 
 
 
 
1.2. Targeting Transporters to Attenuate Oxidative Stress in TBI 
1.2.1. Oxidative Stress in TBI 
Oxidative stress is one of the major and well-established injury mechanisms of TBI that causes 
neuronal damage and death [7, 196, 197]. The role of oxidative stress in the pathophysiology of 
TIB was first described 30 years ago in a fluid percussion model of TBI in cats where a rapid 
release of superoxide in the extracellular space during and at least 1h after the injury was 
observed [198, 199]. Subsequently, numerous studies, both in various animal models of TBI and 
human TBI patients, have confirmed that different type of reactive oxygen species (ROS) and 
reactive nitrogen species (RNS) are released excessively during TBI [200, 201] [202] [203] [204, 
205]. Oxidative stress occurs when the body’s antioxidant defenses which is comprised of 
enzymes such superoxide dismutase and non-enzymes such as glutathione and ascorbic acid 
becomes overwhelmed by the excess reactive oxygen species (ROS) and reactive nitrogen 
species (RNS) creating an imbalanced redox state. The excess and highly reactive ROS and RNS 
then interact with proteins, lipids and DNA causing structural and functional alterations to these 
macromolecules eventually leading cell damage and death.  
 
42 
 
 
1.2.2. Targeting Transporters with Probenecid to Simultaneously Increase Brain Levels of 
N-acetylcysteine and Glutathione 
Based on the demonstrated significance of oxidative stress in the pathophysiology of TBI, 
several approaches to counter oxidative stress as a therapeutic strategy have been proposed 
including attempts to replenish the components of the anti-oxidative stress reservoir [8, 196]. 
This is based on the observation that the endogenous cellular scavengers of ROS and RNS, 
specifically alpha-tocopherol, ascorbate, and GSH, while effective in their function, become 
depleted fairly quickly after TBI [201]. We will focus on GSH here.  
 
GSH, a tripeptide of glutamic acid, cysteine and glycine, a critical role in maintaining the redox 
homeostasis in the brain cells (and virtually all body cells) [167]. There are at least two ways to 
maintain or supplement that brain GSH levels: 1) provide precursors that are critical for the 
biosynthesis of GSH. N-acetylcysteine which acts as a donor of cysteine -- the rate-limiting 
substrate in the biosynthesis of GSH -- is extensively used for this function in numerous disease 
conditions and will be used in that capacity in this dissertation. 2) preventing the efflux of GSH 
and its conjugates from the brain thereby increasing the overall GSH pool available for neurons 
and other brain cells. As mentioned in section 1.1.5.3 some ABCC transporters are involved in 
the efflux of GSH, hence inhibiting these transporters provids an opportunity to maintain brain 
GSH levels. In this dissertation, probenecid, an FDA approved drug, will be used to test this 
strategy.  
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These two approaches have several advantages that would allow them to synergistically enhance 
brain GSH level. First by inhibiting of organic anion transporters, probenecid could increase the 
exposure of NAC in plasma and importantly in the brain. Second, NAC, chemically a thiol, can 
act as an antioxidant by itself by reacting with and scavenging a number of radicals including 
•OH, •NO2, CO3•− and thiyl radicals [206]. Third, both NAC and probenecid are already FDA 
approved drugs with excellent safety profile, hence providing an opportunity for rapid translation 
to the clinic. Fourth, the combination therapy targets multiple processes vis-à-vis TBI and 
oxidative stress. Many of the agents targeting oxidative stress were single agents that target one 
aspect of oxidative stress, and although many of them show effectiveness in preclinical models 
of TBI, none prove to be effective in clinical trials. This is in part because oxidative stress 
involves multiple ROS and RNS that propagate oxidative damage via multiple pathways before 
eventually leading cell damage and death. As such, a single agent that targets a single point in 
the oxidative might not provide sufficient protection [7, 207]. To circumvent this problem, a 
combination therapy that targets multiple points in the oxidative stress cascade has been 
proposed to achieve an adequate level of neuroprotection (Hall, 2015).  
 
Hypothesis: Probenecid, an inhibitor of OAT and MRP transporters, could simultaneously 
increase the brain levels of the co-administered antioxidant drug NAC, and the endogenous 
antioxidant GSH to enhance the antioxidative stress reservoir of the brain, and improve 
functional outcomes after TBI.  
This hypothesis is tested in Chapters 2, 3, and 4. The aim of chapter 2 is to investigate whether 
probenecid when co-administered with NAC could increase the systemic and brain levels of 
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NAC by inhibiting OAT and/or MRP transporters. The aim of chapter 3 is to examine whether 
co-administration of probenecid and NAC would improve the motor and behavior functional 
outcome after TBI in a pediatric rat, CCI model of TBI. The aim of chapter 4 is to assess the 
capacity of the combination of NAC and probenecid to modulate GSH-associated anti-oxidative 
stress biochemical processes in the CSF of human TBI patients using a combination of 
metabolomics, and pathway and network analyses. Also, relevant biochemical processes linked 
to the pharmacological action of the combination therapy especially that of transporter inhibitor 
probenecid would be elucidated. 
 
1.3. Examining the Role of SLC16A1, SLC16A3 and SLC16A7 transporters in Human 
TBI Patients with a Genetic Approach 
The function of MCT transporters to direct the movement of lactate, pyruvate and ketone bodies 
between systemic circulation and brain, as well as within the neurovascular system is discussed 
in section 1.1.4.2. Also, the role of MCT transporters in traumatic brain injuries was discussed. It 
was indicated that due consideration of the role of MCT transporters within the neurovascular 
system could provide significant insight and help resolve the long-running controversy on 
whether lactic acid is shuttled to neurons to be utilized as an alternative/preferred energy source 
in TBI. In the brain, MCT1, 2 and 4 work in coordination – as reflected by their distinctive 
expression patterns and kinetic properties – to facilitate the movement of lactic acid from 
peripheral or astrocytic sources into the neurons especially in conditions such as TBI where the 
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normal energetics of the brain is disrupted. In Chapter 5 of this dissertation, using candidate-gene 
approach and focusing on well-studied SNPs, we aim to evaluate the association of genetic 
alteration in MCT1, 2 and 4 with neurological outcomes in TBI. 
 
Hypothesis: TBI patients with variants in the genes SLC16A1, A3 or A7 that result in 
increased function or expression would show higher recovery rate in clinical outcomes. 
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2. Pharmacokinetic interaction between probenecid and n-acetylcysteine, in-vitro and in-
vivo evidence. 
2.1. Introduction 
N-acetylcysteine is a thiol-containing, acetylated derivative of cysteine that has been in clinical 
use for over 50 years [206, 208, 209]. It acts as an antioxidant by directly scavenging reactive 
oxygen and nitrogen radicals via its thiol group, as well as by acting as a cysteine donor in the 
biosynthesis of glutathione, the most abundant intracellular antioxidant [206, 210, 211]. N-
acetylcysteine is FDA-approved for prevention of liver toxicity due to 
acetaminophen/paracetamol overdose and as a mucolytic for patients such as those with cystic 
fibrosis or chronic bronchitis [208, 212-214]. It has also been investigated as a cytoprotective 
agent in several conditions including TBI [215], contrast-induced nephropathy, cancer 
chemotherapy, cardiovascular disease, diabetes, human immunodeficiency virus infection, 
neuropsychiatric disorders, and heavy metal toxicity (reviewed here, [208, 209, 211].  N-
acetylcysteine is a hydrophilic molecule (log D = -5.4; [216]) that is approximately 30% renally 
eliminated [217]. Despite its extensive clinical and research use, an understanding of how n-
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acetylcysteine crosses certain biological barriers and its interactions with membrane transporters 
remains incomplete.  Additionally, controversy exists regarding the extent to which n-
acetylcysteine can enter the central nervous system (CNS) through the blood-brain barrier (BBB) 
[206]. 
 
Our group is investigating the use of n-acetylcysteine in combination with probenecid, the 
prototypical organic anion transporter inhibitor, in the treatment of pediatric traumatic brain 
injury [218] .  We proposed that a potentially synergistic interaction between n-acetylcysteine 
and probenecid exists to enhance antioxidant capacity of the brain after injury. While n-
acetylcysteine acts as donor of cysteine, the rate limiting substrate in biosynthesis of glutathione, 
probenecid has been shown to prevent active efflux of glutathione and its conjugates by 
inhibiting MRP transporters [219].  Probenecid is known to increase the plasma and CNS 
exposure of a number of drugs such as acyclovir, zidovudine and bumetanide by inhibiting 
transport systems in renal tubules, BBB, and/or blood-cerebrospinal fluid barrier [220-223]. The 
objectives of the current study were to evaluate the effect of probenecid on the brain and plasma 
exposure of n-acetylcysteine, and to assess the mechanism through which their interaction may 
be mediated.  
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2.2. Material and Methods 
2.2.1. Animals and treatment.   
All studies were approved by the Institutional Animal Care and Use Committee at the University 
of Pittsburgh. Healthy, male Sprague-Dawley rats (n=48), were purchased from Harlan 
Laboratories (Indianapolis, Indiana, USA) and acclimated for one week prior to study initiation 
when rats were 17-18 days old. The animals were allowed free access to food and water and 
were housed on a 12 h light/dark cycle. 
 
2.2.2. Drug administration and pharmacokinetic sampling. 
Rats were administered a single dose of either 163 mg/kg of n-acetylcysteine (Sigma-Aldrich, St. 
Louis, MO, USA) alone or in combination with 150 mg/kg of probenecid (Sigma-Aldrich, St. 
Louis, MO, USA) via intraperitoneal injection. Blood was collected at 0.5, 1, 2, 4, 6 and 8 h after 
injection by cardiac puncture into heparinized tubes, centrifuged immediately to isolate plasma, 
and frozen at -80°C for drug analysis. Similarly, brain tissue was harvested following 
decapitation at each time point and brain hemispheres were isolated carefully to avoid 
contamination with blood. Hemispheres were then homogenized by sonication in brain 
homogenization buffer (containing 137mM of NaCl, 2.7mM of KCl, 10mM of Na2HPO4, 
1.8mM KH2PO4 and 1mM of EDTA dissolved in H2O and adjusted to pH of 7.4) and an aliquot 
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of the homogenate was used for LC-MS/MS analysis. Four rats were studied per time point in 
each group.  Concentration-time data is reported as mean ± SEM. 
2.2.3. Drug analysis by LC-MS/MS.   
Total n-acetylcysteine concentrations were quantified in plasma and brain tissue using ultra-
performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS). Deuterated 
internal standard (d3- n-acetylcysteine, Cambridge Isotopes (Andover, MA) was added to plasma 
(50 µL) or brain homogenate (50 µL) and samples were reduced by adding dithiothreitol, 
derivatized with n-ethylmaleimide (NEM), and proteins were precipitated with acetonitrile. The 
supernatant was dried out under nitrogen and reconstituted with water before injecting onto the 
UPLC-MS/MS system. Chromatographic separation was achieved using a porous graphitic 
carbon hypercarb column 3.0 µm (1.0 X 100 mm) and an acetonitrile-formic acid gradient on an 
Accela series UPLC system (Thermo, San Jose, CA) with an 8 min run time.  MS/MS detection 
of NAC-NEM (m/z 433.1→304.2) was performed on a Thermo TSQ Quantum Ultra mass 
spectrometer with a heated electrospray source (Thermo, San Jose, CA). Calibration curves were 
linear from 100-10,000 ng/mL (r2 > 0.995). Inter-day accuracy (% bias) and precision (RSD) 
determined at the concentrations of 300, 2000, and 7000 ng/mL ranged from -1.11% to 10.5% 
and 1.88% to 7.63%, respectively.  All samples were diluted as necessary to be within the linear 
range of the assay. 
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2.2.4. Pharmacokinetic analysis.   
Pharmacokinetic parameters were estimated using standard noncompartmental methods 
(WinNonlin Phoenix, Certara, St. Louis, MO). Area under the curve (AUC) profiles for plasma 
and brain concentrations were calculated using the trapezoidal rule. The AUC from the last 
measured time point to infinity (AUC0-inf) was estimated by dividing the last measured 
concentration by the elimination rate constant. Apparent plasma clearance was calculated by 
dividing the dose given by AUC0-inf. 
 
2.2.5. Cell uptake studies.   
Human embryonic kidney cell lines stably transfected with human OAT3 (HEK-OAT3), human 
OAT1 (HEK-OAT1), and the corresponding HEK-empty vector (HEK-EV, control cells) were 
kindly provided by Professor Kathleen Giacomini (University of California, San Francisco, CA, 
USA). Cell lines were maintained in Dulbecco’s modified Eagle’s medium (DMEM) high 
glucose (4.5g/L) supplemented with L-glutamine (Life Technologies, Long Island, NY, USA), 
10% fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA), Hygromycin-B (100ug/mL, 
Corning, Corning, NY) and penicillin-streptomycin (100 ug/mL, Mediatech Inc., Manassas, VA) 
at 37°C in a humidified atmosphere with 5% CO2. Cells were plated in 6-well, poly-D-lysine 
coated tissue culture plates (Corning, Corning, NY, USA) 48-72 hours before the uptake study. 
On the day of the experiment, medium was removed and cells were washed twice with warm 
Dulbecco’s Phosphate Buffered Saline containing calcium and magnesium (DPBS, Mediatech 
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Inc., Manassas, VA, USA). Cells were then incubated in a DPBS solution containing 5mM of the 
transporter activator glutaric acid (Acros Organics, Geel, Belgium) for 30 minutes at 37°C. This 
solution was then replaced with incubation buffer (containing 128mM NaCl, 4.73mM KCl, 
1.25mM CaCl2, 1.25mM MgSO4 and 5mM HEPES in H2O and adjusted to pH 7.4) for 10 
minutes as previously described [224]. Uptake was initiated by adding 14C–Acetyl-L-Cysteine 
(14C-NAC; specific activity 0.0581 Ci/mmol or 0.054 Ci/mmol; Moravek Biochemicals, Brea, 
California) and unlabeled NAC (Sigma-Aldrich, St. Louis, MO, USA) followed by incubation at 
37°C for the indicated period of time. Uptake studies were terminated by removing the 
incubation solution and washing cells with ice-cold DPBS three times. Cells were then lysed 
with a solution of 0.1N NaOH containing 0.1% sodium dodecyl sulfate. Lysate radioactivity was 
then measured using a LS 6500 Scintillation System (Beckman Coulter, Brea, CA).  Protein 
concentration was also assayed using the BCA Protein Assay Kit (Pierce, Rockford, IL, USA) 
per the manufacturer’s protocol. The resultant uptake rates were normalized for protein content 
to account for differences in cell number between plates. Inhibition experiments were performed 
as described above except that cells were pre-incubated with 200 µM of probenecid in incubation 
media for 5 minutes. For the concentration-dependent uptake study, varying amounts of 
unlabeled n-acetylcysteine were added to the loading buffer containing a fixed amount of 
radiolabeled n-acetylcysteine to give total NAC concentrations ranging from 1 µM to 10 mM. 
All experiments were conducted in triplicate and means ± SD were calculated.  Uptake activity 
due to OAT1 and OAT3 was calculated by subtracting NAC uptake in HEK-EV cells from that 
of HEK-OAT1 and HEK-OAT3 at each of the corresponding concentrations. Michaelis-Menten 
kinetic analysis of the uptake data was conducted using Prism 5.04 (Graphpad Software, La 
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Jolla, CA). Data were first plotted and then the best-fit curve was fit using the following 
equation: V = Vmax · [S]/(Km + [S]), where V is the rate of uptake activity, Vmax is the maximum 
rate of uptake activity, [S] is the substrate concentration and Km is the concentration of the 
substrate where rate of uptake activity is half of the maximum.  
 
2.2.6. Vesicular uptake assay.   
Human MRP1 and MRP4 membrane vesicles, negative control vesicles, and ABC Transport 
Assay Reagent Kit were purchased from Life Technologies (Carlsbad, CA, USA).  A positive 
control substrate, 3H-estradiol-17β-D- glucuronide (E217βG; 41.4 Ci/mmol) was obtained from 
Perkin Elmer,Inc. (Boston, MA, USA). MultiScreenHTS 96-well glass fiber filter plates were 
purchased from EMD-Millipore Corporation (Billerica, MA, USA).  ATP-dependent and 
independent uptake was measured using either 50 µg of control, MRP1, or MRP4 baculovirus-
transfected Sf9 insect cells.  Assays were performed at 37⁰C in a final volume of 50 µl in a 
reaction mixture containing either 4 mM ATP or AMP, 2 mM glutathione, 10 µM cold E217βG, 
200 nM 3H-E217βG (for MRP1) or 100 nM (for MRP4).  The reaction was initiated by adding 
vesicles to reaction mix, incubating for 0.5, 1, 2.5, or 5 minutes, and stopped by adding 200 µl 
ice-cold buffer.  Samples were added to glass fiber filter plates and rapid filtration was 
performed using a Bio-Rad vacuum filtration unit.  Wells were washed 5 times, filters collected, 
and counted using the liquid scintillation counter. Additional experiments were performed using 
varying concentrations of the known MRP1 substrate E217βG (0.25-100 µM) for 0.5 minutes as 
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described above.  Radioactivity counts in wells without membrane vesicles were subtracted to 
account for any 3H-E217βG bound to the filter.  n-acetylcysteine assays were performed as 
above using MRP1 or MRP4 vesicles with ATP or AMP, with and without glutathione, using 15 
µM cold NAC and 10 µM of radiolabeled n-acetylcysteine for a final concentration of 25 µM.  
Reactions were carried out for 3.5, 7, and 10 minutes. 
 
2.2.7. Statistical analysis.   
Between groups comparisons were made using unpaired Student’s t tests. p < 0.05 was 
considered significant. All analyses were conducted using Graphpad Prism 5.04 (Graphpad 
Software, La Jolla, CA). 
 
2.3. Results 
2.3.1. Probenecid increased n-acetylcysteine plasma and brain exposure and decreased 
apparent plasma clearance.   
The impact of probenecid co-administration on n-acetylcysteine plasma and brain levels was first 
investigated. N-acetylcysteine plasma concentrations were increased significantly in the presence 
of probenecid starting at 2 h after administration compared to when n-acetylcysteine was given 
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alone (Figure 1.A). Moreover, the n-acetylcysteine AUC was increased by 1.65 fold by 
probenecid co-administration (Figure 1.B). Probenecid reduced apparent plasma clearance of n-
acetylcysteine by 65% (CL/F: 1113±29 vs 674±8.2 mL/h/kg; p < 0.001). 
 
Figure 1. N-acetylcysteine plasma concentration-time profile (A) and total plasma 
exposure, AUC, (B) with or without co-administration of probenecid. 
 
  
Sprague-Dawley rats were administered a dose of either n-acetylcysteine (163 mg/kg) alone 
or in combination with probenecid (150 mg/kg) intraperitoneally and serial n-acetylcysteine 
plasma concentrations were measured. (A) Probenecid increased n-acetylcysteine plasma 
concentration starting from the 1h up to the last sampling time point (mean ± SEM, n = 4 
per time point; *, p  < 0.05). (B) Probenecid increased n-acetylcysteine plasma AUC0-inf by 
1.65-fold (mean ± SEM; p < 0.01). 
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Similarly, n-acetylcysteine brain concentration-time profile was significantly increased by 
probenecid (Figure 2.A). Differences were observed starting from 1 h up to the 4 h time point. 
While n-acetylcysteine levels remained measurable until the last sampling time point (8 h) in the 
group that received both n-acetylcysteine and probenecid, n-acetylcysteine levels were below the 
limit of quantification at the 6 h and 8 h time points in the group that received n-acetylcysteine 
only. Figure 2.B shows that n-acetylcysteine total brain exposure was significantly increased by 
2.46 fold by probenecid co-administration. Interestingly, the proportional increase in n-
acetylcysteine total brain exposure with co-administration of probenecid was higher than that 
observed in plasma (2.46 vs 1.65 fold increase, respectively).  
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Figure 2. N-acetylcysteine brain concentration-time profile (A) and total brain exposure, 
AUC, (B) of N-acetylcystiene, with or without co-administration of probenecid. 
  
Sprague-Dawley rats were administered a dose of either n-acetylcysteine (163 mg/kg) alone 
or in combination with probenecid (150 mg/kg) intraperitoneally and brain hemispheres were 
collected at several time points for n-acetylcysteine analysis. (A) Probenecid increased n-
acetylcysteine brain concentrations starting from 1h up to the 4h time point. n-acetylcysteine 
levels were measurable until the last sampling time point (8h) in the group that received both 
n-acetylcysteine and probenecid, but were below limit of quantification at 6h and 8h in the 
group that received n-acetylcysteine only (mean ± SEM, n = 4 per time point, * p  < 0.05). 
(B) Probenecid increased brain AUC0-inf of NAC 2.46-fold (mean ± SEM;  p < 0.01). 
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2.3.2. N-acetylcysteine uptake by OAT3 and OAT1.   
To understand the mechanism of interaction between n-acetylcysteine and probenecid, we 
examined the time- and concentration-dependent uptake of n-acetylcysteine by transporters 
known to be inhibited by probenecid. OAT3- and OAT1-mediated transport activities were 
evaluated using cell lines that stably express those transporters and their negative controls (cell 
lines stably transfected with the empty vector). Figure 3 shows that the uptake of n-
acetylcysteine by OAT3- and OAT1-overexpressing cells is linear up to at least 15 and 42.5 
(latest time point measured) minutes, respectively. At 25 µM n-acetylcysteine, update rates were 
37.7±1.9 and 4.2±0.1 pmol/mg/min respectively. Subsequent concentration dependent uptake 
studies were then examined within the established linear range, 25 minutes for OAT1 and 10 
minutes for OAT3.  
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Figure 3. Time-dependent Uptake of n-acetylcysteine by OAT1- and OAT3-overexpressing 
cells 
 
 
 
 
 
 
N-acetylcysteine uptake by either of the transporter overexpressing cell lines was concentration-
dependent, but did not reach saturation even at very high substrate concentration of 10 mM 
(Figure 4).  
 
Figure 5 shows that probenecid significantly decreased n-acetylcysteine uptake by both OAT1 
(59% decrease, 3.88±0.26 to 1.59±0.0.34 pmol/min/mg of protein, n = 3; p < 0.01) and OAT3 
Human OAT1-, OAT3- and EV-HEK291 cells were incubated in transport buffer containing 25 
µM of n-acetylcysteine traced with 14C–Acetyl-L-Cysteine at 37°C for designated incubation 
times. N-acetylcysteine uptake was linear up to 15 minutes for HEK-OAT3 (A), 42.5 minutes 
(latest time point measured) for HEK-OAT1 (B) and 40 minutes (latest time point measured) in 
control HEK-EV cells (C). Each value represents the mean ± SD of three determinations. 
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(93.9% decrease, 51.08±3.8 to 3.1±0.15 pmol/min/mg of protein, n = 3; p < 0.001). There was no 
difference in n-acetylcysteine uptake by control cells in the presence or absence of probenecid (n 
= 3; N.S.). 
 
.   
  
Figure 4. Concentration-dependent n-acetylcysteine uptake by OAT1- and OAT3-
overexpressing cells 
HEK-OAT3 (A) and HEK-OAT1 (B) cells were incubated in transfer buffer  for 10 minutes 
(HEK-OAT3), 25 minutes (HEK-OAT1)  with increasing concentrations of n-acetylcysteine 
traced with 14C–Acetyl-L-Cysteine. Non-specific uptake was accounted for by subtracting uptake 
activity in HEK-EV cells from that of HEK-OAT1 or HEK-OAT3. The rate of uptake of n-
acetylcysteine did not reach saturation even at high substrate concentrations. Each value represents 
the mean ± SD of three determinations.  
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To evaluate whether n-acetylcysteine is a substrate for probenecid-sensitive efflux transporters 
that are expressed in the renal proximal tubules and in the brain, n-acetylcysteine uptake in 
MRP1- and MRP4-overexpressing membrane vesicles was evaluated. However, n-acetylcysteine 
transporter-medicated uptake by either of the transporters was not detected despite observing 
saturable uptake of E217βG, a well established substrate for both transporters as a positive 
control (Figure 6).  
Figure 5. Inhibition of OAT1- and OAT3-mediated n-acetylcysteine uptake by probenecid 
Uptake of 25 µM of n-acetylcysteine traced with 14C–Acetyl-L-Cysteine was evaluated in human 
OAT1-, OAT3- and EV-HEK291 cells with or without  200 µM of probenecid  for 10 minutes 
(HEK-OAT3), 25 minutes (HEK-OAT1) and 25 minutes (HEK-EV). N-acetylcysteine uptake 
activity was reduced in HEK-OAT1 and HEK-OAT3, but not HEK-EV cells following pre-
incubation with probenecid.  Each value represents the mean ± SD of three determinations. **p < 
001. ****p < 0.001. 
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Figure 6. Effect of MRP1 or MRP4 on n-acetylcysteine uptake in membrane vesicles 
 
 
 
 
 
 
 
Uptake was measured in the presence of ATP or AMP and data corrected by subtracting the 
amount of substrate bound to filters in the absence of protein vesicles. Final ATP-dependent 
uptake of E217βG  by membrane vesicles expressing MRP1 (A) or MRP4 (B) was determined by 
substrating uptake in the presence of AMP from that in the presence of AMP .  Membranes were 
incubated for 30 seconds at 37°C.  Time-course of n-acetylcysteine  uptake in presence of AMP or 
ATP by MRP1 (C) and MRP4 (D) membrane vesicles. Membranes were incubated with 25 µM n-
acetylcysteine (15 µM cold + 10 µM 14C- n-acetylcysteine). There was no statitically significant 
difference in the uptake rate (i.e., slope) between AMP- or ATP-dependnet uptake with either 
transporter. Each value represents the mean ± SD of two determinations. 
 
62 
 
 
2.4. Discussion 
We report the novel finding that probenecid increases n-acetylcysteine plasma and brain 
exposure in vivo, which   suggests that n-acetylcysteine is a likely putative transporter susbstrate. 
Further, we demostrated that NAC is an OAT1 and OAT3, but not a MRP1 and MRP4, substrate. 
N-acetylcysteine has been touted as a potential therapeutic agent for a number of ailments, 
including CNS injuries, but the process by which this hydrophilic molecule (log D = -5.4; [216]) 
crosses certain biological barriers is poorly understood.   
 
N-acetylcysteine plasma exposure was significantly increased and its apparent clearance was 
signficantly decreased by probenecid co-administration in the rat. Probenecid is a well-
established organic anion transport inhibitor and has been used both clinically and preclinically 
(in rats) to determine the role of OAT1 and OAT3 in the clearance of renally-excreted drugs.  
Human and rat forms of both OAT3 and OAT1 show overlapping substrate specificity and 
comparable level of activity [225, 226]. This is suggestive that these transporters mediate the 
uptake of n-acetylcysteine into the renal tubule for eventual secretion into the urine. In order to 
determine if n-acetylcysteine is substrate for OAT1 and/or OAT3, we conducted an in vitro 
uptake study of n-acetylcysteine with HEK-293 cell lines that overexpress human OAT1 or 
OAT3 transporters.  
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In vitro uptake and inhibition experiments confirm that n-acetylcysteine is a substrate for OAT1 
and OAT3.  However, OAT1 and OAT3 concentration-dependent uptake did not reach saturation 
even after incubation with 10 mM of n-acetylcysteine. One possible explanation for the apparent 
inconsistency between the lack of saturability and inhibition of uptake by probenecid is that n-
acetylcysteine may exist in various chemical forms following admininistration. Once n-
acetylcysteine enters the systemic circulation, it exists in a reduced form and in various oxidized 
forms that are products of redox reactions between n-acetylcysteine, cysteine, glutathione and 
proteins [227, 228].  Consistent with the possibility that some conjugate forms of n-
acetylcysteine could be the substrates for OAT1 and OAT3, previous reports have demonstrated 
that endogenous and exogenous mercapturic acid conjugates of n-acetylcysteine as well as 
methylmercury conjugates of n-acetylcysteine are substrates of OAT1 in Xenopus Laevis oocytes 
that overexpress rat Oat1 [229, 230]. Further investigation is warranted in order to elucidate 
which among the different froms of n-acetylcysteine are substrates of OAT1 and OAT3.  
Furthermore, since probenecid is also known to inhibit organic anion transporting 
polypeptide(OATP) transporters, albeit less potently [139, 225, 231, 232], future studies should 
investigate whether NAC or any of its derivatives are substrates of the OATPs.  
 
Adequate brain penetration is of paramount importance for treating CNS pathologies such as 
traumatic brain injury. Prior to our study, contradictory reports have been published regarding 
the capacity of NAC to cross the BBB. Following administration of a single dose of n-
acetylcysteine IP or IV into the tail vein of mice, n-acetylcysteine levels in the brain and spinal 
cord are below the lower limit of quantification [233, 234]. However, Offen et al. administered 
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n-acetylcysteine and N-acetylcysteine amide both IP and orally and were able to detect N-
acetylcysteine amide but not n-acetylcysteine in the brain of mice [235]. Similarly, low levels of 
n-acetylcysteine were measurable in the brain of mice after IP administration and were 
significantly increased with coadministration of lipopolysaccharide [236]. Route of 
administration also appears to impact n-acetylcysteine brain distribution. Farr et al. reported that 
n-acetylcysteine crosses BBB readily and accumulated in the brain after administration via 
jugular vein in mice [237] while Neuwelt et al. showed that n-acetylcysteine can cross the BBB 
when given into the carotid artery in rats [238].  
 
In the current study, we show that NAC is detectable in the brain of juvenile rats after single IP 
administration using ultra sensitive methods; but that brain clearance of NAC is rapid with 
undetectable levels by 4 h. Importantly, we also report that NAC brain penetration can be 
enhanced with probenecid coadministration. NAC brain exposure increased by nearly 2.5 fold 
and an additional 46% over that expected by the increase in plasma exposure alone, suggesting a 
possible transporter effect at the BBB or blood-CSF barrier . In addition to renal tubules, OAT3 
is expressed in the basolateral side of the endothelial cells on the BBB and epithelial cells of the 
choroid plexus. Uptake transporters such as OAT3 that are expressed in the basolateral side of 
the endothelial cells on the BBB and the apical side of the choroid plexus epithelial cells that 
constitute the blood-CSF barrier have been implicated as initiators of a vectorial transport 
process that transfers molecules out of the brain into the circulating blood [139]. Such a 
mechanism has been proposed in the clearance of PGE2, zidovudine and bumetanide from the 
brain tissue through the choroid plexus and/or BBB [221-223, 239]. Inhibitors of OAT3 
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decreased the clearance of PGE2, zidovudine, and bumetanide from the CSF and increased levels 
of these molecules in the brain. The enhanced n-acetylcysteine brain exposure following 
administration of OAT3 inhibitor probenecid could be explained by the same mechanism.  
Although we explored the possibility of involvement of MRP1 and MRP4 given their known 
expression in the brain and probenecid-sensitivity [240], our in vitro data suggest that n-
acetylcysteine is not a substrate of these transporters.  
 
Recently, clinical modulation of efflux transporters at the BBB as a therapeutic strategy to 
increase CNS drug levels has been ruled improbable [241].  The findings in this study are 
provocative in that they support the possibility of increasing the brain exposure of certain drugs 
by inhibiting uptake transporters at the BBB and/or choroid plexus using an FDA-approved drug 
with a favorable safety profile. A Phase I/II study is underway (ClinicalTrials.gov Identifier 
#NCT01322009) to test the safety of n-acetylcysteine and probenecid co-administration in 
children with TBI as a first step to evaluate this potential therapeutic strategy. 
 
Limitations to the study should be noted.  The n-acetylcysteine LC-MS/MS assay used employs 
sample reduction and derivitization to achieve high sensitivity to detect n-acetylcysteine in 
biological matrices.  While this approach is ideal to measure overall exposure following n-
acetylcysteine administration, it cannot distinguish potential downstream forms of n-
acetylcysteine such as conjugates.  Similarly, an inherant limitation to radiolabeled-based assays 
is they cannot differentiate between parent molecules such as n-acetylcysteine and conjugates or 
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degradation products.  The work was also conducted in control animals and it is also possible or 
even likely that n-acetylcysteine pharmacokinetics and/or brain penetration may differ is disease 
conditions or following injury. Future work will focus on molecular speciation and potential 
varying interactions with OAT3, OAT1, and probenecid as well as n-acetylcysteine 
pharmacokinetics following traumatic brain injury.   
 
In summary, we report that co-administration of probenecid reduces the clearance of n-
acetylcysteine and increases both plasma and brain levels of n-acetylcysteine in the rat. In vitro 
data reveal that the mechanism of interaction between probenecid and n-acetylcysteine include 
transport by OAT1 and OAT3. To the best of our knowledge, this is the first study to report the 
interaction of n-acetylcysteine with OAT1 and OAT3 transporters, and the effect of probenecid 
on the n-acetylcysteine pharmacokinetics mediated through these transporters. With expanding 
interest in the use of n-acetylcysteine as an antioxidant therapy for several pathologies, including 
those within the CNS, these findings have particular relevance for understanding how n-
acetylcysteine crosses certain biological barriers. Repurposing the FDA-approved transporter 
inhibitor, probenecid, is a promising therapeutic strategy to increase n-acetylcysteine exposure. 
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3. The effect of a combination of n-acetylcysteine and probenecid on functional outcomes 
in rat, traumatic brain injury model 
3.1. Introduction 
The objective of the current study is to assess the capacity of a combination of n-acetylcysteine 
and probenecid to improve histological and neurological functional outcomes in a rats subjected 
to controlled cortical injury (CCI), a well-established TBI model. 
 
Oxidative stress is a well-established injury mechanism of TBI that cause neuronal damage and 
death (Bains & Hall, 2012; Hall, 2015, 2016). Numerous studies, both in various animal models 
of TBI and human TBI patients, have confirmed that reactive oxygen species (ROS) and reactive 
nitrogen species (RNS) are released excessively during TBI (Awasthi, Church, Torbati, Carey, & 
Pryor, 1997; Bayir et al.., 2002; Deng, Thompson, Gao, & Hall, 2007; Hall & Braughler, 1993; 
Rodriguez-Rodriguez, Egea-Guerrero, Murillo-Cabezas, & Carrillo-Vico, 2014; Singh, Sullivan, 
Deng, Mbye, & Hall, 2006). A number therapies such as polyethylene glycol-conjugated 
superoxide dismutase (PEG-SOD) and tirilazad have been developed to target oxidative stress, 
for TBI (Bains & Hall, 2012; Kochanek et al.., 2015) and have demonstrated effectiveness in 
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preclinical models of TBI, but none prove to be effective in clinical trials. This may be in part 
because oxidative stress involves multiple ROS and RNS that propagate oxidative damage via 
multiple pathways before eventually leading cell damage and death. As such a single agent that 
targets a single point in the oxidative might not provide sufficient protection (Hall, 2015; 
Margulies, 2009).  
 
Combination therapy that targets multiple points in the oxidative stress cascade has been 
proposed to achieve adequate level of neuroprotection (Hall, 2015). In this study, we evaluate a 
combination of n-acetylcysteine and probenecid, both FDA-approved drugs, to synergistically 
counter the effects of oxidative stress following TBI through multiple mechanisms. First, n-
acetylcysteine, as a thiol, can act as antioxidant by itself by reacting with and scavenging a 
number of radicals including •OH, •NO2, CO3•− and thiyl radicals (Samuni, Goldstein, Dean, & 
Berk, 2013). Second, n-acetylcysteine is an acetylated derivative of cysteine and acts a donor of 
cysteine, the rate limiting substrate in the biosynthesis of glutathione. Hence, n-acetylcysteine 
can play important role in replenishing intracellular glutathione which is depleted following TBI 
(Bayir et al.., 2002). Third, probenecid can preserve the intracellular pool of glutathione by 
virtue of its ability to inhibit multidrug resistance protein (MRP) transporters which are involved 
in active efflux of glutathione and its conjugated from cells (Versantvoort, Bagrij, Wright, & 
Twentyman, 1995). Finally, by inhibiting of organic anion transporter (OAT)-1 and OAT3, 
probenecid can increase the exposure of n-acetylcysteine in plasma and importantly in the brain 
[242]. This is particularly important since inadequate pharmacokinetics and brain distribution 
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characteristics of CNS targeted drugs has been described as one of the reasons for failed clinical 
trials.  
 
Previously, we have demonstrated that a combination of probenecid and n-acetylcysteine 
increases n-acetylcysteine exposure and prevents loss of intracellular glutathione and inhibits 
neuronal death after mechanical stretch injury in vitro [242, 243].  
 
3.2. Methods 
3.2.1. Animals 
Male pediatric Sprague-Dawley rats, postnatal day 17 (PND-17), 35-43g Harlan Laboratories 
(Indianapolis, Indiana, USA) were used for pharmacokinetics study (n=18) and for functional 
outcome and histological studies (n=66). Rat pups were initially housed with dams in a Plexiglas 
cages in a temperature (21±1°C) and light (on 0700 to 1900) controlled environment, acclimated 
for one week prior to study, and were allowed access to food and water ad libitum throughout the 
study. Pups were weaned on PND23 and subsequently pair-housed. All studies were approved by 
the Institutional Animal Care and Use Committee at the University of Pittsburgh. 
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3.2.2. Surgery 
On the day of surgery, rats weighing 35 - 43g were randomly assigned to either controlled 
cortical impact (CCI) or sham injury groups. Surgical procedures were performed as previously 
published [1]. Briefly, rats were weighed, placed in an induction chamber, and exposed to 4% 
isoflurane in 2:1 N2O:O2, for approximately 1.5 minutes. Rats were then placed into a 
stereotaxic frame and maintained with a constant flow of inspired anesthetizing mixture of 2% 
isoflurane, 2:1 N2O: O2 carrier gases via nose cone. All rats were maintained at 37±0.5°C during 
surgery with a heating blanket. Utilizing aseptic techniques a ~9 mm craniotomy was made over 
the right hemisphere (between bregma/lambda and the sagittal suture/coronal ridge) with a hand-
held high speed dental drill (Aseptico Torque Plus +, Woodinville WA).   The impact tip (6mm, 
flat) was lowered and centered through the craniectomy such that it produced a brain injury of 
moderate severity (2.4 mm tissue deformation at 4m/sec). After the impact, anesthesia was 
discontinued, the incision was promptly sutured, and the rats placed in a temperature controlled 
recovery chamber (maintained at 37±0.5oC) until the effects of anesthesia abated. Rectal 
temperatures were monitored for 2hrs post-surgery every 15minutes and then rats were returned 
to their dam and the colony.  Sham-operated control rats, received all surgical manipulations; i.e. 
anesthesia and craniotomy, but did not receive an impact.   
3.2.3. Animal pharmacokinetics study 
15 minutes after CCI, rats were administered a single dose of 163 mg/kg of n-acetylcysteine 
(Sigma-Aldrich, St. Louis, MO, USA) in combination with 150 mg/kg of probenecid (Sigma-
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Aldrich, St. Louis, MO, USA) or vehicle via intraperitoneal injection. Blood was collected 1 
hour after injection by cardiac puncture into heparinized tubes, centrifuged immediately to 
isolate plasma, and frozen at -80°C for drug analysis. Brain tissue was harvested following 
decapitation 1 hour after injection and brain hemispheres were isolated. Hemispheres were then 
homogenized by sonication in brain homogenization buffer (containing 137mM of NaCl, 2.7mM 
of KCl, 10mM of Na2HPO4, 1.8mM KH2PO4 and 1mM of EDTA dissolved in H2O and adjusted 
to pH of 7.4) and an aliquot of the homogenate was used for LC-MS/MS analysis. Six rats were 
studied in each group. The assays for probenecid and n-acetylcysteine assay were described in 
chapter 2. 
3.2.4. Drug preparation and administration for functional outcomes study 
Both NAC and probenecid dosing solutions were prepared in NaOH and adjusted to an 
approximate pH of 7.4 and sodium content of about 0.9%. According to a priori block 
randomization scheme, each of the CCI and sham groups were divided into four groups: 
CCI+NAC+Probenecid (n=11), CCI+NAC+vehicle1 (n=10), CCI+Probenecid+vehicle2 (n=10), 
CCI+vehicle1+vehicle2 (n=10), Sham+NAC+Probenecid (n=5), Sham+NAC+vehicle1 (n=5), 
Sham+Probenecid+vehicle2 (n=5) and Sham+vehicle1+vehicle2 (n=5). Drugs and/or vehicles 
were administered together intraperitoneally at 15 minutes, 1h, 12h, 24h, 36h and 48h after 
injury. Due to the short half-life of NAC, a dose of NAC (or vehicle 2) was also given at 4h. 
Doses of NAC and probenecid were 163 mg/kg and 150 mg/kg, respectively. Vehicle1 and 
vehicle2 were normal saline solutions.  Equivalent dosing solution volumes (on a per kg weight 
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of rat basis) and sodium concentrations of all treatments were used to ensure equivalent fluid 
status and to maintain blinding. 
3.2.5. Motor function test  
Motor function was evaluated using the beam balance and inclined plane tests on days 1–5 after 
CCI or sham injury[2, 3], and similar to measures associated with adult motor function post-
injury[4-9];  however, slightly modified to accommodate for reduced size of pediatric rat pups. 
The beam balance task consisted of three trials per day (days 1-5 post-injury), placing the rat on 
an elevated narrow beam (1.2 cm wide) and recording the time it remained on the beam, for a 
maximum of 60sec/trial, were recorded and use for statistical analysis. The incline plane task 
(days 1-5 post-injury) consisted of an adjustable angled surface, which began at 45o to horizontal 
and progressed at 5o increments to a maximum of 80o to horizontal. Three 10 sec trials per angle 
were measured (pass/fail). Three failures to complete 10 sec on a single angle resulted in the 
completion of the task for that day and marked as the maximum angle achieved.  The maximum 
angle achieved each day was used for statistical analysis. Training was conducted for both the 
beam balance and incline plane task prior to surgery. Rat pups were able to achieve criterion, i.e. 
three consecutive 60 sec trials on the beam balance, and a maximum angle of 70o. Immediately 
prior to surgery baseline measures of motor ability were collected. 
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3.2.6. Spatial learning test 
Spatial learning was assessed in a Morris water maze (MWM)[1, 2, 5, 6, 8, 10], which is 
sensitive to cognitive function/dysfunction after TBI[11-13]. Briefly, the maze consisted of a 
plastic pool (180 cm diameter, 60 cm high) filled with tap water (26±1°C) to a depth of 28 cm, 
and was situated in a room with visual cues that remained constant throughout the study. The 
platform was a clear acrylic glass stand (10 cm diameter, 26 cm high), that was positioned 26 cm 
from the maze wall in the southwest quadrant and held constant for each rat. Spatial learning 
acquisition began on postoperative day 11, and consisted of providing a block of four daily trials 
(4-min inter-trial interval) for 5 consecutive days (11−15) to locate the platform when it was 
submerged 2 cm below the water's surface (i.e., invisible to the rat). For each daily block of trials 
the rats were placed in the pool facing the wall at each of the four possible start locations (north, 
east, south, and west quadrants) in a randomized manner. Each trial lasted until the rat climbed 
onto the platform or until 120 sec had elapsed, whichever occurred first. Rats that failed to locate 
the goal within the allotted time were manually guided to it. All rats remained on the platform for 
30 sec before being placed in a heated incubator between trials. The times of the four daily trials 
for each rat were averaged and used in the statistical analyses. The data were obtained using 
ANYMAZE (Stoelting, Wood Dale, IL).  
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3.2.7. Memory Retention Test   
One day after the final acquisition training session in the MWM (i.e., day 16), all rats were given 
a single probe trial to measure memory retention. During this trial, the platform was removed 
from the pool, and the rats were placed in the maze from the location point most distal to the 
southwest quadrant (i.e., the ‘‘target quadrant’’ where the platform was previously located) and 
allowed to freely explore the pool for 30 sec and the percent time spent in the target quadrant 
was recorded. The data were obtained using ANYMAZE (Stoelting, Wood Dale, IL) to record 
the search areas relative to time, i.e. percent time in the target quadrant. 
 
3.2.8. Histology, cortical lesion volume.   
Cortical lesion volumes (mm3) were determined by first calculating the area of the lesion (mm2) 
by outlining the inferred area of missing cortical tissue for each section taken at 1-mm intervals 
(MCID software; Imagining Research, Ontario, Canada), and then multiplying the distance 
between each section (1 mm) by the sum of the lesion area obtained from each section. 
 
3.2.9. Histology, hippocampal neurons survival 
An observer blinded to experimental conditions analyzed one coronal section underlying the area 
of contusion (-3.5 mm posterior to Bregma) from each rat in all groups for determination of 
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treatment efficacy on selectively vulnerable hippocampal CA1 and CA3 neurons. To reduce 
counting errors associated with false positive identification of dying neurons, only 
morphologically intact neurons (i.e., those with a clearly defined cell body and nucleus) were 
counted using a Nikon Eclipse i90 microscope (Nikon Corporation, Tokyo, Japan) with a 40X 
objective. Thus, neurons partially seen due to the level of sectioning were not included. All data 
are reported as the percent of total neurons in the ipsilateral (injured) CA1 and CA3 regions 
relative to the contralateral hippocampus. 
 
3.2.10. Statistical analysis 
A two-tailed Student’s t-test was used for two group comparison. Statistical significance among 
more than two groups was determined by analysis of variance (ANOVA), followed by the Tukey 
post hoc test for multiple comparisons.  A p value less than 0.05 was considered as statistically 
significant. 
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3.3. Results  
3.3.1. Probenecid increases the brain and plasma levels of NAC after CCI 
First, the concentration of probenecid that can be achieved with the chosen dose and route of 
administration was assessed and compared to the Ki of probenecid for various transporters. One 
hour after administering a single dose of 150mg/kg probenecid via intraperitoneal route, 
concentrations of 51.23 ± 12.99 µg/g wet brain tissue and 52.69 ± 3.73 µg/g of wet brain tissue 
were achieved in the contralateral (uninjured) and ipsilateral (injured) hemispheres respectively, 
and the plasma level was 313.3 ± 12.99 µg/mL. Next, In order to determine if probenecid 
increases the plasma and brain levels of NAC in rats after CCI, NAC plasma and brain levels 
were measured 60 minutes after injection of NAC (and 75 minutes after CCI) in the presence or 
absence of probenecid. Figure 7A shows that co-administration of probenecid increased NAC 
plasma levels 1.76-fold (59.01 ± 7.5 to 10.41 ± 11.1 µg/mL; n = 5-6/group, p < 0.0001) at 1 h. 
When given alone, the concentration of NAC was higher in the ipsilateral (injured) hemisphere 
as compared to the contralateral (uninjured) hemisphere (496.6 ± 186.2  vs 83.9 ± 34  ng/g of 
wet brain tissue, n = 5-6/group, p < 0.05  ). Co-administration of probenecid significantly 
increased brain concentration of NAC by 2 fold in the ipsilateral hemisphere (496.6 ± 186.2 to 
1004 ± 293.6 ng/g of wet brain tissue, n = 5-6/group, p = 0.0088) and by 3 fold in the 
contralateral hemisphere (83.9 ± 34 to 254.0 ± 22.76 ng/g of wet brain tissue; n = 5-6/group, p < 
0.0001) (Figure 7B and 7C). 
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Figure 7. Brain and plasma exposure of NAC after controlled cortical impact (CCI) in the 
presence or absence of probenecid. 
 
 
 
 
3.3.2. Motor performance 
Prior to surgery, animals in all groups were able to balance on the beam for the allotted 60 sec on 
each of three trials (Figure 8A). Two-way, repeat measure ANOVA analysis of the sham groups 
only shows following surgery, there was a significant Treatment (F3,16 = 4.30; p < 0.05) and 
Time (F5,80 = 21.26; p < 0.0001) effects, and interaction between Treatment and Time (F15,80 
= 3.91; p < 0.0001; Figure 8A). Bonferroni multiple comparison post tests reveal that at Day 1 
Following CCI, administration of probenecid (150mg/kg) resulted in increased plasma (1.76 
fold, panel A) and brain levels (panel B, 2 fold in ipsilateral and 3 fold in contralateral 
hemispheres) of NAC as compared when NAC was administered alone (163mg/kg). n = 5-
6/group, p<0.0001). NAC = n-acetylcysteine, PB=probenecid. 
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two of the sham groups (i.e., Sham+NAC+Probenecid and Sham+Probenecid+vehicle2) showed 
slight but statistically significant impairment compared to each of the other sham groups, 
Sham+NAC+vehicle1 or Sham+vehicle1+vehicle2 on day 1 (p < 0.001 for all comparisons) . 
However, the impairment was resolved on day 2. Figure 8B shows that all TBI groups showed 
statistically significant impairment on days 1 and 2.  However, two of the TBI groups, 
CCI+Probenecid+vehicle2 and CCI+NAC+Probenecid, showed worse impairment as compared 
to the CCI+vehicle1+vehicle2 group which was statistically significant on day 1 (p < 0.001 vs 
CCI+NAC+Probenecid; p < 0.01 vs CCI+Probenecid+vehicle2) but not on day2. All TBI groups 
showed slight impairment on day 3 which was not statistically significant, and their motor 
function returned to baseline starting on day 4. 
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Figure 8. Assessment of the ability of rats to maintain balance on elevated narrow beam before 
and after CCI or Sham surgery, and drug treatment. 3-A shows sham groups only. 3-B shows all 
groups.  
In the Shams only groups, the presence of probenecid lead to significant motor impairment (p < 0.05) 
in day that was resolved in day 2 (A). Compared to shams, all CCI groups showed significant 
impairment on days 1 and 2 (B). Two of the TBI groups, CCI+PB+vehicle2 and CCI+NAC+PB, 
showed more impairment as compared to the other TBI groups, which was statistically significant on 
day 1 (p < 0.05) but not on day2. CCI, n=10-11 per treatment group. Sham surgery, n=5 per treatment 
group. NAC = n-acetylcysteine, PB=probenecid. 
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3.3.3. Acquisition of spatial learning 
Analysis of the water maze data revealed that all animals acquired spatial learning ability as it 
took them progressively shortened latencies to locate the hidden platform (Two-way, RM-
ANOVA analysis, significant Day differences, F5,280 = 64.36, p < 0.0001; Figure 3.3). The 
analysis also shows that there is significant Group differences (F4,56 = 12.07, p < 0.0001; Figure 
9). Bonferroni multiple comparison analysis revealed that the group difference was due to the 
Sham group learning to locate the hidden platform faster than each of the CCI groups except the 
CCI+NAC+vehicle group (for at least 2 days out of total 6 days of testing, p < 0.05). There was 
not Group x Day interaction (F20,280 = 1.21, p > 0.05). Analysis of the visible platform 
performance task reveals a significant group difference as the SHAM group took significantly 
less time to locate the platform than each of the CCI groups (F4,57 = 7.204, p < 0.05). The CCI 
groups didn’t differ in terms of performance from one another 
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Figure 9. Evaluation of time to locate hidden and visible platform in a water maze. 
Analysis of the MWM, hidden platform trial data shows a significant difference among groups (F4,56 
= 12.07, p < 0.0001). Bonferroni multiple comparison analysis revealed that the group difference was 
due to the Sham group performing better than each of the CCI groups except the CCI+NAC+vehicle 
group (p < 0.05). CCI, n=10-11 per treatment group. Sham surgery, n=5 per treatment group. NAC = 
n-acetylcysteine, PB=probenecid. 
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3.3.4. Memory Retention. 
Spatial memory retention was determined by single probe trial where the time the rats spent the 
target quadrant is measured. Analysis of the single probe trial data shows a significant difference 
among groups (F4,57 = 3.269, p < 0.05) which after post-hoc analysis was found to be due to the 
SHAM group performing better than the CCI+NAC+Probenecid (p < 0.05) and 
CCI+Probenecid+vehicle (p < 0.05). The CCI+NAC+vehicle group performed better than any of 
the other CCI groups, but the difference didn’t reach significant level against any of the groups. 
 
 
 
 
 
 
Figure 10. Evaluation of percentage of time spent in the quadrant where the platform was 
previously located. 
Sham group performed better as compared to the CCI+NAC+PB (p < 0.05) and 
CCI+PB+vehicle (p < 0.05). In both MWM tests, the CCI+NAC+vehicle group performed 
better than any of the other CCI groups, but the difference did not reach significance after a 
single trial 16 days after CCI or Sham surgery. CCI, n=10-11 per treatment group. Sham 
surgery, n=5 per treatment group. NAC, N-acetylcysteine; PB, Probenecid. 
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3.3.5. Tissue loss volume. 
Analysis of tissue volume loss after injury showed that probenecid and n-acetylcysteine, when 
given alone, didn’t result in improvement of tissue loss as compared to those treated with vehicle 
only. When given in combination, probenecid and n-acetylcysteine, attenuated tissue loss in 
significant manner (Figure 11, 59±3.5 mm3 vs 80±4.5 mm3, p < 0.05).  
 
 
 
 
 
 
 
  
Figure 11. Tissue volume loss  
Treatment with a combination of probenecid and n-acetylcysteine resulted in significant attenuation 
of tissue volume loss after CCI (p<0.05). CCI, n=10-11 per treatment group. Sham surgery, n=5 per 
treatment group. NAC = n-acetylcysteine, PB=probenecid. 
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3.3.6. Hippocampal neuronal survival.  
As shown in Figure 12, as compared to sham groups, each of the injury groups demonstrate 
decreased neuronal survival in both CA1 and CA3 regions of the hippocampus (p<0.05). 
However, there was not difference among each of the injury groups indicating that treatment 
with either probenecid or n-acetylcysteine, alone or in combination, didn’t improve neuronal 
survival in the hippocampus (p>0.05).  
 
 
 
 
 
Figure 12. Hippocampal neuronal survival analysis 
No treatment benefit was observed in hippocampal neuronal survival when probenecid or n-
acetylcysteine were given alone or in combination (p>0.05). CCI, n=10-11 per treatment group. 
Sham surgery, n=5 per treatment group. NAC = n-acetylcysteine, PB=probenecid 
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3.4. Discussion 
In this study we assessed the capacity of a combination therapy strategy involving the transporter 
inhibitor probenecid and the antioxidant n-acetylcysteine to attenuate oxidative stress thereby 
improving histological and functional outcomes in pediatric rat model of TBI.  
 
Over the past thirty years, oxidative stress has been studied intensity as one of the main TBI 
injury mechanisms [198, 199]. It was a target of numerous therapeutic interventions, albeit with 
no clinical efficacy reported to date. Limited penetration of antioxidant drug candidates has been 
attributed as one of the reasons for failure of TBI clinical trials [7]. In this study, we 
demonstrated that probenecid can increase the delivery of n-acetylcysteine into the brain in CCI 
model of pediatric TBI rats. First, we showed that a single dose of 150mg/kg probenecid via 
intraperitoneal route can achieve concentrations of 51.23 ± 12.99 µg/g of wet brain tissue and 
52.69 ± 3.73 µg/g of wet brain tissue in the contralateral and ipsilateral hemispheres respectively. 
The plasma level was 313.3 ± 12.99 µg/mL. The concentrations achieved in all cases were at 
least twice the Ki of probenecid for several transporters which ranges 0.5-30 µg/mL [232, 244-
247]. Next, we showed that the n-acetylcysteine penetration into the brain was increased 2-3 fold 
by probenecid as early as 1h after injury. The findings in this chapter corroborate what we 
observed in naïve pediatric rats in the Chapter two of this dissertation. The mechanism behind 
the effect of probenecid on systemic and brain pharmacokinetics of n-acetylcysteine is discussed 
in detail in Chapter two. It involves inhibiting OAT1, OAT3 and/or MRP transporters in renal 
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tubules, BBB and choroid plexus. This finding highlights the therapeutic potential of inhibiting 
transporters in order to enhance brain penetration of candidate drugs for TBI.  
 
Another major reason for failure of TBI clinical trials of drugs targeting oxidative stress is the 
notion that a single agent can’t match the complex and multiple ways oxidative stress propagates 
before eventually leading to neuronal injury and death [7, 207, 218]. In this study, we utilize 
probenecid to, not only increase brain levels of n-acetylcysteine, but also to preserve the brain 
levels of the major endogenous antioxidant, glutathione, which is depleted following TBI [201, 
248]. Since n-acetylcysteine is antioxidant on itself, and a precursor to glutathione, the 
combination of n-acetylcysteine and probenecid could have a synergistic effect in countering 
oxidative stress in TBI. We assessed this therapeutic strategy in rat CCI model of pediatric TBI. 
 
 In the motor function test, we observed that administration of probenecid, alone or in 
combination of probenecid, causes temporary impairment of motor function in both SHAM 
groups and CCI groups (Figure 8). The clinical relevance of this transient effect is unclear. On 
one hand, if the adverse effect of probenecid in limited to motor deficit, given most sever TBI 
patients are bed-ridden in the few days after injury, the clinical implication of this finding will 
also be limited. Admittedly, it is difficult to specifically measure motor function immediately 
after injury, however, in the phase-I safety clinical study of a combination of probenecid and n-
acetylcysteine in pediatric severe TBI patients, no indications of motor deficit were observed 
[249]. On the other hand, if the transient motor deficit observed with administration of 
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probenecid is related to or is an indication of long-term functional outcomes, the clinical 
consequence will be significant. Either way, more preclinical study to establish the mechanism 
of this adverse effect of probenecid in TBI should be conducted. 
 
In cognitive assessment, n-acetylcysteine, when given alone, attenuated both spatial learning and 
memory retention deficits but the improvements versus CCI groups (i.e., placebo group or the 
other treatment groups) did not reach statistical significance. However, the performance of the n-
acetylcysteine treated group was also not statistically different from that of the SHAM injured 
group (Figure 9). Interestingly, the mean scores in both tests for probenecid only treated group 
was the worst compared to all the other groups. Also, the mitigating effects observed with n-
acetylcysteine only group was not observed with the probenecid and n-acetylcysteine treated 
group although probenecid is expected to enhance the brain penetration of n-acetylcysteine. This 
suggests that the adverse effects of probenecid may be negating any potential beneficial effects 
of n-acetylcysteine.  
 
A recent review has evaluated the efficacy of n-acetylcysteine and its analogs in clinical and 
preclinical studies of TBI [250]. The review concluded that the lack of well-designed and 
controlled clinical studies made the proper evaluation of effectiveness of n-acetylcysteine in 
human TBI patients impossible based off the currently completed studies. In animal models, 
however, the study which reviewed 20 preclinical studies,  found overall strong effect of n-
acetylcysteine and its analogues in improving neurological functional outcomes and attenuating 
88 
 
 
various inflammatory and oxidative stress markers in brain tissues. Differences in animal 
models, routes of administration, injury types and assessment methods make it difficult to assess 
dose-effect relations from the past experiments and our experiment. However, the overall strong 
signal of effectiveness n-acetylcysteine in TIB observed warrants continued examination of n-
acetylcysteine alone or in combination in TBI with higher doses. Risk of adverse effects of 
higher doses of n-acetylcysteine also appear to be minimal since no safety concerns were raised 
by both clinical and preclinical studies [250].  
 
Interestingly, although undesirable in the context of current objectives of the therapeutic 
intervention, the adverse effects observed with probenecid is highly suggestive of potentially 
important role that membrane transporters inhibited by probenecid, including OAT1, OAT3, 
OATP1B3 and MRPs [232, 244-247, 251], play in re-gaining homeostasis after brain injury.  
 
In histological assessment, rats treated with n-acetylcysteine in combination of probenecid 
showed modest improvement in tissue volume loss that was statistically significant (Figure 11). 
No treatment benefit was observed in hippocampal neuronal survival either drug alone or in 
combination (Figure 12).  
The main limitation of the study was that it didn’t incorporate multiple doses of n-acetylcysteine 
and probenecid to establish dose-effect relationship for both drugs. With regards to n-
acetylcysteine, higher or more frequent dose would have helped assess whether the spatial 
learning and memory deficit attenuation of observed with the given dose is a true effect, in that 
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these effects would have reached statistical significance. Similarly, study design with multiple 
doses of probenecid in both the pharmacokinetic and function outcomes studies would have 
allowed thorough evaluation of the capacity of probenecid to increase levels of n-acetylcysteine 
without adverse effects. Given the levels of probenecid achieved with the dose used in this study 
are significantly higher than the Ki of probenecid of most transporters [232, 244-247, 251], it is 
possible that significant increase of level of n-acetylcysteine could be achieved even with lower 
doses of probenecid.  
 
In conclusion, in this study we found that, following experimental TBI, at the given dosage 
regime, n-acetylcysteine appears to attenuating spatial learning and memory retention deficits 
that didn’t reach statistical significance. Probenecid seems to cause acute motor deficit, and the 
combination of n-acetylcysteine and probenecid improved tissue volume loss. However, 
probenecid increased plasma and brain levels of n-acetylcysteine significantly. Hence, a 
combination of n-acetylcysteine and probenecid with dose regimen optimization of both drugs to 
enhance the beneficial effects of NAC and minimize the adverse effects of PB should be pursued 
as therapeutic strategy in TBI.  
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4. Neuropharmacometabolomics of Treatment Response of a Combination of 
Probenecid and N-Acetylcysteine in Traumatic Brain Injury 
4.1. Introduction  
The biochemical milieu of the CNS is dynamic and tightly regulated, and can be explored in 
exquisite detail using metabolomics [252]. Recently, metabolomics has been used to evaluate 
biochemical responses and identify relevant metabolic pathways in CNS disease [253]. However, 
to-date the metabolomics profile after TBI—an important cause of mortality and morbidity in 
humans [254]—has not been investigated [255]. In TBI, the primary impact onto the brain and/or 
disruption of brain tissue is followed by a set of secondary biochemical processes including a 
surge in excitatory amino acids, glycolysis, oxidative stress, and mitochondrial dysfunction 
[256]. Given that CSF provides a window into the CNS, evaluation of the metabolomics profile 
in CSF after TBI and identification of prominent biochemical pathways altered in response to 
injury, could uncover new and validate suspected pathophysiologic mechanisms in humans, and 
define clinically relevant therapeutic targets. In addition to establishing the metabolomics 
signature of TBI, evaluation of CSF metabolites could also be used to determine in detail the 
holistic effects of pharmacotherapies, such as target engagement or potential toxicity. 
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While there are many regulators of the biochemical milieu of the brain at the BBB and blood-
CSF barriers, membrane transporters such as ABC and SLC transporters such as organic anion 
transporters (OAT) are particularly important in terms of brain bioavailability of clinically used 
drugs, especially those that are lipophilic and do not readily cross the BBB. Probenecid is a 
promiscuous SLC and ABC transporter inhibitor that has been used to identify CSF elimination 
pathways for endogenous organic acids and monoamines such as homovanillic acid and 
serotonin [257], and exogenous drugs such as methotrexate [258]) and N-acetylcysteine [242].  
 
We recently reported the repurposed use of probenecid and NAC in a randomized, placebo-
controlled phase I trial (Pro-NAC I) after severe TBI in children [160, 249] to capitalize on this 
drug interaction. As part of the Pro-NAC I trial, CSF was collected for pharmacokinetic 
assessment of probenecid and NAC, providing an opportunity for a “pharmacometabolomics” 
interrogation of the CNS. Accordingly, the purpose of the present study was twofold, to evaluate 
metabolomic changes in human TBI compared with control subjects, and to evaluate 
pharmacometabolomic changes in TBI patients treated with probenecid and NAC compared with 
placebo.  
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4.2. Materials and Methods 
4.2.1. Parent Study 
Samples for this study represent CSF obtained from patients who participated in an Institutional 
Review Board approved, randomized, double-blind, Phase I study (Trial Registration 
NCT01322009) of the combination of probenecid and NAC (n = 7) versus placebo (n = 5) in 
children 2 to 18 years-of-age after severe TBI (Glasgow Coma Scale [GCS] score ≤ 8) recruited 
from November 2011-September 2013 at a single, tertiary children’s hospital [160]. The study 
was approved by the University of Pittsburgh Institutional Review Board and informed consent 
was obtained from parents and/or legal guardians of all children enrolled in the study. Control 
CSF samples were obtained from five age-matched control subjects who underwent lumbar 
puncture to rule out meningitis.  
 
4.2.2. Sample Collection 
CSF Samples for this study were collected 41.7 hours (range 34-47.25) after injury and 24 hours 
after the first dose of probenecid (25 mg/kg) and NAC (140 mg/kg). Drugs or placebo were 
administered via naso/orogastric tube. CSF was immediately centrifuged at 3000 ×g for 10 min 
and supernatant was stored at -80°C for batch analysis. 
 
93 
 
 
4.2.3. UPLC-QTOFMS Analysis  
CSF samples were prepared by first precipitating protein by addition of acetonitrile at a 3:1 ratio 
followed by centrifugation. Five μL of supernatant was injected into ultra-performance liquid 
chromatography coupled with quadrupole time-of-flight mass spectrometry (UPLC-QTOFMS, 
Synapt G2-S Waters, Milford, MA). An Acquity UPLC BEH C18 column (2.1 × 100 mm, 1.7 
µm; Waters, Milford, MA) was used to separate metabolites. The flow rate of the mobile phase 
was 0.5 mL/min using a gradient ranging from 2% to 98% acetonitrile/water containing 0.1% 
formic acid over 12 min. The column temperature was maintained at 50°C. Time-of-flight mass 
spectrometry (TOFMS) was operated in positive and negative modes with electrospray 
ionization. The source and desolvation temperatures were set at 150°C and 500°C, respectively. 
Nitrogen was applied as cone and desolvation gas, and the gas flow rates were set as 50 L/h and 
800 L/h, respectively. Capillary and cone voltages were set at 0.8 kV and 40 V, respectively. 
TOFMS was calibrated with sodium formate and monitored by the intermittent injection of 
lockspray leucine encephalin in real-time. Mass spectrometry (MS) data were acquired in 
centroid format over a range of 50-1000 Da with an acquisition time of 0.1 sec/scan.  
 
4.2.4. Metabolomics Analysis 
The XCMS-online metabolomics platform (Scripps Research Institute, CA) was used for data 
management and analysis including feature detection, retention time correction, alignment, 
annotation, principal component analysis (PCA), statistical analysis, and data visualization [259-
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262]. Raw data files were initially converted to mzData files using ms2mz. mzData was 
uploaded to XCMS-online and the data was processed as a pair-wise experiment in positive and 
negative MS modes when comparing control subjects versus placebo-treated TBI groups, and 
when comparing placebo-treated TBI versus probenecid + NAC treated TBI groups. A multi-
group experiment setup was also used in positive and negative MS modes where the three groups 
were compared simultaneously.  
 
For data analysis with XCMS-online, the centWave method was used for feature detection with 
15 ppm m/z tolerance, minimum peak width of 2 sec and maximum peak width of 25 sec. The 
Obiwarp function was used for retention time correction. Chromatogram alignment was 
performed with mzwid (mz width) = 0.1, minfrac (minimum fraction) = 0.05, and bw  
(bandwidth) = 2. Isotopes and adducts were annotated using CAMRRA with m/z absolute error 
of 0.015 and 5 ppm. Selection and filtering of metabolite features for inclusion in 
pathway/network analysis were done based on fold change ≥ 1.5 and p-value ≥ 0.01 based on 
unpaired parametric t-test (Welch t-test) when comparing only two groups, or one-way ANOVA 
with Tukey’s post-hoc test when comparing the three groups together. Metabolites were 
identified by searching the Human Metabolome Database (HMDB) and with Δppm < 10.   
 
4.2.5. Pathway and Network Analysis 
Network and pathway analyses were performed using the software Mummichog (Emory 
University, GA) which is incorporated within the XCMS-online platform [261]. The significant 
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metabolite features in the pair-wise comparisons were used as input, and the total list of features 
were used as reference. For the pathway analysis, the Mummichog software tested the 
enrichment of input metabolites against random data resampled from the reference list (in the 
background of known human metabolic pathways) and provided adjusted p-values while 
accounting for the fact that single m/z values can map to different metabolites and different m/z 
features can represent a single metabolite. Network analysis was done in a similar way to 
pathway analysis except that compounds are placed within the human metabolic network model. 
Modules, which by definition show more internal connectivity than expected randomly in the 
whole network, are identified by their connectivity. Output data from the network analysis were 
imported to Cytoscape 3.4.0 [263] to generate network visualization. Excel 2013 (Microsoft 
Corporation, WA) was used to generate cloud plots of the impacted pathways. R-Studio 1.0.136 
was used to generate volcano plots of metabolite features.  
 
4.3. Results 
 
4.3.1. Patient Characteristics 
In the parent study 14 patients were randomized into either probenecid + NAC (n = 7) or placebo 
groups (n = 7) [160]. Residual CSF was available from 12 patients collected 24 hours after the 
first drug or placebo administration, seven in the probenecid + NAC group and five in the 
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placebo group. The demographic characteristics of the study participants are summarized in 
Table 4.1.  
Table 2. Summary of Patient Characteristics 
Patient Characteristics  Control Subjects  TBI Placebo  TBI Probenecid+NAC  
N 5  5  7  
Age (years), mean (SD)  10.0 (8.9)  7.5 (5.0)  8.6 (4.9)  
Weight (Kg), mean (SD)  Unknown  26.4 (14.3)  37.9 (21.3)  
Male sex (%)  2 (40%)  2 (40%)  6 (86%)  
White race (%)  Unknown  5 (100%)  6 (86%)  
Glasgow Coma Scale score, 
median [range]  N/A  6 [4-7]  6 [4-6]  
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4.3.2. Multi-group metabolomics analysis  
Multi-group analysis was performed to compare the CSF metabolomics profiles of control 
subjects, TBI patients administered placebo, and TBI patients treated with the combination 
probenecid and NAC. Two-component PCA revealed clustering within each of the study groups 
(Figure 13), and separation between groups, demonstrating that the three groups have different 
metabolomics signatures.  
 
 
 
 
 
 
 
 
 
 
 
Figure 13. PCA analysis based on the first two components shows clustering of the three 
study groups based on their difference in metabolic profile.  
Blue = control subjects, red = TBI treated with placebo, green = TBI treated with probenecid and 
NAC .The dot size indicated values of DModX which indicates the observed distance of a 
particular individual to the principal components model. 
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As a means of internal validation, we sought to identify drugs and their metabolites uniquely 
administered to one or more groups. We specifically evaluated probenecid, as a study drug 
received only in the probenecid + NAC TBI group, and phenytoin, which was administered to 11 
of 12 TBI patients for seizure prophylaxis. Searching for either the parent drugs or metabolites of 
probenecid and phenytoin among the putative metabolites list shows matching features with 
expected differential abundance in the three different groups (Figure 14A and B). In addition, the 
peak area of probenecid determined by UPLC-QTOFMS correlated with previously quantified 
probenecid concentrations determined by UPLC-MS/MS [160, 249][158, 247](Clark, Empey et 
al. 2017, Jha, Puccio et al. 2017)[249]in individual patients treated with probenecid and NAC 
(Figure 14C; r2 = 0.76, p = 0.01).  
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Figure 14. The abundance of probenecid and phenytoin in the three study groups. 
(A) Shows that the feature in the mass spec, putatively identified as probenecid was increased in 
the treated TBI group as compared to either the placebo treated TBI group or HC 
group (***p>0.001, n=5-7). (B) Shows that phenytoin, administered as a standard of care after 
TBI to prevent seizures, increased in both TBI groups as compared to the healthy control group 
(***p>0.01, *p>0.01 n=5-7). PB = Probenecid, NAC=n-acetylcysteine, CS=Control 
Subjects. (C) Shows good correlation between peak area of probenecid determined by UPLC-
QTOFMS and previously quantified probenecid concentrations determined by UPLC-MS/MS in 
individual patients treated with probenecid and NAC (R2 = 0.76, p = 0.01). 
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4.3.3. Pair-wise analysis of control subjects vs. placebo treated TBI patients  
To identify metabolites that are altered in response to TBI, CSF samples from placebo treated 
TBI patients and control subjects were run through UPLC-QTOF MS. Retention time, ion 
fragments, and abundance were entered into XCMS-online for pair-wise comparison. The m/z-
retention time cloud plots in Figure 15 show 1010 features in the positive MS mode and 89 
features in the negative MS mode that were significantly increased or decreased based on a p-
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Cloud plots of features increased (green) or decreased (red) in TBI patients 
compared to HC in positive MS mode. 
The size of the circle corresponds to the fold change of a particular feature between the two 
groups. The intensity of the color corresponds to the p-value with more intense shades 
representing a smaller p-value.   
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value of ≤ 0.01 and fold change of ≥ 1.5. Note that the majority of features appeared to decrease 
in TBI patients vs. control subjects (red vs. green circles in the cloud plot, respectively).  
 
4.3.4. Pathway analysis of control subjects vs. placebo treated TBI patients. 
To gain insight into the molecular mechanisms underlying the pathogenesis of TBI by 
identifying previously suspected or novel biological pathways altered after TBI, we conducted a 
 
 
 
 
 
 
 
 
 
 
Figure 16. Cloud plots of features increased (green) or decreased (red) in TBI patients 
compared to HC in negative MS mode.  
The size of the circle corresponds to the fold change of a particular feature between the two 
groups. The intensity of the color corresponds to the p-value with more intense shades 
representing a smaller p-value.   
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pathway analysis of CSF metabolites in placebo treated TBI patients compared with control 
subjects. Metabolites that were significantly changed in response to TBI were enriched in six 
pathways in the positive MS mode and 17 pathways in the negative MS mode. One pathway in 
the positive MS mode and six pathways in the negative MS mode showed ≥ 50% overlap of 
significantly altered putative metabolites with known components of human biological pathways 
(Figure 17 and Table 2). 
 
Table 3. Metabolic pathways altered in TBI patients compared with control subjects 
 
 
 
 
Pathway Mode 
Overlap 
size 
Pathway 
size 
Percentage 
overlap Overlapping features 
α-tocopherol degradation + 3 6 50% 
α-tocopherol, 
13'-hydroxy-α-tocopherol 
5'-α-
carboxylmethylbutylhydroxychroman 
Lactate fermentation (re-
oxidation of cytosolic 
NADH) 
- 2 2 100% 
(S)-Lactate 
Pyruvate 
Pyrimidine 
deoxyribonucleosides 
degradation 
- 3 4 75% 
2'-deoxyuridine, 2-deoxy-α-D-ribose 
1-phosphate 
Thymidine 
Methylglyoxal 
degradation VI 
- 3 4 75% 
(R)-Lactate 
Methylglyoxal 
Pyruvate 
Spermine and spermidine 
degradation I 
- 2 3 66.7% 
3-acetamidopropanal 
N1-acetylspermidine 
Methylglyoxal 
degradation I 
- 3 5 60% 
Glutathione 
Pyruvate 
Methygyloxal 
(R)-S-Lactoylglutathione 
(R)-Lactate 
Cysteine biosynthesis/ 
homocysteine degradation 
(trans-sulfuration) 
- 2 4 50% 
2-oxobutanoate 
L-Homocysteine 
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4.3.5. Individual metabolites altered in control subjects vs. placebo treated TBI patients  
Figure 18 shows a volcano plot of metabolites in CSF in control subjects and TBI patients. 
Similar to the cloud plots in Figure 13, the majority of features appeared to decrease in TBI 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. Cloud plot of affected pathways in placebo treated TBI patients as compared to 
control subjects.  
Darker circles mean more than one pathways with the same average overlapping metabolites 
and p-value are represented. The radius of each circle represents the number of metabolites 
relative to the number of metabolites represented by other circles. 
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patients vs. control subjects. Metabolites with maximum absolute intensity ≥ 2,500, -log(p) > 3, 
and log2(fold change) > 1 were selected for possible identification. Excluding metabolites with 
poor chromatographic resolution by manual inspection yielded 41 significant features. To 
identify putative metabolites that correspond to these features, their masses were searched in the 
HMDB based on a 10 ppm error margin [264-266]. Twelve of the searched features returned 
metabolites or putative metabolites that were of dietary or exogenous drug source. The rest of the 
features yielded one or more endogenous metabolites with a previously known or biologically 
plausible association with TBI. Putative metabolites in 19 of these features corresponded to long-
chain fatty acids, which because of the known difficulty with distinguishing among analogues 
with the same m/z, were not further characterized. The final list of 10 features and their 
corresponding TBI-associated metabolites is shown in TableA1 in Appendix A. Of potential 
interest, are changes in multiple species of gangliosides, ceramide, and dipeptides in TBI patients 
relative to control subjects.  
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4.3.6. Pair-wise analysis of TBI patients receiving placebo vs. probenecid + NAC  
To elucidate the impact of probenecid and NAC treatment on the CSF metabolomics profile after 
TBI, a pair-wise comparison of placebo-treated TBI patients and combination therapy treated 
TBI patients was performed. The cloud plot in Figure 19 and Figure 20 shows that using criteria 
of a p-value ≤ 0.01 and fold change ≥ 1.5, there are 153 features in the positive mode and 296 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. Volcano plot of metabolome profiles of the CSF of placebo treated TBI patients 
as compared to control subjects in both positive and negative mass-spectrometry modes.  
Metabolites that were upregulated or downregulated by ≥ two-fold with a p-value < 0.001 are 
shown in blue. 
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features in the negative mode that were significantly different between the two groups 
respectively. Seventy-four in the positive mode and four in the negative mode were down-
regulated in the probenecid + NAC group, while 79 in the positive mode and 294 in the negative 
mode, were up-regulated.   
 
 
 
 
 
 
 
 
 
 
 
Figure 19. Cloud plots of features increased (green) or decreased (red) in TBI patients 
treated with probenecid+NAC as compared to placebo treated TBI patients in positive 
MS mode. 
The size of the circle corresponds to the fold change of a particular feature between the two 
groups. The intensity of the color corresponds to the p-value with more intense shades 
representing a smaller p-value.   
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Figure 20. Cloud plots of features increased (green) or decreased (red) in TBI patients 
treated with probenecid+NAC as compared to placebo treated TBI patients in negative MS 
mode. 
The size of the circle corresponds to the fold change of a particular feature between the two 
groups. The intensity of the color corresponds to the p-value with more intense shades 
representing a smaller p-value.   
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4.3.7. Pathway analysis of TBI patients receiving placebo vs. probenecid + NAC  
Pathway analysis was performed to identify biochemical processes modified by the combination 
therapy of probenecid and NAC after TBI, which could yield insight into the mechanism of 
action of these repurposed drugs as well as any potential undesirable biochemical effects after 
TBI. In the positive MS mode, a total of 77 pathways were found to be enriched in the 
metabolites that were differentially dysregulated between the two groups, with 45 pathways 
showing ≥ 50% overlap between putative metabolites with a known component of the particular 
pathway (Figure 21 and TableA2 in Appendix A). In the negative MS mode, a total of 47 
pathways were found to be significantly dysregulated, with eight pathways showing ≥ 50% 
overlap between putative metabolites (Figure 21 and TableA2 in Appendix A).  
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Figure 21. Cloud plot of select pathways affected by treatment with probenecid and NAC 
vs. placebo in TBI patients, identified by metabolomics analysis of CSF. 
The radius of each circle increases with the number of metabolites relative to the number of 
metabolites represented by other circles. 
110 
 
 
4.3.8. Network analysis of TBI patients receiving placebo vs. probenecid + NAC  
Network analysis identified five modules that are significantly affected by probenecid + NAC 
treatment in the positive MS mode and four modules in the negative MS mode. Modules 
represent internal connectivity more than what is expected randomly in the whole network. The 
complete list of modules and the putative metabolites that constitute the modules are in Table A4 
(for positive MS mode) and Table A3 (for negative MS mode) in Appendix A. It is possible that 
a bigger module consist of smaller modules that are also identified independently. For example, 
in the negative MS mode analysis, modules 2 and 3 are identified independently but are also part 
of module 1. Similarly, in the positive MS mode, module 1 comprises of modules 2, 3, and 4.  
 
Notable features of these modules include module 3 in the negative MS mode where glutathione 
and its conjugates are upregulated (Figure 22A). Similarly, module 5 in the positive MS mode 
(Figure 23B) shows glutathione in dynamic interaction among glutathione conjugates and 
reactive molecules detoxified by glutathione. Module 4 in the negative MS mode (Figure 22B) 
shows upregulation of sulfate donors in sulfate conjugation process and two metabolites with 
sulfate conjugation characteristics that are confirmed substrates of probenecid-inhibitable 
transporters [267]. A segment of module 1 in the positive MS mode (Figure 23D) shows a 
collective downregulation of prostaglandins which are also known to be substrates of a number 
of transporters inhibited by probenecid [268]. Module 2, which is also a component of the bigger 
module 1, in the positive MS mode is centered around 2-ketoglutarate which is closely related to 
the OATs, which are the main transporters inhibited by probenecid (Figure 23A). Also, some 
members of module 2 such as kynurenic acid, 3-hydroxykynurenine and dipeptides are substrates 
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of OAT transporters [269-272]. Another interesting feature of module 1 is the distinctive up-
regulation of UDP-conjugated monosaccharides, i.e., nucleotide sugars, UDP-alpha-D-galactose 
and UDP-alpha-D-galactose, and the down-regulation of their interacting counterparts, 
acetylated sugar moieties (Figure 23C). The transporters responsible for the translocation of the 
sugar nucleotides are known to be sensitive to inhibition by probenecid [270, 273].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22. Network connectivity of representative modules in negative MS mode 
enriched in probencid+n-acetylcystiene treated TBI patients.  
In module 4 (A), the module shows upregulation of glutathione and a number of its 
conjugates and connectivity between NADP-dependent pathways are highlighted. In module 
3 (B), the module shows upregulation of sulfate donors in the sulfate conjugation process, and 
two sulfate-conjugated metabolites that are confirmed substrates of probenecid-inhibitable 
transporters. Red nodes are upregulated while the blue nodes are downregulated relative to 
other nodes within individual mode. The color intensity indicates the extent of upregulation or 
downregulation. 
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Figure 23. Network connectivity of representative modules in positive MS mode enriched 
in probencid+n-acetylcystiene treated TBI patients.  
(A) Module 2, alterations in pathways centered around 2-ketoglutarete. (B) Module 5, 
glutathione in dynamic interaction among glutathione conjugates and reactive molecules 
detoxified by glutathione.  (C) Segment of module 1, upregulation of UDP-conjugated 
monosaccharides and downregulation of their counterparts, acetylated sugar moieties. (D) 
Segment of module 1 showing collective downregulation of prostaglandins. Red nodes are 
upregulated while the blue nodes are downregulated relative to other nodes within individual 
mode. The color intensity indicates the extent of upregulation or downregulation. 
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4.3.9. Individual metabolites altered in TBI patients receiving placebo vs. probenecid + n-
acetylcysteine 
Figure 24 shows a volcano plot of metabolites in CSF from TBI patients that received placebo or 
probenecid + NAC. Similar to the cloud plots in Figure 6, the majority of features appeared to 
increase in TBI patients treated with probenecid and NAC vs. placebo. Metabolites with 
maximum absolute intensity ≥ 2,500, -log(p) > 2.3, and log2(fold change) > 1 were selected for 
possible identification. Excluding metabolites with poor chromatographic resolution by manual 
inspection yielded 67 significant features. To identify putative metabolites that correspond to 
these features, their masses were searched in the HMDB based on a 10 ppm error margin [264-
266]. Forty-two of the searched features returned metabolites or putative metabolites that were of 
dietary or exogenous drug source, leaving 25 metabolites that may be affected by probenecid + 
NAC treatment after TBI (TablesA5 in Appendix A). Probenecid is one of the metabolites that 
are highly upregulated confirming the TBI group assignment and validating the XCMS-online 
platform’s capacity to discriminate patients based on their metabolic signature. Glutathione was 
also increased in probenecid + NAC treated patients vs. placebo, consistent with drug 
combination target engagement. 
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4.4. Discussion 
To our knowledge, this is the first study to perform a comprehensive LC-MS based 
metabolomics analysis of TBI patients. This study is also the first clinical application of 
“neuropharmacometabolomics” after administration of potentially therapeutic drugs, including 
one with known impact on the biochemical milieu of the CSF, probenecid [257, 258]. PCA 
analysis shows that patients cluster into their respective groups (control subjects, TBI placebo, 
TBI probenecid + NAC) based on the unique signature of their metabolomics profile in the CSF 
 
Figure 24. Volcano plot of metabolome profiles of the CSF of TBI patients treated with 
placebo or a combination of PB and NAC in both positive and negative MS modes.  
Metabolites that are upregulated or downregulated by two fold or more with a significance p 
value of 0.005 (blue dots) are selected for further investigation. 
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(Figure 1), validating the metabolomics approach. We focused on pathway and network analysis 
of the metabolomics data, leveraging recent advances that enable exploration of metabolomics 
data without exhaustive verification of individual metabolites [261]. Advantages of pathway and 
network analyses in terms of gaining insight into biological systems over analysis at the 
individual metabolite or gene level have been described previously [274], and include increasing 
statistical power by consolidating multiple metabolites into a smaller number of pathways and 
networks. Pathway and network analyses allow for interpretation of altered processes rather than 
metabolites, provide a framework for quantitative modeling based on experimental observations, 
and assist in identifying potential causal mechanisms. Pathway analysis revealed novel 
biochemical processes associated with TBI, while also confirming others with a previously 
known role. Treatment with probenecid and NAC resulted in a significant alteration in the 
metabolomic signature of TBI, with the majority of features showing relative increases compared 
with placebo (Figures 6 and 9). Importantly, relative glutathione levels were increased 665-fold 
(Table 5) and both pathway and network analyses showed that biochemical processes involving 
detoxification with glutathione and glutathione recycling were enriched in the probenecid + NAC 
treated group (Figures 7 and 8), verifying target engagement of at least one of the components of 
the combination therapy. Furthermore, a number of modules and pathways with components 
known to be substrates of transporters inhibited by probenecid were identified, providing insight 
into the pharmacological actions of probenecid. These data validate the anticipated effects of the 
probenecid and NAC treatment and demonstrate the value in pathway-based metabolomics 
analysis. 
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Comparing the TBI placebo-treated patients with the control subjects revealed several 
biochemical pathways that were activated in TBI. Previous studies have reported TBI-related 
catabolism of various types of small molecules such as amino acids, catecholamines, hormones, 
and polyamines. All or several components of a number of these molecular pathways were 
amplified in the TBI group. These include: tyrosine degradation, noradrenaline and adrenaline 
degradation, spermine and spermidine degradation I, nicotine degradation IV, thyroid hormone 
metabolism II via conjugation and/or degradation, and L-carnitine biosynthesis. Other pathways 
found to be enriched that are implicated in the pathophysiology of TBI include oxidative stress 
(alpha-tecopherol degradation, ubiquinol-10 biosynthesis), bioenergetics (lactate fermentation 
pathway), lipid peroxidation (leukotriene biosynthesis, resolvin-D biosynthesis), and heme 
metabolism (tetrapyrrole biosynthesis and heme biosynthesis from uroporphyrinogen-III I). 
Cystathionine-β-synthase, which catalyzes the first step in the transulfuration of homocysteine to 
cystathionine, plays a critical role in a variety of physiological processes of the CNS, has also 
been reported to mediate a number of pathological processes after TBI [275]. Furthermore, two 
pathways, cysteine biosynthesis/homocysteine degradation and hydrogen sulfide biosynthesis, 
were also found to be upregulated.  
 
Some of the enriched pathways uncovered have not been associated with TBI previously, e.g. 
morphine biosynthesis. Endogenous morphine biosynthesis by human neuroblastoma cells has 
been reported [276, 277], and the activation of this pathway in TBI patients may indicate a role 
in pain modulation after injury. Two methylglyoxal-related pathways were found to be 
upregulated in the CSF of TBI patients, indicating potential involvement of methoglyoxal in 
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TBI. Methylglyoxal, a potentially toxic byproduct of glycolysis, threonine catabolism, and lipid 
peroxidation has been implicated in models of cerebral ischemia in vivo and in vitro [278, 279], 
but its involvement in TBI is undefined. Also in the present study, pathways related to purine and 
pyrimidine metabolism were enriched, namely pyrimidine deoxyribonucleoside salvage and 
degradation, and purine ribonucleoside degradation. Purine and pyrimidine nucleotides and 
nucleosides mediate activation of astrocytes and other glia, described before in relation to acute 
and chronic neuroinflammation [280].  
 
Treatment with a combination of probenecid and NAC resulted in significant changes in the 
metabolomics signature of TBI, as detected in the CSF. Pathway and network analyses revealed 
over 80 pathways and nine modules, respectively, that were dysregulated in the treatment group 
vs. placebo. Interestingly, seven pathways that involve glutathione as a component of 
detoxification processes were enhanced in the treatment group: glutathione redox reactions I, 
glutathione redox reaction II, 4-hydroy-2-nonenal detoxification, methylglyoxal degradation I, 
ascorbate recycling, arsenate detoxification, and formaldehyde oxidation. These observations 
were congruent with the network analysis, with glutathione-centered modules prominently 
featuring in both negative and positive MS modes. These findings are important as they serve as 
internal validation for the metabolomics-based pathway and network, given that probenecid and 
NAC can increase intracellular glutathione via two distinct mechanisms, preventing cellular 
efflux of glutathione disulfide (GSSG) and glutathionylated xenobiotics and serving as cysteine 
donor for glutathione synthesis, respectively. Furthermore, NAC is a substrate for probenecid 
inhibitable OAT1 and OAT3 providing additional drug synergy [242]. Collectively, our findings 
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indicate that, as hypothesized, a combination of probenecid and NAC modulate levels of 
glutathione and its conjugates, strongly implicating target engagement. 
 
Other prominent pathways changed by treatment represent biochemical processes such as purine 
and pyrimidine nucleotide and nucleoside metabolism; catabolism, salvage and biosynthesis of 
amino acids; cathecolamines; co-factors; hormones; peptides and polyamines; oxidation, 
degradation and biosynthesis of fatty acids and other lipids; and glycolysis and aerobic cellular 
respiration. This suggests that many substrates, intermediates, and end products of biochemical 
pathways and/or signaling molecules may be substrates of transporters inhibited by probenecid. 
Some components of the enriched pathways and modules such as urate (urea cycle and urate 
biosynthesis pathways [281], kynurenate and xanthurenate (tryptophan degradation via 
tryptamine), indoxyl sulfate (module 4 in negative MS mode) [269, 270],  cyclic nucleotides 
(several pathways and modules) [282], and prostaglandins (module 1 in positive MS mode) [268] 
are trafficked by transporters that are inhibited by probenecid. Additionally, one of the biggest 
modules identified by network analysis is centered around 2-ketoglutarate. 2-Ketoglutarate is 
intimately related to the mechanism of transport of organic anions by the family of OAT 
transporters, acting as a gradient exchanger. As such, its intra and extracellular levels are 
expected to change in presence of modulators of OAT transporters [283].  
 
Many alterations in the biochemical milieu observed in probenecid and NAC treated compared 
with placebo treated TBI patients can be explained by the known properties of probenecid. Some 
of these changes, such as increased abundance of kynurenine may be beneficial after TBI, as 
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kynurenine is considered neuroprotective and in fact had been studied in combination with 
probenecid to attenuate seizures, quinolinic acid-induced neurotoxicity, and neuropathic pain 
[284-286]. Other effects, such as increased abundance of indoxyl sulfate may represent 
undesirable effects – indoxyl sulfate, a uremic toxin, has been linked with CNS toxicity in 
patients with impaired kidney function [287].  
 
We also sought to tentatively identify individual metabolites significantly altered in TBI patients 
vs. control subjects, as well as probenecid + NAC vs. placebo treated TBI patients. Initial 
screening yielded ten features in CSF that distinguished TBI patients from control subjects. 
Subsequent querying of the human metabolome database showed that gangliosides appear as 
putative metabolites in four out of ten features. This is consistent with a previously reported role 
for gangliosides in TBI [26, 288]. Comparing placebo and probenecid + NAC treated TBI 
patients, after initial screening and excluding non-endogenous metabolites, yielded 24 putative 
metabolites. Congruent with pathway and network analyses, glutathione and its conjugates were 
commonly featured. Other molecules included dipeptides, nucleotides, and glucuronide- or 
sulfate- conjugated molecules. Many of these are known to be transporter substrates.   
 
Some limitations to the present study should be noted. First, the sample size is relatively small, 
although it does represent the first comprehensive metabolomics analysis of any kind in human 
TBI. Second, the MS assay was performed after sample preparation with acetonitrile. Thus, the 
analytical approach does not cover the entire spectrum of molecules, such as large proteins 
including those currently being evaluated as TBI biomarkers. Third, individual 
120 
 
 
metabolites/features (with the exception of probenecid) and pathways were not confirmed 
independently in this study. Future studies using MS/MS fragmentation patterns and 
comparisons to pure standards for individual metabolite validation, and stable isotope marking 
for pathway confirmation using clinical samples and preclinical models will be necessary. 
 
In this, first of its kind, CNS metabolomics and pharmacometabolomics study, we demonstrate 
that global metabolomics signatures can differentiate control subjects, placebo treated TBI 
patients, and TBI patients treated with a combination of probenecid and NAC. Using advances in 
pathway and network analysis of metabolomics data, this study revealed pathways and networks 
that are dysregulated by TBI. Some of these pathways have previously documented involvement 
in TBI while others represent novel findings potentially bringing new insights into the 
pathogenesis of TBI. Similarly, treatment with a combination of probenecid and NAC resulted in 
enrichment of numerous pathways and networks including several glutathione mediated 
detoxification pathways supporting the a priori hypothesis for using this drug combination in 
patients with severe TBI. Several individual features, pathways, and networks with biologically 
plausible interactions with the combination therapy were also identified. Furthermore, several 
potential markers for probenecid and/or NAC therapeutic target engagement (efficacy and/or 
toxicity) were identified. Neuropharmacometabolomics may represent a powerful tool for 
developing a comprehensive understanding of the multiple biochemical processes and 
mechanisms involved in the pathogenesis of TBI, and in comprehending the effects of 
pharmacological interventions. 
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5. Association of SLC16A1, SLC16A3 and SLC16A7 genetic variants with long-term 
outcomes in TBI patients 
5.1. Introduction  
 
The metabolic crisis that occurs during the early phase traumatic brain injury and other acute 
brain injuries is one of the main determinants of the pathogenesis of TBI and is associated with 
unfavorable disease progression and long-term outcomes [105, 289-291]. The brain’s adaptive 
response to the metabolic crisis includes increased production, mobilization and/or utilization of 
lactate [31, 106] . A number of preclinical and clinical studies in TBI have reported the 
trafficking of lactate from astrocytes and peripheral sources to neurons to be used as energy 
source [94, 104, 109, 110, 292]. [105, 106, 115] .This agrees with the astrocytic-neuronal lactate 
shuttle (ANLS) hypothesis which posits that synaptically released glutamate initiates neuronal 
activity that is followed by increased rate of glucose uptake and glycolysis by astrocytes and 
subsequent release of lactate that can be used as energy substrate by neurons via oxidative-
derived ATP production [99] [98]. However, the ANLS itself and the notion that lactate could be 
traffic into neurons and used as energy source in TBI are not far from controversy. Citing 
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technical shortcoming of human studies using microdialysis, limitations of in-vivo and in-vitro 
TBI models, stoichiometry considerations and lack of biological plausibility, some have 
questioned the notion that lactate could be preferentially and beneficially used as a fuel in TBI 
[94, 100, 114, 293]. A study by Lama et al. reported that while lactic acid is continuously 
produced during TBI, but might be more of a toxic by product that results in neuronal death than 
a beneficial and neuroprotective energy source [113]. 
 
Little attention has been paid to the specific role of monocarboxylates transporters (MCTs) – 
responsible for trafficking lactic acid, which exist as ionic species in the body – in this 
controversy. In the brain, members of the SLC16A family of transporters, MCT1 (SLC16A1), 2 
(SLC16A7) and 4 (SLC16A3) function in coordination – as reflected by their distinctive 
expression patterns and kinetic properties – to facilitate the movement of lactic acid from 
peripheral or astrocytic sources into the neurons [91, 92]. This is particularly important in 
conditions such as TBI, where the normal energetics of the brain is disrupted [103, 104, 291]. In 
fact, MCT1, 2, and 4 constitute central part of the ANLS [99]. As discussed in Chapter one of 
this dissertation, the study of role of MCT transporters in TBI and other acute brain injuries has 
been limited to observations of changes in mRNA and/or protein expression, and the 
interrogation of the consequences of largely non-selective MCT inhibitors in preclinical models 
of acute brain injuries. Nevertheless, despite their limitations, these studies provide evidence that 
MCT transporters are crucial components of the brains adaptation mechanism to altered energy 
requirement following acute brain injuries. In the current study, using candidate-gene approach 
and focusing on well-studies SNPs in the genome of SLC16A1, SLC16A7 and SLC12A3, we 
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aim to evaluate the association of genetic alterations in these transporters with neurological 
function outcomes in TBI patients. Previous studies have found association between the genetics 
of these transporters in other conditions such as injury-susceptibility in elite athletes, male 
infertility, juvenile idiopathic arthritis and cancer [294-297]. To the best of our knowledge, this 
is the first study to investigate the role of MCT transporters in human TBI patients and will help 
clarify whether endogenously generated or exogenously administered lactate would be beneficial 
in TBI. 
 
5.2. Methods 
5.2.1. Patients 
This study was approved by the University of Pittsburgh Institutional Review Board and 
informed consent was obtained from the study subject’s surrogate. The University of Pittsburgh 
Brain Trauma Research Center database was used to identify two independent cohorts, separated 
by date of enrollment, based on the following inclusion criteria: age 16 and older, GCS score of 
8 or less, external ventricular drain (EVD) placement, and positive computed topography (CT) 
scan confirming TBI. Patients with penetrating trauma and previous neurological impairment 
were excluded. Study subjects were divided into discovery and replication cohorts based on data 
of injury with at least four years of separation. Glasgow Outcome Scale (GOS) scores ranging 1 
to 5 were collected by qualified neuropsychologist at 3, 6, 12 and 24 months post injury. A score 
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of 1 corresponds to deceased, 2 corresponds to a persistent vegetative state, 3 corresponds to 
sever disability, 4 corresponds to minor disability, and 5 corresponds to little or no disability.  
5.2.2. SNP selection 
For the current study, attempts were made to identify well-characterized SNPs with published 
reports of association of these SNPs with functional outcome measures. For SLC16A1, 
rs1049434 was the only well-studied SNP which was previously associated with injury-
susceptibility, accumulation of lactate in capillaries during high-intensity training and 
hyperinsulinism [295, 297, 298].  Other two SNPs, rs9429505 and rs7169 which are in perfect 
LD with each other and pin partial LD with rs1049434, were also reported to have association 
with hyperinsulinism. However, these SNPs were tagged as low-quality sites in the gnomAD 
browser. Thus, rs1049434 was selected for analysis in this study. For SLC16A7, rs10506399 and 
rs3763980, are the two well-studied SNPs associated with male-infertility and methotrexate 
response in juvenile idiopathic arthritis respectively [294, 296]. They are also in perfect LD with 
each other, so we chose rs10506399 for this study since it has a better call-rate in our genotyping 
assay. For SLC16A3, there are no reported SNPs associated with any functional outcome. 
Additionally, based on search results in the gnomAD browser, all SNPs with missense and loss 
of function characteristics have low MAFs that prohibit statistical analysis in this study’s 
population. Hence, no SNP from SLC16A3 were included in this study.  
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5.2.3. Sample collection and genotyping 
Blood or CSF samples were used to extract DNA using a commercially available kit per 
manufacturer’s protocol (Qiaamp kit, Qiagen, Chatsworth, CA, USA). Genotyping was 
performed with a TaqMan-allelic discrimination assay for the discovery cohort (Applied 
Biosystems, Foster City, CA) and a mix of TaqMan + Illumina Human Core Exome v1.2 
(Illumina, San Diego, CA) for the replication cohort. Genotype data quality were addressed by 
using technical replicates, and blinded double calls of raw data. Hardy-Weinberg equilibrium test 
was performed for both SNPs to assess genotype distributions in each cohort were within the 
expected proportions based on comparisons with published genotype frequencies for the non-
Finnish European population from the Broad Institute’s gnomAD Browser. 
5.2.4. Statistical Analysis 
Comparison of demographic data between discovery and replication cohorts were performed 
using two-tailed Student’s t-test for continuous variables or chi-square test for categorical 
variables. Additive and common dominant genetic models of disease were considered for both 
SNPs, and the most significant genetic model was selected at the end. The outcome measure, 
GOS, was treated as multilevel ordinal variable. Analysis of association of the SNPs with GOS 
was performed using multilevel mixed effects ordered logistic regression approach in Stata 14.2 
(Stata Corp LLC, College Station, TX, USA). All model runs were initially performed by forcing 
potentially clinically relevant covariates that include age, post-injury time period, GCS score, 
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sex, and race, but only those that shown statistically significant effect were kept in the final 
model.   
5.3. Results 
The demographic and clinical characteristics of the study subjects is summarized in Table 3. 
There were 285 and 179 subjects identified in the discovery and replication cohorts respectively. 
The characteristics of both cohorts are similar except for age, where the replication cohort 
subjects were significantly older than the discovery cohort. Adherence to Hardy-Weinberg 
equilibrium was confirmed for both SNPs in each cohort separately and in the combined 
population set (p>0.05 for all comparisons). The calculated minor allele frequencies (MAFs) for 
each SNP in each cohort and the combined cohort were not statistically significant different from 
MAF for non-Finnish European population based on the gnomAD Browser (p>0.05 for all 
comparisons) 
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Table 4. Summary of patient characteristics 
 Cohort 1 
(N=285) 
Cohort 2 
(N=179) 
 
p-value 
Age, Median, (IQR) 34 (23-47) 37 (23-54.5) 0.029 
Sex, Female, n (%) 60 (21%) 42 (23%) 0.54 
GCS, Median, (IQR) 6 (4-7) 7 (5-7) 0.25 
Race, n (%) 
Caucasian 
Others 
 
263 (92%) 
22 (8%) 
 
164 (92%) 
15 (8%) 
 
0.79 
Genotype, n (%) 
SLC16A1, rs1049434, AA 
SLC16A1, rs1049434, TA 
SLC16A1, rs1049434, TT 
 
SLC16A1, rs1049434, AA/AT 
 
SLC16A1, rs1049434, TT/AT 
 
 
 
SLC16A7, rs10506399, GG 
SLC16A7, rs10506399, AG 
SLC16A7, rs10506399, AA 
SLC16A7, rs10506399, NA 
  
Gntyp3 SLC16A7, rs10506399, GG/AG 
 
Gntyp2 SLC16A7, rs10506399, AA/AG  
 
 
76 (27%) 
149 (52%) 
60 (21%) 
 
225 (79%) 
 
209 (73%) 
 
 
 
154 (54%) 
116 (41%) 
13 (5%) 
2 (1%) 
 
270 (95%) 
 
129 (45%) 
 
41 (23%) 
90 (50%) 
48 (27%) 
 
131 (73%) 
 
138 (77%) 
 
 
 
107 (60%) 
60 (34%) 
12 (7%) 
- 
 
167 (93%) 
 
72 (40%) 
 
 
0.321 
 
 
0.153 
 
0.388 
 
 
 
 
0.216 
 
 
 
0.329 
 
0.258 
 
The mixed-effects multi-level ordinal regression model was built with relevant clinical and 
demographic covariates that were also found be statistically significant factors in the model. 
Based on these criteria, the final model consists of age, time post-injury and GCS as covariates. 
Each of these covariates were tested with genotype for two-way interactions. The dominant 
genetic model and the additive genetic model were employed in for SLC16A7 and for SLC16A1 
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respectively in the final model as each resulted in more significant differences compared to the 
alternative disease model for respective gene.   
 
The final models for both SNPs and both discovery and replication cohorts are summarized in 
Table 3 and the combine model is presented in Table 3. In case of SLC16A7, significant 
association was found between GOS and the rs10506399 genotype in both cohorts and the 
combined model (p = 0.007 [discovery], p = 0.004 [replication] and p<0.0001 [combined 
model]). However, this association was age dependent as significant association between GOS 
and the interaction term between age and rs10506399 genotype was also found in both cohorts 
and the combined model (p = 0.003 [discovery], p = 0.001 [replication] and p<0.0001 [combined 
model]).  
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Table 5. Mixed effects ordered logistic regression model, SLC16A7 and SLC16A1 
SLC16A7    
 
Factor 
Discover Cohort (N=285)  Replication Cohort (N=179) 
Coefficient [95% CI] p-value  Coefficient [95% CI] p-value 
Genotype*LnAge -4.25 [-7.10, -1.40] 0.003  -6.23 [-10.00, -2.47] 0.001 
Genotype 14.105 [3.78, 24.43] 0.007  19.75 [6.23, 33.26] 0.004 
Lnage -8.80 [-11.05, -6.55] <0.0001  -7.51 [-9.90, -5.11] <0.0001 
GCS score  2.80 [2.22, 3.38] <0.0001  1.98 [1.33, 2.62] <0.0001 
Post injury test 
period vs 1 
2 
3 
4 
 
 
1.25 [0.73, 1.77] 
2.13 [1.56, 2.70] 
2.80 [2.22, 3.38] 
 
 
<0.0001 
<0.0001 
<0.0001 
  
 
1.08 [0.38, 1.77] 
2.31 [1.51, 3.12] 
1.85 [0.93, 2.78] 
 
 
0.002 
<0.0001 
<0.0001 
 
 
SLC16A1 
   
 
Factor 
Discover Cohort (N=285)  Replication Cohort (N=179) 
Coefficient [95% CI] p-value  Coefficient [95% CI] p-value 
Genotype*Lnage -2.30 [-4.47, -0.13] 0.038  N/A  
Genotype 6.19 [-1.70, 14.08] 0.124    
Lnage -8.92 [-11.70, -6.13] <0.0001    
GCS score  2.79 [2.21, 3.36] <0.0001    
Post injury test 
period vs 1 
2 
3 
4 
 
 
1.24 [0.72, 1.76] 
2.12 [1.55, 2.68] 
2.79 [2.16, 3.41] 
 
 
<0.0001 
<0.0001 
<0.0001 
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Table 6. Mixed effects ordered logistic regression model of the combined, discovery and 
replication cohorts 
 
To facilitate the interpretation of the findings based on the model above, a more parsimonious 
logistic regression model was developed using the combined cohort and after categorizing the 
outcome, GOS, into two levels, unfavorable (for GOS scores of 1 and 2) and favorable (for GOS 
scores of 3, 4 or 5). The results of this model are presented in Table 6. This binary logistic model 
was then used to calculate the expected probabilities of favorable outcomes for either genotype 
of the SNP and at various values of age. A plot of predicted probabilities versus age for each 
genotype was generated and is shown in Figure 25. The figures show that the probability of 
favorable outcomes was significantly higher for patients which has one or both of the alternate 
alleles. But the beneficial effect of the alternate allele decreases as age increases.  
  
 
Factor 
Combined Cohort (N=464) 
Coefficient [95% CI] p-value 
Genotype*LnAge -5.16 [-7.54, -2.79] <0.0001 
Genotype 16.74 [8.13, 25.35] <0.0001 
Lnage -8.32 [-9.96, -6.69] <0.0001 
GCS score  2.49 [2.04, 2.93] <0.0001 
Post injury test period vs 1 
2 
3 
4 
 
1.18 [0.77, 1.60] 
2.18 [1.72, 2.64] 
2.53 [2.01, 3.04] 
 
<0.0001 
<0.0001 
<0.0001 
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Table 7. Binary logistic regression of the combined, discovery and replication cohorts 
 
Factor 
Combined Cohort (N=464) 
Coefficient [95% CI] p-value 
Genotype*LnAge -0.67 [-1.21, -0.12] <0.01 
Genotype 1.98 [0.084, 3.88] <0.05 
Lnage -1.42 [-1.76, -1.08] <0.0001 
GCS score  0.4 [0.31, 0.49] <0.0001 
Post injury test period vs 1 
2 
3 
4 
 
0.58 [0.25, 0.91] 
0.96 [0.62, 1.29] 
0.82 [0.47, 1.17] 
 
<0.001 
<0.0001 
<0.0001 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25. The margins of probability of favorable outcome for the genotypes at 
rs10506399 across age based on logistic regression. 
Patients with that carry one or two ‘A’ allele have significantly better favorable outcome, but 
the effect diminishes with age.  
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To assess the functional consequence of the rs10506399 SNP, the Genotype-Tissue Expression 
(GTEx) Project portal was queried using the SNP ID rs10506399 [299, 300]. The search yielded 
currently available eQTL data for four tissues for this particular SNP.  The expression of 
SLC16A7 by rs10506399 genotype in cerebellum tissue, shown in Figure 26, was statistically 
significant (p= 3.8x10-8, FDR>0.05) based on linear regression analysis. The effect size of the 
eQTLs – defined as the slope of the linear regression, comparing the alternate allele (A) to the 
reference allele (G) – was 0.710 indicating a strong effect of the genotype on expression. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26. SLC16A7 gene expression by genotype of rs10506399.  
The data was obtained from GTEx portal and represent the gene expression levels in brain 
cerebellulm tissue of 135 donor individuals. The presence of two minor allele ‘A’ is 
associated with highest expression level of SLC16A7.  
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In case of SLC16A1, the association between GOS and the rs1049434 genotype was not 
statistically significant in the discovery cohort (p = 0.124). According to our a priori rule, further 
analysis of this SNP was not conducted. 
 
5.4. Discussion 
In this chapter, we examined the role of MCT transporters in TBI patients using genetic 
association study. We report that patients who have one or both of the alternate allele at 
rs10506399 have a higher probability of favorable outcome after TBI. We also showed that the 
alternate allele at rs10506399 are associated with increased expression of SLC16A7 in the brain 
cerebellum hemisphere. Additionally, we found that s1049434, the most studied SLC16A1 SNP 
was not associated with outcomes in TBI. MCT transporters are responsible for trafficking of 
lactate and other monocarboxylates within the neurovascular unit in the brain [87]. The findings 
in this study suggest important role of these transporter in determining the signaling and 
metabolic function of lactate and possibly other monocarboxylates.  
 
There is an ongoing controversy on whether lactic acid is shuttled to neurons to be utilized as an 
alternative or preferred energy source in TBI. The fact that there is increased lactate production 
following TBI is agreed up on consensus. However, the specific origin of the lactate and/or the 
relative contribution of several plausible sources, the fate of lactate after production (i.e., 
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whether taken-up by neurons or trafficked out into blood stream), and whether neurons could 
effectively use lactate to generate ATP are all matters of considerable debate [92, 94, 100, 108, 
301]. The debate about the role of lactate in TBI is focused on its movement within the 
neurovascular unit. Lactate exists as an ionic species at the physiological pH, hence it needs 
transporters to cross biological barriers, which makes MCT transporter critical regulators of the 
function of lactate. As discussed in Chapter one of this dissertation, numerous in vitro and in vivo 
studies have underlined the importance of MCT transporters in the setting of neuronal injury. 
Specifically, inhibition or down regulation of MCT transporters either using small molecules or 
siRNA leads to greater harm in various models of acute brain injury. Also, the expression level 
and pattern of this transporters change in response to injury. This study is the first one to assess 
the role of MCT transporters in human TBI patients. We sought to understand the role of brain 
MCT transporters, MCT1, MCT2 and MCT4 using genetic association study. To limit the 
chances of false positive, we only included SNPs that previously have been reported to be 
associated with functional outcomes, and those SNPs that have sufficient MAF to conduct 
statistical analysis. According to our criteria, no SNP in MCT4 were selected for analysis. One 
SNP each were selected for MCT1 (rs10494340 and MCT2 (rs10506399).  
 
In case SLC16A7, significant association of was found between the SNP rs10506399 and the 
outcome of interest, GOS, in age dependent manner. MCT2 is deemed the neuronal MCT 
transporter because it is mainly expressed in neuronal cells [91, 92]. Previous studies have 
reported that the SNP rs10506399, which is located in the 3’ UTR region, is associated with 
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infertility in Asian men [296]. Also, rs3763980, which is in perfect LD with rs10506399 is 
associated with treatment response to methotrexate in juvenile idiopathic arthritis [294].  
 
We also demonstrated that the SNP rs10506399 is associated with expression of SLC16A7. 
Specifically, the presence of one or more of the alternate allele was associates with increased 
expression of SLC16A7 with strong effect size in the cerebellum hemisphere of brain tissue. 
Since MCT2 is a high affinity transporters [92], changes in expression such as observed as a 
result of alternation in the SNP rs10506399 could have profound effect on its function, hence the 
observed association with clinical outcome in TBI. If the findings of this study would be 
confirmed, it would suggest that there is an increased uptake of lactate or other monocaboxylates 
by neurons duo to increased expression of MCT2 in the patients with the one or both of the 
alternate allele, and that this is beneficial in TBI.  
 
With regards to MCT1, we didn’t find statistically significant association of genotype at 
rs1049434 and GOS in the discovery cohort, and we didn’t pursue it further in the replication 
cohort. The SNP rs1049434 was previously reported to be associated with susceptibility to 
muscle injury in elite soccer players with statistically significant barely below the 0.05 present 
threshold (p=0.048)[295]. Another study has also reported that there was 35-40% reduction of 
lactate transport rate in erythrocytes of individuals carrying the alternate allele ‘T’, but this 
observation was only in two individuals [302]. Search in the GTEx portal shows that there was 
no statistically significant association of the genotype at rs1049434 with expression of SLC16A1 
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in any of the brain tissues examined except the hypothalamus where a weak association with low 
effect size (p=0.04, normalized effect size=0.23) was identified (Figure 27). Put together, this 
findings suggest minimal functional consequence of the SNP rs1049434, particularly in the brain 
tissues. 
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Figure 27. Multi-tissue eQTL comparisons of the SNP rs1049434.  
There was no statistically significant association between genotype and SLC16A1 expression in 
all brain tissue (shown in yellow) except hypothalamus. The effect size (NES) of the association 
in hypothalamus was weak at only 0.23. 
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Some limitations of the study should be noted. This is a single center study that needs to be 
replicated with multi-center study. However, the replication of the findings, with patients that are 
separated from the discovery cohort by time, reduces some of the bias that could emanate from a 
single-center study. For this study, important clinical variables such as comorbidity and 
medication use were not available for analysis. This is particularly important for older patients, 
and possible explains why the influence of genotype diminished with age, which appears as age-
genotype interaction in the model. Finally, although plausible explanation – change in expression 
of SLC16A7 – is provided, because this is a retrospective association study, causation could not 
be established. More clinical and molecular studies are needed to fully elucidate the relationship 
between SLC16AT rs10506399 genotype and GOS in TBI.  
 
In conclusion, we report that in this genetic association study comprising of discovery and 
replication cohorts, the genotype at rs10506399 of SLC16A7 is associated with GOS scores in 
TBI patients. A genotype-age interaction was also detected indicating the effect of genotype was 
age dependent. Specifically, the beneficial effect having one or two alternative alleles at 
rs10506399 decreases as age increases. The findings in this study reveal potentially important 
role for MCT2 and its substrates, especially lactate, in regulating the brain energetics following 
TBI. In the light of current findings, patient stratification by MCT genotype at rs10506399 
should be considered in clinical studies investigating the function, kinetics and clinical effect of 
endogenous and exogenous lactate.  
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6. Summary and Perspectives 
6.1. Major Findings and Implications 
 
6.1.1. Probenecid, transporter inhibitor, increases brain levels of antioxidant drug n-
acetylcysteine 
In this chapter, we sought to understand how the transporter inhibitor, probenecid, affects n-
acetylcysteine pharmacokinetics and to evaluate the interaction of n-acetylcysteine with 
transporters. Juvenile Sprague-Dawley rats were administered n-acetylcysteine alone or in 
combination with probenecid intraperitoneally. Plasma samples and brain hemispheres were 
collected serially and n-acetylcysteine concentrations were measured. Transporter studies were 
conducted with human embryonic kidney (HEK)-293 cells that overexpress organic anion 
transporter (OAT)1 or OAT3 and with human multi-drug resistance-associated protein (MRP)1 
and MRP4 membrane vesicles. 
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N-acetylcysteine area under the curve was increased in plasma (1.65-fold) and brain (2.41-fold) 
by probenecid co-administration. The apparent plasma clearance was decreased by 65%. Time- 
and concentration-dependent n-acetylcysteine uptake was inhibited by probenecid in OAT1 and 
OAT3, but not in MRP1 or MRP4 overexpression systems. Our results indicate for the first time 
that n-acetylcysteine is substrate for OAT1 and OAT3 and that probenecid increases n-
acetylcysteine plasma and brain exposure in vivo. These data provide insight regarding how n-
acetylcysteine crosses biological barriers and suggest a promising therapeutic strategy to increase 
n-acetylcysteine (and possibly other drugs) exposure in the brain (and plasma) by inhibiting 
membrane transporters.  
 
6.1.2. The effect of a combination of n-acetylcysteine and probenecid on functional 
outcomes in rat, traumatic brain injury model 
In this chapter we examined the capacity of a combination of n-acetylcysteine and probenecid to 
improve functional and histological outcomes in a preclinical model of pediatric TBI. This was 
based on the observation that a combination of n-acetylcysteine and probenecid can counter 
oxidative stress through multiple ways. While n-acetylcysteine donates cysteine, the rate limiting 
substrate in biosynthesis of glutathione, probenecid prevents active efflux of glutathione and its 
conjugates by inhibiting MRP transporters. Additionally, as described in Chapter 2, as 
transporter inhibitor probenecid increases plasma and brain levels of the antioxidant n-
acetylcysteine.  
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Seventeen day old rats underwent either controlled cortical impact (CCI; n = 10-11 per treatment 
group) or sham surgery (n = 5 per treatment group) and divided into four treatment groups each; 
n-acetylcysteine (163m/Kg)+vehicle, probenecid (150mg/Kg)+vehicle, n-acetylcysteine 
+probenecid and vehicle+vehicle. Drugs or vehicle were administered twice a day for the 3 days 
with additional dose of n-acetylcysteine in the first day. Motor function was assessed using beam 
balance tests on day 1-5 following surgery. Spatial learning and memory retention were 
evaluated with Morris water maze on days 11-16.  Rats were sacrificed on day 19 and brain 
tissue fixed and stained with H&E followed by assessment of tissue volume lost and 
hippocampal neuronal survival.  
 
In the motor function test with beam balance, compared to shams, all CCI groups showed 
significant impairment on days 1, and 2. Two of the TBI groups, CCI+probenecid+vehicle2 and 
CCI+ n-acetylcysteine + probenecid, showed worse impairment as compared to the other TBI 
groups, which was statistically significant on day 1 but not on day2.   In the MWM, hidden 
platform trial that tested acquisition of Spatial learning, all CCI groups performed worse that 
sham groups. Results of the MWM, single probe trial that tested spatial memory retention show 
that the sham group performed better than the CCI+ n-acetylcysteine+PB (p < 0.05) and CCI+ 
probenecid +vehicle (p < 0.05). In both MWM tests, the CCI+ n-acetylcysteine +vehicle group 
performed better than any of the other CCI groups, but the difference didn’t reach significant 
level. No treatment benefit was observed in hippocampal neuronal survival analysis while the 
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CCI+ n-acetylcysteine +probenecid showed significant attenuation of tissue volume loss after 
CCI.  
 
Following TBI, at the given dosage regime, n-acetylcysteine appears to attenuating spatial 
learning and memory retention deficits that didn’t reach statistical significance; probenecid 
seems to cause acute motor deficit; and the combination of both improved tissue volume loss. 
Optimization of the dosage regime for both drugs is justified to enhance the beneficial effects of 
n-acetylcysteine and minimize the adverse effects of probenecid. 
 
6.1.3. Neuropharmacometabolomics of treatment response of a combination of probenecid 
and n-acetylcysteine in traumatic brain injury 
Metabolomics is a powerful tool for comprehensively profiling metabolites, altered biochemical 
processes, and discovery of perturbed systems due to injury and/or drug administration. In this 
chapter, we employed metabolomics along with pathway and network analyses to evaluate the 
CSF metabolome after severe TBI in children. The capacity of combination therapy with 
probenecid and n-acetylcysteine to modulate glutathione metabolism and related pathways after 
TBI—the purported mechanism of action—were also evaluated. CSF was obtained from 12 
children enrolled in an IRB-approved, Phase I, randomized, placebo-controlled trial of a 
combination of probenecid and n-acetylcysteine after severe TBI (Trial Registration 
NCT01322009), 24 h after the first of dose of drugs (n = 7) or placebo (n = 5), and age-matched 
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control subjects (n = 5). After protein precipitation with acetonitrile, samples were injected into 
an UPLC-QTOFMS to analyze the CSF metabolome. Feature detection, retention time 
correction, alignment, annotation, and principal component analysis (PCA) and statistical 
analysis were conducted using XCMS-online. The software mummichog was used for pathway 
and network analyses. A two-component PCA revealed clustering of each of the groups, with 
distinct metabolomics signatures. Several novel pathways with plausible mechanistic 
involvement in TBI were identified. A combination of metabolomics and pathway/network 
analyses showed that seven glutathione-centered pathways and two networks were enriched in 
the CSF of TBI patients treated with probenecid and n-acetylcysteine vs. placebo treated 
patients. Several pathways/networks consisting of components that are known substrates of 
probenecid-inhibitable membrane transporters such as prostaglandins, kynurenate and urate were 
also enriched, providing additional mechanistic validation.  
 
This first of its kind neuropharmacometabolomics assessment reveals alterations in known and 
previously unidentified metabolic derangements after TBI, and supports target engagement of the 
combination of probenecid and n-acetylcysteine in the treatment of severe TBI in children 
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6.1.4. Association of SLC16A1, SLC16A3 and SLC16A7 genetic variants with long-term 
outcomes in TBI patients 
In Chapter 5, using candidate-gene approach and focusing on well-studied SNPs, we evaluated 
the association of genetic alteration in MCT1 (SLC16A1), MCT2 (SLC16A7) and MCT4 
(SLC16A3) with neurological outcomes in TBI. These MCT transporters are responsible 
trafficking lactic acid within the neurovascular unit, and hence understanding their role could 
help resolve the controversy on whether lactate could be used as alternative or preferred energy 
source in TBI.  
 
Adults (age 17-78 years) with sever TBI (n=275 in discovery cohort and 189 in replication 
cohort, Glasgow Coma Scale (GCS) score ≤ 8) were genotyped for the SNPs rs10506399 of 
SLC16A7 and rs1049434 of SLC16A1. No relevant SNP was identified for SLC16A3 as there 
were no previously reported association of any SNP in SLC16A3 with functional outcomes. 
Glasgow Outcome Scale (GOS) scores were evaluated at 3, 6, 12 and 24 months post injury. A 
mixed effects ordered logistic regression model with GCS score, age and time posit-injury 
incorporated as covariates was used to assess the association between GOS and genotype at each 
of the SNPs. The GTEx Project portal was searched to determine the consequence of the SNPs 
found to be significantly associated with GOS. Adherence to Hardy-Weignberg equilibrium was 
achieved with both SNPs in both cohorts and the combined cohort. The mixed-effect ordered 
logistic regression model analysis showed patients with one or both of the alternate variants in 
rs10506399 were associated with GOS (p>0.0001). The association was age dependent as the 
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probably of favorable outcome associated with the alternate allele diminished with age. The SNP 
rs1049434 was not associated with GOS in the discovery group and hence not investigated in the 
replication cohort. The genotype at rs10506399 was significant associated with expression of 
SLC16A7 with the alternate allele showing higher expression.  
 
The findings in this study reveal potentially important role for MCT2 and its substrates, 
especially lactate, in regulating the brain energetics following TBI. In the light of current 
findings, patient stratification by MCT2 genotype at rs10506399 should be considered in clinical 
studies investigating the function, kinetics and clinical effect of endogenous and exogenous 
lactate.  
6.2. Limitations and Future Directions 
Overall, this dissertation has mainly focused on translational and clinical aspects of the role of 
membrane transporters in TBI. It is outside the scope of this dissertation, but some outstanding 
mechanistic details at the molecular level remain to be studied. Some limitations specific for 
each chapter are discussed below.  
 
In Chapter two of this thesis, we showed that inhibition of OAT1 and OAT3 transporters with 
probenecid increased plasma and brain levels of n-acetylcysteine. The fact that the increased in 
levels in the presence of probenecid was higher in the brain than plasma is indicative of possible 
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effect on BBB and/or choroid plexus, our method was not sufficient to conclusively attribute the 
effect to inhibition of transporters on these barriers. Future studies, through tissue specific 
knockout models, should investigate the significant of inhibiting of transporters on BBB and 
choroid plexus in altering the levels of drugs and endogenous molecules.  
 
In Chapter three, we showed that while n-acetylcysteine appear to have beneficial effects, 
probenecid was implicated in some side effects. The main limitation of the study was that it 
didn’t incorporate multiple doses of n-acetylcysteine and probenecid to establish dose-effect 
relationship for both drugs. With regards to n-acetylcysteine, higher or more frequent dose would 
have helped assess whether the spatial learning and memory deficit attenuation of observed with 
the given dose is a true effect, in that these effects would have reached statistical significance. 
Similarly, study design with multiple doses of probenecid in both the pharmacokinetic and 
function outcomes studies would have allowed thorough evaluation of the capacity of probenecid 
to increase levels of n-acetylcysteine without adverse effects. Given the levels of probenecid 
achieved with the dose used in this study are significantly higher than the Ki of probenecid of 
most transporters [232, 244-247, 251], it is possible that significant increase of level of n-
acetylcysteine could be achieved even with lower doses of probenecid.  
 
In Chapter four, we reported that global metabolomic signatures can differentiate among control 
subjects, placebo treated TBI patients, and TBI patients treated with a combination of probenecid 
and n-acetylcysteine. We also reported discovery of system level and individual markers of TBI 
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and pharmacological action of a combination of probenecid and n-acetylcysteine in TBI. Some 
limitations to the present study should be noted. First, the sample size is relatively small, 
although it does represent the first comprehensive metabolomics analysis of any kind in human 
TBI. Second, the MS assay was performed after sample preparation with acetonitrile. Thus, the 
analytical approach does not cover the entire spectrum of molecules, such as large proteins 
including those currently being evaluated as TBI biomarkers. Third, individual 
metabolites/features (with the exception of probenecid) and pathways were not confirmed 
independently in this study. Future studies using MS/MS fragmentation patterns and 
comparisons to pure standards for individual metabolite validation, and stable isotope marking 
for pathway confirmation using clinical samples and preclinical models will be necessary. 
 
In Chapter five, we showed that genetic variation in SLC16A7, specifically rs10506399, was 
associated with GOS in age dependent manner in TBI patients. Some limitations of the study 
should be noted. This is a single center study that needs to be replicated with multi-center study. 
However, the replication of the findings with patients that are separated from the discovery 
cohort by time, reduces some of the bias that could emanate from a single-center study. For this 
study, important clinical variables such as comorbidity and medication use were not available for 
analysis. This is particularly important for older patients, and possible explains why the influence 
of genotype diminished with age, which showed up as age-genotype interaction in the model. 
Finally, although plausible explanation – change in expression of SLC16A7 – is provided, 
because this is a retrospective association study, causation could not be established. More 
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clinical and molecular studies are needed to fully elucidate the relationship between SLC16AT 
rs10506399 genotype and GOS in TBI. 
6.3. Commentary and Conclusion 
In summary, in this dissertation work, we sought to understand the role of membrane transporters 
in TBI. Through in vitro and in vivo methods, we demonstrated that it is possible to inhibit 
membrane transporters, such as with probenecid, to enhance the brain penetration capacity of 
candidate drugs, such as n-acetylcysteine, both in the presence or absence of brain injury. A 
recent report had indicated that inhibiting ABC efflux transporters in the intact BBB is unlikely 
to results in clinical meaningful increase in brain levels of substrate drugs without causing 
significant systemic toxicity [241]. Our finding, along with other previous reports [221, 222, 
225], suggest uptake transporters on BBB or choroid plexus could possibly targeted to cause 
increased brain penetration of certain drugs. In the setting of TBI, even a small, non-toxic 
increase in either systemic Cmax or AUC through transporters inhibition together with breakage 
in BBB, the smaller volume of the brain tissue (relative to blood) and inhibition of transporters in  
BBB or choroid plexus could result in meaningful increase in brain levels of drugs [303, 304]. 
These possibility indicate that transporter inhibition as useful therapeutic strategy to overcome 
pharmacokinetic related challenges in TBI drug development.  
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We also showed that membrane transporters, such as OAT1, OAT3 and MRP transporters, could 
be therapeutically targeted to increase the brain levels of potentially beneficial endogenous 
molecules, such as glutathione. In this study, relatively high dose of probenecid was used and 
probably lead to adverse effects, including transient motor deficit. This highlights the notoriety 
transporters for having overlapping substrates and poor selectivity of transporter inhibitors [169] 
and shows how critical appropriate dose selection is to achieve optimal effects. Recently, there 
has been concerted effort to try to understand transporters as a class, identify common features 
and interrelationships, develop and standardize tools and methods for investigating transports, 
and characterize their structure-activity relationship [23]. Such efforts could be key in 
overcoming the challenges of targeting transporters therapeutically, in TBI or otherwise, such as 
identifying the optimal doses, or discover specific inhibitors or alternative ways of targeting 
transporters. 
 
Furthermore, we showed that inhibition of transporters could profoundly alter the metabolome 
and associated pathways and networks of the CSF. The study in Chapter 4 of this dissertation 
underscores the usefulness of metabolomics as a tool to understand the range of substrates and 
functions of transporters, and in identifying markers of efficacy and toxicity for drugs that target 
transporters, as we were able to do in this case for a combination of probenecid and n-
acetylcysteine in TBI.  
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Finally, we reported that understanding the role of transporters could provide unique insight in 
revealing the role of endogenous and exogenous small molecules, such as lactate, in a particular 
cellular processes, such as brain energetics after TBI. The lack of specific transporter inhibitors 
makes genetic methods that take advantage of naturally existing genetic variations as valuable 
approach to study the function of membrane transporters in humans.  
 
Altogether, this dissertation project has provided experimental and clinical evidence that 
membrane transporters, as mediators of the movement of small molecules within the 
neurovascular unit, significantly contribute to the pathogenesis and pharmacotherapy of TBI and 
hence deserve due consideration as components of injury mechanism and as therapeutic targets 
in TBI.  
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APPENDIX A. Extended Data, Metabolomics 
Table A1. Tentative identification of metabolites in CSF that are altered by TBI compared 
to control subjects 
METLIN 
Name 
RT 
Measured mass 
(m/z) 
Compound ID Compound Name 
Molecular 
Formula 
Mass Error 
(delta) 
Fold 
Change 
M252T6* 5.54 252.085 
HMDB00953 Suberylglycine C10H17NO5 0.000339 
+68 
HMDB00726 Isovalerylglutamic acid C10H17NO5 0.000339 
M549T9_2 8.85 549.1804 
HMDB28737 Asparaginyl-methionine C9H17N3O4S 0.003229 
+2 
HMDB28968 Methionyl-asparagine C9H17N3O4S 0.003229 
HMDB41685 5'-hydroxy-o-desmethylangolensin C15H14O5 0.004877 
HMDB41654 3'-hydroxy-o-desmethylangolensin C15H14O5 0.004877 
HMDB41695 6'-hydroxy-o-desmethylangolensin C15H14O5 0.004877 
M125T6 5.54 124.5233 
HMDB28840 Glycyl-glutamate C7H11N2O5 0.000684 
+7 HMDB28819 Glutamyl-glycine C7H11N2O5 0.000684 
HMDB12259 Methylarsonite CH5AsO2 0.000928 
M603T8 7.93 602.4463 
HMDB11847 Ganglioside gd2 (d18:0/24:0) C85H153N3O34 0.00226 
+92 
HMDB12535 12S-HHT C17H28O3 0.004787 
M617T10_1 9.79 616.9443 
HMDB04898 Ganglioside ga2 (d18:1/25:0) C63H118N2O18 0.004768 
+261 
HMDB04887 Trihexosylceramide (d18:1/25:0) C61H115NO18 0.004769 
M646T9 9.02 646.4535 
HMDB37830 Xi-7-hydroxyhexadecanedioic acid C16H30O5 0.001029 
-484 
HMDB37831 Xi-8-hydroxyhexadecanedioic acid C16H30O5 0.001029 
HMDB11498 Lysope (0:0/24:1(15z)) C29H58NO7P 0.00196 
HMDB11528 Lysope (24:1(15z)/0:0) C29H58NO7P 0.00196 
HMDB28714 Arginyl-lysine C12H26N6O3 0.0064 
HMDB28945 Lysyl-arginine C12H26N6O3 0.0064 
M603T9_3 9.10 603.4283 
HMDB04884 Trihexosylceramide (d18:1/26:1(17z)) C62H117NO18 0.005783 
-111 
HMDB04896 Ganglioside ga2 (d18:1/26:0) C64H120N2O18 0.005784 
M624T10_2 10.16 623.9521 
HMDB04896 Ganglioside ga2 (d18:1/26:0) C64H120N2O18 0.004742 
-115 
HMDB04884 Trihexosylceramide (d18:1/26:1(17z)) C62H117NO18 0.004744 
M573T9_4 8.82 573.4075 HMDB02890 3-cis-hydroxy-b,e-caroten-3'-one C40H54O 0.000816 -212 
M974T5_2 4.60 974.2563 
HMDB41729 (-)-epicatechin 7-o-glucuronide C21H22O12 0.000225 
-10 
HMDB41728 (-)-epicatechin 3'-o-glucuronide C21H22O12 0.000225 
HMDB60161 
3(S)-Hydroxy-4(R),8-dimethyl-
nonanoyl-CoA 
C32H56N7O18P3S 0.005544 
HMDB02992 S-2-octenoyl CoA C29H48N7O17P3S 0.008093 
HMDB03949 (2e)-octenoyl-CoA C29H48N7O17P3S 0.008093 
ECMDB23397 trans-Oct-2-enoyl-CoA C29H48N7O17P3S 0.008093 
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Table A2. Metabolic pathways altered in probenecid+n-acetylcystiene treated TBI patients 
compared to placebo treated TBI patients 
Pathway Mode 
Pathway 
Size 
Percentage 
Overlap 
Overlapping Features 
Melatonin degradation II + 6 66.7% 
5-methoxyindoleacetaldehyde 
5-methoxytryptophol 
Melatonin acetate 
5-methoxytryptamine 
5-methoxyindole acetate 
CMP phosphorylation + 3 66.7% 
ATP 
CMP 
CDP 
N-acetylglucosamine degradation I + 3 66.7% 
β-D-fructofuranose 6-phosphate 
α-D-glucosamine 6-phosphate 
Acetate 
Methylglyoxal degradation I + 3 66.7% 
Glutathione 
Pyruvate 
(R)-S-lactoylglutathione 
Formaldehyde oxidation + 3 66.7% 
Glutathione 
S-formylglutathione 
S-hydroxymethylglutathione 
Melatonin degradation III + 3 66.7% 
N-acetyl-5-methoxykynurenamine 
Melatonin, 
N1-acetyl-N2-formyl-5-methoxykynuramine 
Geranylgeranyldiphosphate biosynthesis + 3 66.7% 
(2E,6E)-farnesyl diphosphate 
Geranylgeranyl diphosphate 
Isopentenyl diphosphate 
Glutathione redox reactions II + 3 66.7% 
Glutathione 
Glutathione disulfide 
NADPH 
Glutathione redox reactions I + 3 66.7% 
Glutathione 
Glutathione disulfide 
NADPH 
α-tocopherol degradation + 5 60.0% 
13'-hydroxyα-tocopherol 
α-carboxyethylhydroxychroman 
5'-α-carboxylmethylbutylhydroxychroman 
α-tocopherol 
NADPH 
2-oxoisovalerate decarboxylation to 
isobutanoyl-CoA 
+ 5 60.0% 
NAD+ 
3-methyl-2-oxobutanoate 
Coenzyme A 
Isobutanoyl-CoA 
4-aminobutyrate degradation + 5 60.0% 
L-glutamate 
NAD+ 
Succinate 
2-oxoglutarate, 
Succinate semialdehyde 
Estradiol biosynthesis I + 5 60.0% 
19-hydroxyandrostenedione 
17-β-estradiol 
Estrone 
Androst-4-ene-3,17-dione 
19-oxoandrostenedione 
Fatty acid α-oxidation + 7 57.1% 
AMP 
ATP 
NAD+ 
Succinate 
2-oxoglutarate 
Coenzyme A 
4-hydroxyproline degradation + 7 57.1% 
L-glutamate 
NAD+ 
Pyruvate 
2-oxoglutarate 
(3R,5S)-1-pyrroline-3-hydroxy-5-carboxylate 
L-4-hydroxyglutamate semialdehyde 
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Erythro-4-hydroxy-L-glutamate 
Ascorbate recycling (cytosolic) + 7 57.1% 
Glutathione 
Glutathione disulfide 
NAD+ 
L-ascorbate, 
L-dehydro-ascorbate 
NADPH 
Monodehydroascorbate 
Putrescine degradation III + 7 57.1% 
NAD+ 
Coenzyme A 
Acetate 
N-acetylputrescine 
Acetyl-CoA 
4-acetamidobutanoate 
4-acetamidobutanal 
Serine biosynthesis (phosphorylated route) + 7 50% 
L-glutamate 
NAD+ 
2-oxoglutarate 
3-phospho-D-glycerate 
3-phospho-L-serine 
3-phospho-hydroxypyruvate 
trans, trans-farnesyl diphosphate biosynthesis + 6 50% 
Dimethylallyl diphosphate 
Geranyl diphosphate 
(2E,6E)-farnesyl diphosphate 
Isopentenyl diphosphate 
Fatty acid α-oxidation III + 4 50% 
AMP 
ATP 
NAD+ 
Coenzyme A 
Thyronamine and iodothyronamine 
metabolism 
+ 4 50% 
3,3',5,5'-tetraiodothyronamine 
3'-iodothyronamine 
Thyronamine 
3-iodothyronamine 
Asparagine degradation + 4 50% 
L-glutamate 
2-oxoglutarate 
Oxaloacetate 
N4-(beta-N-acetyl-D-glucosaminyl)-L-
asparagine 
Epoxysqualene biosynthesis + 4 50% 
Squalene 
(2E,6E)-farnesyl diphosphate 
(3S)-2,3-epoxy-2,3-dihydrosqualene 
NADPH 
Thiamin salvage III + 4 50% 
AMP 
ATP 
Thiamin 
Thiamin diphosphate 
Phospholipases - 2 100% 
Phosphocholine 
D-myo-inositol (1,4,5)-trisphosphate 
Glutathione redox reactions II - 4 75% 
Glutathione 
Glutathione disulfide 
NADP+ 
NADPH 
Glutathione redox reactions I - 4 75% 
Glutathione 
Glutathione disulfide 
NADP+ 
NADPH 
Ascorbate recycling (cytosolic) - 8 50% 
Glutathione 
Glutathione disulfide 
NAD+ 
NADH  
NADP+ 
NADPH  
L-ascorbate 
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L-dehydro-ascorbate 
Dolichol and dolichyl phosphate biosynthesis - 6 50% 
CDP 
CTP 
NADP+ 
NADPH  
(2E,6E)-farnesyl diphosphate, diphosphate 
Sulfate activation for sulfonation - 4 50% 
Diphosphate 
Adenosine 5'-phosphosulfate 
3'-phosphoadenylyl-sulfate 
ADP 
Pentose phosphate pathway (oxidative branch) - 4 50% 
NADP+ 
NADPH  
6-phospho D-glucono-1,5-lactone 
β-D-glucose 6-phosphate 
Epoxysqualene biosynthesis - 4 50% 
NADP+ 
NADPH 
(2E,6E)-farnesyl diphosphate 
Diphosphate 
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Table A3. Top Network Modules, TBI vs TBI+PB+NAC, Negative MS mode 
Module Metabolites 
Module 1, p=0.02738, 24 
metabolites 
 
glutathione, NAD+, leukotriene B4, 3-methoxy-4-hydroxyphenylglycol, NADP+, 
glutathione disulfide, riboflavin, S-adenosyl-L-homocysteine, quinine, 
bisorganyltrisulfane, XMP, urate, (R)-S-lactoylglutathione, albendazole s-oxide, 2-
dihydro-NAD, 2-oxoadipate, S-sulfanylglutathione, 6-phospho D-glucono-1,5-lactone, 2-
aminomuconate 6-semialdehyde, 6-dihydro-NAD, 6-dihydro-NADP, 2-dihydro-NADP, 
S-formylglutathione, GDP-4-dehydro-&alpha-D-rhamnose 
Module 2, p=0.02835, 6 
metabolites 
 
R)-S-lactoylglutathione, glutathione, S-sulfanylglutathione, bisorganyltrisulfane, S-
formylglutathione, glutathione disulfide 
Module 3, p=0.02998, 9 
metabolites 
 
albendazole s-oxide, riboflavin, leukotriene B4, quinine, 6-phospho D-glucono-1,5-
lactone, NADP+, 6-dihydro-NADP, 2-dihydro-NADP, GDP-4-dehydro-&alpha-D-
rhamnose 
Module 4, p=0.0441, 4 
metabolites 
 
adenosine 5'-phosphosulfate, indoxyl sulfate, estrone, 3'-phosphoadenylyl-sulfate 
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Table A4: Top Network Modules, TBI vs TBI+PB+NAC, Positive MS mode 
Module Metabolites 
Module 1, p=0.00252, 86 
metabolites 
 
3-methoxy-4-hydroxyphenylpyruvate, NAD+, allopregnanolone, 4-oxoglutaramate, N4-
(&beta-N-acetyl-D-glucosaminyl)-L-asparagine, acetate, erythro-4-hydroxy-L-glutamate, 
2-hydroxy-5-oxoproline, 18-hydroxyoleate, 4-imidazoleacetate, octanoyl-CoA, L-
erythro-5,6,7,8-tetrahydrobiopterin, &beta-D-galactosyl-1,4-N-acetyl-&beta-D-
glucosamine, 5-methoxytryptamine, riboflavin cyclic-4',5'-phosphate, morphinone, 
codeine, isobutanoyl-CoA, molybdopterin adenine dinucleotide, biotin, &beta-alanine, 
nicotinamide, oleate, 3-sulfinopyruvate, AMP, biotin amide, (25R)-
3&alpha,7&alpha,12&alpha-trihydroxy-5&beta-cholestan-26-al, N-acetyl-D-
galactosamine 6-phosphate, prostaglandin E2, 2-oxoglutaramate, 2-phenylethanol, 3-
methyl-2-oxobutanoate, (S)-2,3,4,5-tetrahydropiperidine-2-carboxylate, thiamin 
diphosphate, 4-methylumbelliferyl acetate, L-alanine, prostaglandin I2, succinate, 
anthranilate, 6-pyruvoyl tetrahydropterin, thromboxane A2, 2-methyl-3-hydroxybutyryl-
CoA, UDP-&alpha-D-glucose, &alpha-linolenate, 4-acetamidobutanoate, 4-(2-
aminophenyl)-2,4-dioxobutanoate, prostaglandin D2, prostaglandin-H2, androst-4-ene-
3,17-dione, XMP, decanoate, L-citrulline, N2-succinylglutamate, 19-
hydroxyandrostenedione, 3-[(3aS,4S,7aS)-7a-methyl-1,5-dioxo-octahydro-1H-inden-4-
yl]propanoate, UDP-&alpha-D-galactose, (25R)-3&alpha,7&alpha,12&alpha-trihydroxy-
5&beta-cholestan-26-oate, (25R)-3&alpha,7&alpha-dihydroxy-5-&beta-cholestanate, 
oripavine, neopinone, L-saccharopine, NMNH, 2-aminomuconate, N-acetyl-&alpha-L-
aspartyl-L-glutamate, kynurenate, N-acetyl-&beta-D-glucosamine, xanthosine, 1,6-
anhydro-N-acetyl-&beta-muramate, 3-phospho-D-glycerate, 4-hydroxyphenylpyruvate, 
D-galactosamine 6-phosphate, 3-hydroxy-L-kynurenine, codeinone, 2-methylacetoacetyl-
CoA, N-acetyl-4-O-acetylneuraminate, 5-androstene-3,17-dione, acetoacetyl-CoA, 4-
tyrosol, D-glycerate, L-arginino-succinate, 2-oxoglutarate, L-alanyl-L-aspartate, 2-
phospho-D-glycerate, 3-oxo-2-(cis-2'-pentenyl)-cyclopentane-1-octanoate, N-acetyl-L-
aspartate, prostaglandin F2&alpha 
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Module 2, p=0.02238, 24 
metabolites 
 
kynurenate, 3-methoxy-4-hydroxyphenylpyruvate, succinate, anthranilate, codeine, 
isobutanoyl-CoA, 4-oxoglutaramate, &beta-alanine, erythro-4-hydroxy-L-glutamate, 4-
hydroxyphenylpyruvate, 3-hydroxy-L-kynurenine, 2-hydroxy-5-oxoproline, codeinone, 
4-(2-aminophenyl)-2,4-dioxobutanoate, 3-sulfinopyruvate, 2-oxoglutarate, 2-
oxoglutaramate, L-alanyl-L-aspartate, 3-methyl-2-oxobutanoate, morphinone, oripavine, 
neopinone, L-saccharopine, L-alanine 
Module 3, p=0.02357, 21 
metabolites 
2-methyl-3-hydroxybutyryl-CoA, 3-phospho-D-glycerate, androst-4-ene-3,17-dione, 4-
tyrosol, 4-imidazoleacetate, 2-phospho-D-glycerate, NAD+, (S)-2,3,4,5-
tetrahydropiperidine-2-carboxylate, 4-acetamidobutanoate, 6-pyruvoyl tetrahydropterin, 
D-glycerate, N2-succinylglutamate, 19-hydroxyandrostenedione, 2-methylacetoacetyl-
CoA, L-erythro-5,6,7,8-tetrahydrobiopterin, prostaglandin E2, 2-phenylethanol, 
allopregnanolone, 5-androstene-3,17-dione, 2-aminomuconate, nicotinamide 
Module 4, p=0.02741, 22 
metabolites  
xanthosine, molybdopterin adenine dinucleotide, biotin, &alpha-linolenate, oleate, AMP, 
acetoacetyl-CoA, biotin amide, XMP, decanoate, (25R)-3&alpha,7&alpha,12&alpha-
trihydroxy-5&beta-cholestan-26-al, L-citrulline, octanoyl-CoA, L-arginino-succinate, 18-
hydroxyoleate, 3-[(3aS,4S,7aS)-7a-methyl-1,5-dioxo-octahydro-1H-inden-4-
yl]propanoate, (25R)-3&alpha,7&alpha,12&alpha-trihydroxy-5&beta-cholestan-26-oate, 
(25R)-3&alpha,7&alpha-dihydroxy-5-&beta-cholestanate, riboflavin cyclic-4',5'-
phosphate, thiamin diphosphate, 3-oxo-2-(cis-2'-pentenyl)-cyclopentane-1-octanoate, 
NMNH 
Module 5, p=0.04775, 8 
metabolites 
L-dehydro-ascorbate, (R)-S-lactoylglutathione, glutathione, S-sulfanylglutathione, 4-
hydroxy-2-nonenal, glutathione disulfide, S-formylglutathione, 4-hydroxy-2-nonenal-
glutathione conjugate 
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Table A5. Tentative identification of metabolites in CSF altered by treatment with 
probenecid and NAC after TBI  
*Negative MS mode, otherwise positive MS mode 
METLIN 
Name 
RT 
Measured 
mass (m/z) 
Compound ID Compound Name 
Molecular 
Formula 
Mass 
Error 
(delta) 
Fold 
Change 
M352T7* 6.93 352.0831 HMDB00125 Glutathione C10H17N3O6S 0.001093 +665 
M353T7* 6.94 353.086 
HMDB41723 
Dihydroferulic acid 4-o-
glucuronide 
C16H20O10 0.001257 
+81 HMDB01015 N-formyl-l-methionine C6H11NO3S 0.001348 
HMDB59611 Thiomorpholine-3-carboxylic acid C5H9NO2S 0.001351 
M432T7* 6.94 432.0258 HMDB61355 
([(2-
azaniumylethoxy)(hydroxy)phosp
horyl] oxy}({[5-(2-hydroxy-4-
imino-1,4-dihydropyrimidin-1-yl)-
1,3-oxathiolan-2-
yl]methoxy))phosphinic acid 
C10H19N4O9P2S 0.001721 +18 
M354T7* 6.93 354.082 
HMDB10319 Inodxyl glucuronide C14H15NO7 0.001053 
+75 
HMDB59804 Inodxyl glucuronide C14H15NO7 0.001053 
M521T7* 6.93 521.0661 HMDB12208 
D-erythro-imidazole-glycerol-
phosphate 
C6H11N2O6P 0.003046 +81 
M326T7* 6.931 326.0834 HMDB59609 Albendazole S-oxide C12H15N3O3S 0.001787 +84 
M242T7_1* 6.935 242.1028 
HMDB61717 O-succinylcarnitine C11H19NO6 0.000047 
+115 HMDB13133 Methylmalonylcarnitine C11H19NO6 0.000047 
HMDB12215 Dihydrozeatin C10H15N5O 0.000474 
M520T7* 6.935 520.0636 HMDB00652 Chondroitin 4-sulfate C14H21NO15S 0.002209 +552 
M284T7_1* 6.934 284.0964 HMDB15166 Probenecid C13H19NO4S 0.000197 +7731 
M659T7_2* 6.931 659.1668 HMDB41849 Carboxytolbutamide C12H16N2O5S 0.003036 +156 
M285T7_2* 7.01 285.099 
HMDB61112 
3-carboxy-4-methyl-5-propyl-2-
furan-propanoic acid 
C12H16O5 0.001025 
+430 
HMDB41756 
Isopropyl 3-(3,4-
dihydroxyphenyl)-2-
hydroxypropanoate 
C12H16O5 0.001025 
M653T7* 6.931 653.1501 HMDB60343 
2-(s-glutathionyl)acetyl 
glutathione 
C22H34N6O13S2 0.005151 +162 
M669T7* 6.935 669.1219 
HMDB59645 
beta-nicotinamide D-
ribonucleotide 
C11H16N2O8P 0.000322 
+132 
HMDB06824 Dihydroneopterin phosphate C9H14N5O7P 0.003007 
M268T4* 4.428 268.0796 HMDB02095 Malonylcarnitine C10H17NO6 0.000653 +5 
M202T7 6.948 202.0173 HMDB01274 Thymidine diphospate C10H16N2O11P2 0.001442 +247 
M183T7_1 6.948 183.0463 
HMDB00095 Cytidine monophosphate C9H14N3O8P 0.000175 
+8 
HMDB11692 Cytidine 2'-phosphate C9H14N3O8P 0.000175 
HMDB60024 
(2S,3S,4R,5R,6S)-6-(4-carboxy-2-
methoxyphenoxy)-3,4-dihydroxy-
5-methyloxane-2-carboxylic acid 
C15H18O9 0.000512 
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M286T7_1 6.948 286.1114 HMDB15166 Probenecid C13H19NO4S 0.000645 +643 
M288T7_1 6.948 288.1095 HMDB04328 Temurin C9H12N4O3 0.002795 +52 
M268T7_1 6.950 268.1004 
HMDB29126 Valyl-glutamate C10H17N2O5 0.002565 
+17 
HMDB28832 Glutamyl-valine C10H17N2O5 0.002565 
M121T7 6.929 121.0288 
HMDB00594 Glutamylphenylalanine C14H18N2O5 0.000942 
+24 HMDB28875 Hydroxyprolyl-tyrosine C14H18N2O5 0.000942 
HMDB29106 Tyrosyl-hydroxyproline C14H18N2O5 0.000942 
M467T1_2 0.562 467.1365 HMDB10325 Ethyl glucuronide C8H14O7 0.000624 -3 
M162T7 6.949 162.0554 
HMDB03320 Indole-3-carboxylic acid C9H7NO2 0.000446 
+11 
HMDB02285 2-indolecarboxylic acid C9H7NO2 0.000446 
HMDB04077 4,6-dihydroxyquinoline C9H7NO2 0.000446 
HMDB03426 Pantetheine C11H22N2O4S 0.001168 
M216T1_2 0.562 216.0878 
HMDB01557 Riboflavin reduced C15H16N4O6 0.000485 
-2 
HMDB12149 2-isopropyl-3-oxosuccinate C7H10O5 0.001154 
HMDB61388 Dimethyl 2-oxoglutarate C7H10O5 0.001154 
HMDB00125 Glutathione C10H17N3O6S 0.0012 
M305T1_2 0.583 305.0236 HMDB06512 
3-mercaptolactate-cysteine 
disulfide 
C6H11NO5S2 0.000029 +6 
M335T1_4 0.527 335.0941 
HMDB00052 Argininosuccinic acid C10H18N4O6 0.000306 
+3 
HMDB02032 8-hydroxyguanine C5H5N5O2 0.001825 
HMDB00401 2,8-dihydroxyadenine C5H5N5O2 0.001825 
HMDB00544 5-hydroxymethyl-4-methyluracil C6H8N2O3 0.002102 
HMDB01014 4-imidazolone-5-propionic acid C6H8N2O3 0.002102 
HMDB02320 Imidazolelactic acid C6H8N2O3 0.002102 
HMDB23730 3-(Imidazol-5-yl)lactic acid C6H8N2O3 0.002102 
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APPENDIX B. Copy Right Releases 
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B1. Copy Right Release, Xenobiotica 
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B2. Copy Right Release, Critical Care Medicine 
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